US20050228460A1 - Renal nerve stimulation method and apparatus for treatment of patients - Google Patents

Renal nerve stimulation method and apparatus for treatment of patients Download PDF

Info

Publication number
US20050228460A1
US20050228460A1 US11/144,298 US14429805A US2005228460A1 US 20050228460 A1 US20050228460 A1 US 20050228460A1 US 14429805 A US14429805 A US 14429805A US 2005228460 A1 US2005228460 A1 US 2005228460A1
Authority
US
United States
Prior art keywords
patient
renal
nerve
electrode
electric field
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/144,298
Inventor
Howard Levin
Mark Gelfand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40338859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050228460(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/144,298 priority Critical patent/US20050228460A1/en
Publication of US20050228460A1 publication Critical patent/US20050228460A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1492Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/326Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114Cardiac control, e.g. by vagal stimulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114Cardiac control, e.g. by vagal stimulation
    • A61N1/36117Cardiac control, e.g. by vagal stimulation for treating hypertension
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36125Details of circuitry or electric components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36135Control systems using physiological parameters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00404Blood vessels other than those in or around the heart
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00434Neural system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00505Urinary tract
    • A61B2018/00511Kidney
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577Ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3627Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/10Trunk
    • A61M2210/1078Urinary tract
    • A61M2210/1082Kidney
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3627Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Definitions

  • This invention relates to methods and apparatus for treatment of congestive heart failure, chronic renal failure and hypertension by nerve stimulation.
  • the invention relates to the improvement of these conditions of patients by blocking signals to the renal (kidney) nerve.
  • CHF Congestive Heart Failure
  • the number of patients with CHF is expected to grow even more significantly as an increasing number of the “Baby Boomers” reach 50 years of age.
  • CHF is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function becomes impaired and results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidney and circulatory system. This reduced capacity further reduces blood flow to the kidney, which in turn further reduces the capacity of the blood.
  • CHF While many different diseases may initially damage the heart, once present, CHF is split into two types: Chronic CHF and Acute (or Decompensated-Chronic) CHF.
  • Chronic Congestive Heart Failure is a longer term, slowly progressive, degenerative disease. Over years, chronic congestive heart failure leads to cardiac insufficiency.
  • Chronic CHF is clinically categorized by the patient's ability to exercise or perform normal activities of daily living (such as defined by the New York Heart Association Functional Class). Chronic CHF patients are usually managed on an outpatient basis, typically with drugs.
  • Acute Congestive Heart Failure a sudden, irreversible injury to the heart muscle, commonly referred to as a heart attack.
  • the kidneys are a pair of organs that lie in the back of the abdomen on each side of the vertebral column. Kidneys play an important regulatory role in maintaining the homeostatic balance of the body.
  • the kidneys function like a complex chemical plant.
  • the kidneys eliminate foreign chemicals from the body, regulate inorganic substances and the extracellular fluid, and function as endocrine glands, secreting hormonal substances like renin and erythropoietin.
  • the main functions of the kidney are to maintain the water balance of the body and control metabolic homeostasis. Healthy kidneys regulate the amount of fluid in the body by making the urine more or less concentrated, thus either reabsorbing or excreting more fluid, respectively.
  • Some normal and important physiological functions become detrimental to the patient's health. This process is called overcompensation.
  • CRF Chronic Renal Failure
  • kidney The functions of the kidney can be summarized under three broad categories: a) filtering blood and excreting waste products generated by the body's metabolism; b) regulating salt, water, electrolyte and acid-base balance; and c) secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of wastes toxins in the blood and body.
  • the primary functional unit of the kidneys that is involved in urine formation is called the “nephron”.
  • Each kidney consists of about one million nephrons.
  • the nephron is made up of a glomerulus and its tubules, which can be separated into a number of sections: the proximal tubule, the medullary loop (loop of Henle), and the distal tubule.
  • Each nephron is surrounded by different types of cells that have the ability to secrete several substances and hormones (such as renin and erythropoietin).
  • Urine is formed as a result of a complex process starting with the filtration of plasma water from blood into the glomerulus.
  • the walls of the glomerulus are freely permeable to water and small molecules but almost impermeable to proteins and large molecules.
  • the filtrate is virtually free of protein and has no cellular elements.
  • the filtered fluid that eventually becomes urine flows through the tubules.
  • the final chemical composition of the urine is determined by the secretion into and reabsorbtion of substances from the urine required to maintain homeostasis.
  • the two kidneys filter about 125 ml of plasma water per minute. This is called the Glomerular Filtration Rate (GFR) and is the gold standard measurement of the kidney function. Since measurement of GFR is very cumbersome and expensive, clinically, the serum creatinine level or creatinine clearance are used as surrogates to measure kidney function. Filtration occurs because of a pressure gradient across the glomerular membrane. The pressure in the arteries of the kidney pushes plasma water into the glomerulus causing filtration. To keep the GFR relatively constant, pressure in the glomerulus is held constant by the constriction or dilatation of the afferent and efferent arterioles, the muscular walled vessels leading to and from each glomerulus.
  • GFR Glomerular Filtration Rate
  • kidneys maintain the water balance of the body and control metabolic homeostasis.
  • the kidneys regulate the amount of fluid in the body by making the urine more or less concentrated, thus either reabsorbing or excreting more fluid, respectively.
  • a patient Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of wastes toxins in the blood and body.
  • kidney failure kidney failure
  • kidney failure will cause the heart to further deteriorate as the water build-up and blood toxins accumulate due to the poorly functioning kidneys and in turn, cause the heart further harm.
  • a combination of complex mechanisms contribute to the deleterious fluid overload in CHF.
  • the kidneys cannot function owing to insufficient blood pressure for perfusion and become impaired. This impairment in renal function ultimately leads to a decrease in urine output. Without sufficient urine output, the body retains fluids and the resulting fluid overload causes peripheral edema (swelling of the legs), shortness of breath (from fluid in the lungs), and fluid in the abdomen, among other undesirable conditions in the patient.
  • cardiac output leads to reduced renal blood flow, increased neurohormonal stimulus, and release of the hormone renin from the juxtaglomerular apparatus of the kidney. This results in avid retention of sodium and thus volume expansion. Increased rennin results in the formation of angiotensin, a potent vasoconstrictor.
  • Heart failure and the resulting reduction in blood pressure reduces the blood flow and perfusion pressure through organs in the body, other than the kidneys. As they suffer reduced blood pressure, these organs may become hypoxic causing the development of a metabolic acidosis which reduces the effectiveness of pharmacological therapy as well as increases the risk of sudden death.
  • CHF is associated with an abnormally elevated peripheral vascular resistance and is dominated by alterations of the circulation resulting from an intense disturbance of sympathetic nervous system function.
  • Increased activity of the sympathetic nervous system promotes a downward vicious cycle of increased arterial vasoconstriction (increased resistance of vessels to blood flow) followed by a further reduction of cardiac output, causing even more diminished blood flow to the vital organs.
  • the heart and circulatory system dramatically reduces blood flow to kidneys.
  • the kidneys receive a command from higher neural centers via neural pathways and hormonal messengers to retain fluid and sodium in the body.
  • the neural centers command the kidneys to reduce their filtering functions. While in the short term, these commands can be beneficial, if these commands continue over hours and days they can jeopardize the persons life or make the person dependent on artificial kidney for life by causing the kidneys to cease functioning.
  • the hemodynamic impairment resulting from CHF activates several neurohomonal systems, such as the renin-angiotensin and aldosterone system, sympatho-adrenal system and vasopressin release.
  • GFR filtering rate
  • the kidneys suffer from increased renal vasoconstriction, the filtering rate (GFR) of the blood drops and the sodium load in the circulatory system increases.
  • GFR filtering rate
  • more renin is liberated from the juxtaglomerular of the kidney.
  • the combined effects of reduced kidney functioning include reduced glomerular sodium load, an aldosterone-mediated increase in tubular reabsorption of sodium, and retention in the body of sodium and water.
  • the abnormal activity of the kidney is a principal non-cardiac cause of a progressive condition in a patient suffering from CHF.
  • the autonomic nervous system is recognized as an important pathway for control signals that are responsible for the regulation of body functions critical for maintaining vascular fluid balance and blood pressure.
  • the autonomic nervous system conducts information in the form of signals from the body's biologic sensors such as baroreceptors (responding to pressure and volume of blood) and chemoreceptors (responding to chemical composition of blood) to the central nervous system via its sensory fibers. It also conducts command signals from the central nervous system that control the various innervated components of the vascular system via its motor fibers.
  • renin is a hormone responsible for the “vicious cycle” of vasoconstriction and water and sodium retention in heart failure patients. It was demonstrated that increase (renal nerve stimulation) or decrease (renal nerve denervation) in renal sympathetic nerve activity produced parallel increases and decreases in the renin secretion rate by the kidney, respectively.
  • Baroreceptors are the biologic sensors sensitive to blood pressure. They are present in the different locations of the vascular system. Powerful relationship exists between the baroreceptors in the carotid arteries (supplying brain with arterial blood) and the sympathetic nervous stimulus to the kidneys. When the arterial blood pressure was suddenly reduced in experimental animals with heart failure, the sympathetic tone increased. Nevertheless the normal baroreflex alone, cannot be responsible for the elevated renal nerve activity in chronic CHF patients. If exposed to the reduced level of arterial pressure for a prolonged time baroreceptors normally “reset” i.e.
  • CRF Chronic Renal Failure
  • Kidney is damaged by direct renal toxicity from the release of sympathetic neurotransmitters (such as norepinephrine) in the kidney independent of the hypertension.
  • sympathetic neurotransmitters such as norepinephrine
  • a treatment of heart failure, renal failure and hypertension has been developed to arrest or slow down the progression of the disease. This treatment is expected to delay the morbid conditions and death often suffered by CHF patients and to delay the need for dialysis in renal failure. This treatment is expected to control hypertension in patients that do not respond to drugs or require multiple drugs.
  • the treatment includes a device and method that reduces the abnormally elevated sympathetic nerve signals that contribute to the progression of heart and renal disease.
  • the desired treatment should be implemented while preserving a patient's mobility and quality of life without the risk of major surgery.
  • the treatment breaks with tradition and proposes a counterintuitive novel method and apparatus of treating heart failure, renal failure and hypertension by electrically or chemically modulating the nerves of the kidney. Elevated nerve signals to and from the kidney are a common pathway of the progression of these chronic conditions.
  • Efferent nerves are the nerves leading from the central nervous system to the organ, in this case to the kidney.
  • Sympathetic nervous system is the part of the autonomic nervous system that is concerned especially with preparing the body to react to situations of stress or emergency that tends to depress secretion, decrease the tone and contractility of smooth muscle, and increase heart rate.
  • renal sympathetic activity it is manifested in the inhibition of the production of urine and excretion of sodium. It also elevates the secretion of renin that triggers vasoconstriction.
  • This mechanism is best illustrated by the response of the body to severe bleeding.
  • the blood pressure is artificially reduced by bleeding, and the sympathetic inhibition of the kidney is increased to maintain blood pressure with an ultimate goal of preserving the brain from hypotension.
  • the resulting vasoconstriction and fluid retention work in synchrony to help the body to maintain homeostasis.
  • Efferent renal nerve activity is considered postganglionic, autonomic and exclusively sympathetic.
  • efferent sympathetic nerves can cause a variety of responses in the innervated organs.
  • Studies of sympathetic renal nerves show that they have a strong tendency to behave as a uniform population that acts as vasoconstrictors.
  • the renal postganglionic neurons are modulated by pregangleonic (ganglion is a “knot” or agglomeration of nerve sells) nerves that originate from the brain and thoracic and upper lumbar regions of the spinal cord.
  • the pregangleonic nerves have diverse function and are likely to have high degree of redundancy. Although different pathways exist to achieve reduced efferent renal nerve activity, the simplest way is to denervate the postganglionic nerves with an electric stimulus or a chemical agent. The same desired affect could be achieved by total surgical, electric or chemical destruction (ablation) of the nerve. For two reasons this is not a preferred pathway. As was described before, renal nerves regenerate and can grow back as soon as several months after surgery. Secondarily, total irreversible denervation of the kidney can result in danger to the patient. Overdiuresis or removal of excess water from blood can result in the reduction of blood volume beyond the amount that can be rapidly replaced by fluid intake. This can result in hypovolemia and hypotension.
  • hypotension is especially dangerous in heart failure patients with the reduced capacity of the heart to pump blood and maintain blood pressure.
  • the vasodilation of the renal artery resulting from the renal denervation will cause a significant increase in renal blood flow.
  • renal blood flow can amount to as much as 20% of the total cardiac output.
  • cardiac output is reduced and the renal denervation can “steal” even larger fraction of it from circulation. This, in turn, can lead to hypotension.
  • the heart has limited ability to keep up with the demand for oxygenated blood that can be caused by even modest physical effort. Therefore a heart failure patient that can sustain the increased blood flow to the kidneys while at rest can face serious complications resulting from acute hypotension, if the demand for blood flow is increased by temperature change or exercise.
  • the treatment also breaks with tradition and proposes a counterintuitive novel method and apparatus of treating chronic renal failure (CRF) with the goal of slowing down the progression of CRF to the ESRD by electrically or chemically altering the sympathetic neural stimulation entering and exiting the kidney.
  • CRF chronic renal failure
  • the described method and apparatus can be also used to treat hypertension in patients with renal disease or abnormal renal function.
  • a renal nerve stimulator is implanted and attached to an electrode lead placed around or close to the renal artery. Stimulation effectively blocks or significantly reduces both efferent and afferent signals traveling between the kidney, the autonomic nervous system and the central nervous system.
  • the secretion of renin by kidney should be reduced by 40-50%-translating into the proportionate reduction of systemic angiotensin II, resulting in the reduction of blood pressure in all hypertensive patients including patients refractory to drugs.
  • angiotensin II Similar to renoprotective mechanisms of ACE-I, the reduction of angiotensin II should result in slowed progression of intrarenal changes in glomerular structure and function independent of blood pressure control.
  • Renal nerve stimulation in hypertensive CRF patients is unlikely to cause clinically relevant episodes of hypotension.
  • Systemic blood pressure is tightly controlled by feedbacks from baroreceptors in aorta and carotid sinuses. These mechanisms are likely to take over if the blood pressure becomes too low.
  • PTD polycystic kidney disease
  • Nerve activity can be reversibly modulated in several different ways. Nerves can be stimulated with electric current or chemicals that enhance or inhibit neurotransmission.
  • a stimulator containing a power source is typically connected to the nerve by wires or leads.
  • Leads can terminate in electrodes, cuffs that enclose the nerve or in conductive anchors (screws or hooks) that are embedded in tissue. In the later case, the lead is designed to generate sufficient electric field to alter or induce current in the nerve without physically contacting it.
  • the electrodes or leads can by bipolar or unipolar. There are permanent leads that are implanted for months and years to treat a chronic condition and temporary leads used to support the patient during an acute stage of the disease.
  • the engineering aspects of design and manufacturing of nerve stimulators, pacemakers, leads, anchors and nerve cuffs are well known.
  • Proposed clinical applications of nerve stimulation include: Depression, Anxiety, Alzheimer's Disease, Obesity, and others.
  • the targeted nerves are stimulated to increase the intensity of the transmitted signal.
  • CRF signal traffic traveling to and from the kidney via renal nerves needs to be reduced. This can be achieved by known methods previously used in physiologic studies on animals.
  • a nerve can be paced with electric pulses at high rate or at voltage that substantially exceed normal traffic.
  • a nerve will be “overpaced”, run out of neurotransmitter substance and transmit less stimulus to the kidney.
  • relatively high voltage potential can be applied to the nerve to create a blockade. This method is known as “voltage clamping” of a nerve. Infusion of a small dose of a local anesthetic in the vicinity of the nerve will produce the same effect.
  • Ablation of conductive tissue pathways is another commonly used technique to control aterial or ventricular tachycardia of the heart.
  • Ablation can be performed by introduction of a catheter into the venous system in close proximity of the sympathetic renal nerve subsequent ablation of the tissue.
  • Catheter based ablation devices were previously used to stop electric stimulation of nerves by heating nerve tissue wit RF energy that can be delivered by a system of electrodes. RF energy thus delivered stops the nerve conduction.
  • U.S. Pat. No. 6,292,695 describes in detail a method and apparatus for transvascular treatment of tachycardia and fibrillation with nerve stimulation and ablation. Similar catheter based apparatus can be used to ablate the renal nerve with an intent to treat CRF.
  • the method described in this invention is applicable to irreversible ablation of the renal nerve by electric energy, cold, or chemical agents such as phenol or alcohol.
  • Thermal means may be used to cool the renal nerve and adjacent tissue to reduce the sympathetic nerve stimulation of the kidney.
  • the renal nerve signals may be dampened by either directly cooling the renal nerve or the kidney, to reduce their sensitivity, metabolic activity and function, or by cooling the surrounding tissue.
  • An example of this approach is to use the cooling effect of the Peltier device.
  • the thermal transfer junction may be positioned adjacent the vascular wall or a renal artery to provide a cooling effect. The cooling effect may be used to dampen signals generated by the kidney.
  • Another example of this approach is to use the fluid delivery device to deliver a cool or cold fluid (e.g. saline).
  • FIG. 1 illustrates the role of sympathetic renal nerve stimulation in congestive heart failure (CHF).
  • CHF congestive heart failure
  • FIG. 2 illustrates the preferred implanted electrostimulation embodiment of the present invention.
  • FIG. 3 illustrates stimulation of renal nerves across the wall of the renal vein.
  • FIG. 4 illustrates the drug infusion blocking embodiment with an implanted drug pump.
  • FIG. 5 illustrates the arterial pressure based control algorithm for renal nerve modulation.
  • FIG. 6 illustrates electrostimulation of the renal nerve with an anodal block.
  • FIG. 7 illustrates different nerve fibers in a nerve bundle trunk.
  • FIG. 8 illustrates renal nerve modulation by blocking electric signals at one point and stimulating the nerve at a different point.
  • FIG. 9 illustrates transvenous stimulation of the renal nerve with electric field.
  • FIG. 10 illustrates an embodiment where the stimulation lead is placed using laparoscopic surgery.
  • FIG. 11 illustrates a patient controlled stimulation embodiment
  • FIG. 12 illustrates the progression of CRF to ESRD.
  • FIG. 13 illustrates the physiologic mechanisms of CRF.
  • FIG. 14 illustrates stimulation of renal nerves in a patient with an implanted stimulator with a renal artery cuff electrode.
  • FIG. 15 illustrates the placement of a stimulation cuff on a renal artery end nerve plexus.
  • FIG. 16 illustrates the design of the cuff electrode that wraps around an artery.
  • FIG. 17 illustrates the interface between cuff electrodes and the renal artery surface.
  • a method and apparatus has been developed to regulate sympathetic nerve activity to the kidney to improve a patient's renal function and overall condition, and ultimately to arrest or reverse the vicious cycle of CHF disease.
  • FIG. 1 illustrates the role of sympathetic renal nerves in heart failure. Neural pathways are indicated by solid lines, hormones by interrupted lines. Baroreceptors 101 respond to low blood pressure resulting from the reduced ability of the failing heart 103 to pump blood. Unloading of baroreceptors 101 in the left ventricle of the heart 103 , carotid sinus, and aortic arch (not shown) generates afferent neural signals 113 that stimulate cardio-regulatory centers in the brain 102 . This stimulation results in activation of efferent pathways in the sympathetic nervous system 118 . Sympathetic signals are transmitted to the spinal cord 106 , sympathetic ganglia 107 and via the sympathetic efferent renal nerve 109 to the kidney 111 . The increased activity of sympathetic nerves 108 also causes vasoconstriction 110 (increased resistance) of peripheral blood vessels.
  • efferent sympathetic nerve stimulation 109 causes retention of water (reduction of the amount of urine) and retention of sodium 112 an osmotic agent that is responsible for the expansion of blood volume.
  • the sympathetic stimulation of the kidney stimulates the release of hormones renin 105 and angiotensin II. These hormones activate the complex renin-angiotensin-aldosterone system 117 leading to more deleterious hormones causing vasoconstriction 104 and heart damage 116 .
  • the sympathetic stimulation of the hypothalamus of the brain 102 results in the release of the powerful hormone vasopressin 114 that causes further vasoconstriction of blood vessels.
  • Angiotensin II constricts blood vessels and stimulates the release of aldosterone from adrenal gland (not shown). It also increases tubular sodium reabsorption (sodium retention) in the kidney 111 and causes remodeling of cardiac myocytes therefore contributing to the further deterioration of the heart 103 and the kidney 111 .
  • the renal efferent sympathetic stimulation in heart failure is caused by low blood pressure and is a primary factor responsible for the most debilitating symptom of heart failure i.e. fluid overload. It also contributes to the progression of the disease. Acting through the volume overload and peripheral vasoconstriction (together increasing load on the heart) it accelerates the enlargement of the left ventricle that in turn results in the deteriorating ability of the heart to pump blood. Drugs used to treat heat failure address these issues separately. Diuretics are used to reduce fluid overload by reducing the reabsorption of sodium and increasing the excretion of water 112 .
  • Vasodilators are used to reduce peripheral vasoconstriction 110 by reducing levels of angiotensin 117 .
  • Inotropic agents are used to increase blood pressure and de-activate the signals from baroreceptors 101 . These drugs have limited affect and ultimately fail to control the progression and debilitating symptoms heart failure.
  • the proposed invention corrects the neuro-hormonal misbalance in heart failure by directly controlling the sympathetic neural stimulation 109 of the kidney 111 .
  • FIG. 2 shows a patient 201 suffering from chronic congestive heart failure treated in accordance with the invention.
  • An implantable device 202 is implanted in the patients body.
  • An implantable device can be an electric device similar to a pacemaker or nerve stimulator or a chemical substance infusion device. Such devices are well known in the field of medicine.
  • Internal mechanism of the implantable device typically includes a battery 203 , an electronic circuit and (in the case of a drug delivery device) a reservoir with medication.
  • An example of an implantable drug infusion device is the MiniMed 2007TM implantable insulin pump system for treatment of diabetes or the SynchroMed Infusion System used to control chronic pain, both manufactured by Medtronic Inc.
  • the drug used in this embodiment can be a common local anesthetic such as Novocain or Lidocaine or a more long lasting equivalent anesthetic.
  • a nerve toxin such as the botox can be used to block the nerve.
  • An example of an implantable nerve stimulator is the Vagus Nerve Stimulation (VNSTM) with the Cyberonics NeuroCybernetic Prosthesis (NCP®) System used for treatment of epilepsy. It is manufactured by Cyberonics Inc.
  • the internal mechanism of the implantable device typically includes a battery, an electronic circuit and (in the case of a drug delivery device), a reservoir with medication.
  • Neurostimulation systems from different manufacturers are virtually identical across application areas, usually varying only in the patterns of stimulating voltage pulses, style or number of electrodes used, and the programmed parameters.
  • the basic implantable system consists of a pacemaker-like titanium case enclosing the power source and microcircuitry that are used to create and regulate the electrical impulses.
  • An extension lead attached to this generator carries the electrical pulses to the electrode lead that is implanted or attached to the nerves or tissues to be stimulated.
  • the implantable device 202 is equipped with the lead 204 connecting it to the renal nerve 205 .
  • the lead can contain an electric wire system or a catheter for delivery of medication or both.
  • Renal nerve conducts efferent sympathetic stimulation from the sympathetic trunk 206 to the kidney 208 .
  • Sympathetic trunk is connected to the patient's spinal cord inside the spine 207 .
  • the connection can be located between the kidney 208 and the posterior renal or other renal ganglia (not shown) in the region of the 10 th , 11 th and 12 th thoracic and 1 st lumbar segments of the spine 207 .
  • the implantable device 202 is also equipped with the sensor lead 209 terminated with the sensor 210 .
  • the sensor can be a pressure sensor or an oxygen saturation sensor.
  • the sensor 210 can be located in the left ventricle of the heart 211 , right atrium of the heart or other cavity of the heart. It can also be located outside of the heart in the aorta 213 , the aortic arch 212 or a carotid artery 214 . If the sensor is a pressure sensor, it is used to supply the device 202 with the information necessary to safely regulate the sympathetic nerve signals to the kidney 208 .
  • a venous blood oxygen saturation signal can be used in a similar way to control the sympathetic nerve traffic based on oxygen demand.
  • the sensor will be placed in the right atrium of the heart or in the vena cava. More than one sensor can be used in combination to supply information to the device. Sensors can be inside the vascular system (blood vessels) or outside of it. For example, a motion sensor can be used to detect activity of the person. Such sensor does not require placement outside the implanted device case and can be integrated inside the sealed case of the device 202 as a part of the internal mechanism.
  • FIG. 3 shows external renal nerve stimulator apparatus 306 connected to the electrode tip 308 by the catheter 301 .
  • a catheter is inserted via an insertion site 303 into the femoral vein 305 into the vena cava 302 and further into the renal vein 304 .
  • the tip 308 is then brought into the electric contact with the wall of the vein 304 . Hooks or screws, similar to ones used to secure pacemaker leads, can be used to anchor the tip and improve the electric contact.
  • the tip 308 can have one, two or more electrodes integrated in its design. The purpose of the electrodes is to generate the electric field sufficiently strong to influence traffic along the renal nerve 205 stimulating the kidney 208 .
  • Two potential uses for the embodiment shown on FIG. 3 are the acute short-term stimulation of the renal nerve and the implanted embodiment.
  • a catheter equipped with electrodes on the tip is positioned in the renal vein. The proximal end of the catheter is left outside of the body and connected to the electro stimulation apparatus.
  • the catheter is used to position a stimulation lead, which is anchored in the vessel and left in place after the catheter is withdrawn. The lead is then connected to the implantable stimulator that is left in the body and the surgical site is closed. Patients have the benefit of mobility and lower risk of infection with the implanted stimulator-lead system.
  • an arterial system can be used.
  • Catheter will be introduced via the femoral artery and aorta (not shown) into the renal artery 307 .
  • Arterial catheterization is more dangerous than venous but may achieve superior result by placing stimulation electrode (or electrodes) in close proximity to the renal nerve without surgery.
  • FIG. 4 shows the use of a drug infusion pump 401 to block or partially block stimulation of the kidney 208 by infiltrating tissue proximal to the renal nerve 205 with a nerve-blocking drug.
  • Pump 401 can be an implanted drug pump.
  • the pump is equipped with a reservoir 403 and an access port (not shown) to refill the reservoir with the drug by puncturing the skin of the patient and the port septum with an infusion needle.
  • the pump is connected to the infusion catheter 402 that is surgically implanted in the proximity of the renal nerve 205 .
  • the drug used in this embodiment can be a common local anesthetic such as Novocain.
  • a nerve toxin such as botox (botulism toxin) can be used as a nerve-blocking drug.
  • Other suitable nerve desensitizing agents may comprise, for example, tetrodotoxin or other inhibitor of excitable tissues.
  • FIG. 5 illustrates the use of arterial blood pressure monitoring to modulate the treatment of CHF with renal nerve blocking.
  • the blood pressure is monitored by the computer controlled implanted device 202 ( FIG. 2 ) using the implanted sensor 210 .
  • the controlling device can be incorporated in the external nerve stimulator 306 ( FIG. 3 ) and connected to a standard blood pressure measurement device (not shown).
  • the objective of control is to avoid hypotension that can be caused by excessive vasodilation of renal arteries caused by suppression of renal sympathetic stimulus. This may cause the increase of renal blood flow dangerous for the heart failure patient with the limited heart pumping ability.
  • the control algorithm increases or decreases the level of therapy with the goal of maintaining the blood pressure within the safe range.
  • the oxygen content of venous or arterial blood can be measured and used to control therapy. Reduction of blood oxygen is an indicator of insufficient cardiac output in heart failure patients.
  • FIG. 6 illustrates the principles of modulating renal nerve signal with an anodal block.
  • Renal nerve 601 conducts efferent sympathetic electric signals in the direction towards the kidney 602 .
  • Renal nerve 601 trunk is enveloped with two conductive cuff type electrodes: the anode 603 is a positive pole and the cathode 604 is a negative pole electrode. It is significant that the anode 603 is downstream of the cathode and closer to the kidney while the cathode is upstream of the anode and closer to the spine where the sympathetic nerve traffic is coming from. The electric current flowing between the electrodes opposes the normal propagation of nerve signals and creates a nerve block.
  • Anode 603 and cathode 604 electrodes are connected to the signal generator (stimulator) 306 with wires 606 .
  • This embodiment has a practical application even if the device for renal nerve signal modulation is implanted surgically. During surgery the renal nerve is exposed and cuffs are placed that overlap the nerve.
  • the wires and the stimulator can be fully implanted at the time of surgery. Alternatively wires or leads can cross the skin and connect to the signal generator outside of the body.
  • An implantable stimulator can be implanted later during a separate surgery or the use of an external stimulator can be continued.
  • Antidromic pulse generating wave form for collision blocking is an alternative means of inducing a temporary electric blockade of signals traveling along nerve fibers. See e.g., U.S. Pat. No. 4,608,985.
  • nerve traffic manipulation techniques such as anodal blocking, cathodal blocking and collision blocking are sufficiently well described in scientific literature and are available to an expert in neurology. Most of blocking methods allow sufficient selectivity and reversibility so that the nerve will not be damaged in the process of blocking and that selective and gradual modulation or suppression of traffic in different functional fibers can be achieved.
  • a nerve is composed of the axons of a large number of individual nerve fibers.
  • a large nerve such as a renal nerve, may contain thousands of individual nerve fibers, both myelinated and non-myelinated.
  • Practical implementation of physiological blockade of selective nerve fibers in a living organism is illustrated by the paper “Respiratory responses to selective blockade of carotid sinus baroreceptors in the dog” by Francis Hopp.
  • FIG. 7 illustrates a simplified cross-section of the renal nerve trunk 601 .
  • Trunk 601 consists of a number of individual fibers.
  • the stimulation electrode cuff 603 envelops the nerve trunk.
  • Larger C type fiber 705 exemplifies fibers responsible for diuresis.
  • fibers 702 can be for example afferent fibers. Traffic along these fibers can be blocked by the application of lower blocking voltage or lower dose of anesthetic drug. The resulting effect will be diuresis of the CHF patient (secretion of sodium and water by the kidney) and the relief of fluid overload.
  • Smaller C fiber 704 is responsible for the regulation of renal blood flow.
  • the nerve stimulator or signal generator 306 therefore is capable of at least two levels of stimulation: first (lower) level to block or partially block signals propagating in larger C fibers that control diuresis, and second (higher) level to block signals propagating in smaller C fibers that control renal vascular resistance and blood flow to the kidney.
  • the later method of nerve traffic modulation with higher electric current levels is useful in preventing damage to kidneys in acute clinical situations where the vasoconstriction can lead to the ischemia of a kidney, acute tubular necrosis (ATN), acute renal failure and sometimes permanent kidney damage.
  • ATN acute tubular necrosis
  • This type of clinical scenario is often associated with the acute heart failure when hypotension (low blood pressure) results from a severe decompensation of a chronic heart failure patient.
  • Acute renal failure caused by low blood flow to the kidneys is the most costly complication in patients with heart failure.
  • Similar differentiated response to modulation could be elicited by applying different frequency of electric pulses (overpacing) to the renal nerve and keeping the applied voltage constant.
  • overpacing different frequency of electric pulses
  • renal fibers responsible for rennin secretion responded to the lowest frequency of pulses (0.5 to 1 Hz)
  • fibers responsible for sodium retention responded to middle range of frequencies (1 to 2 Hz)
  • fibers responsible for blood flow responded to the highest frequency of stimulation (2 to 5 Hz).
  • This approach can be used when the renal nerve block is achieved by overpacing the renal nerve by applying rapid series of electric pulses to the electrodes with the intent to fatigue the nerve to the point when it stops conducting stimulation pulses.
  • FIG. 8 shows an alternative embodiment of the invention.
  • the natural efferent signal traffic 804 entering the renal nerve trunk 601 is completely blocked by the anodal block device stimulator 306 using a pair of electrodes 604 and 603 .
  • the third electrode (or pair of electrodes) 803 is situated downstream of the block.
  • the electrode is used to stimulate or pace the kidney.
  • Stimulation signal is transmitted from the generator 306 via the additional lead wire 805 to the electrode 803 .
  • the induced signal becomes the nerve input to the kidney. This way full control of nerve input is accomplished while the natural sympathetic tone is totally abolished.
  • FIG. 9 shows the transvenous embodiment of the invention using anodal blockade to modulate renal nerve traffic.
  • Renal nerve 601 is located between the renal artery 901 and the renal vein 902 . It follows the same direction towards the kidney. Renal artery can branch before entering the kidney but in the majority of humans there is only one renal artery.
  • Stimulation catheter or lead 903 is introduced into the renal vein 902 and anchored to the wall of the vein using a securing device 904 .
  • the securing device can be a barb or a screw if the permanent placement of the lead 903 is desired.
  • Electric field 904 is induced by the electric current applied by the positively charged anode 905 and cathode 906 catheter electrodes.
  • Electrodes are connected to the stimulator (nor shown) by wires 907 and 908 that can be incorporated into the trunk of the lead 903 .
  • Electric field 904 is induced in the tissue surrounding the renal vein 902 and created the desired local polarization of the segment of the renal nerve trunk 601 situated in the close proximity of the catheter electrodes 905 and 907 .
  • catheters or leads can be designed that induce a cathodal block, a collision block or fatigue the nerve by rapidly pacing it using an induced field rather than by contacting the nerve directly.
  • FIG. 10 shows an embodiment where the stimulation lead is placed using laparoscopic surgery.
  • This technology is common in modern surgery and uses a small video-camera and a few customized instruments to perform surgery with minimal tissue injury.
  • the camera and instruments are inserted into the abdomen through small skin cuts allowing the surgeon to explore the whole cavity without the need of making large standard openings dividing skin and muscle.
  • FIG. 11 shows an implanted embodiment of the invention controlled by the patient from outside of the body.
  • the implanted stimulation device 203 is an electric stimulation device to modulate the renal nerve signal but can be an implantable infusion pump capable of infusing a dose of an anesthetic drug on command.
  • the implantable device 203 incorporates a magnetically activated switch such as a reed relay.
  • the reed switch can be a single-pole, single-throw (SPST) type having normally open contacts and containing two reeds that can be magnetically actuated by an electromagnet, permanent magnet or combination of both.
  • SPST single-pole, single-throw
  • Switch is normally open preventing electric or chemical blockade of the renal nerve 209 .
  • the magnetic field 1103 acts on the magnetic switch 1102 .
  • Switch is closed and blocking of the renal nerve is activated.
  • the resulting reduction of the sympathetic tone commands the kidney 208 to increase the production of urine.
  • Patient can use the device when they feel the symptoms of fluid overload to remove access fluid from the body.
  • the device 202 can be equipped with a timing circuit that is set by the external magnet. After the activation by the magnet the device can stay active (block renal nerve activity) for a predetermined duration of time to allow the kidney to make a desired amount of urine such as for an hour or several hours. Then the device will time out to avoid excessive fluid removal or adaptation of the renal nerve to the new condition.
  • FIG. 12 illustrates the progression of CRF to ESRD. Following the original injury to the kidney 1201 some nephrons 1202 are lost. Loss of nephrons lead to hyperfiltration 1203 and triggers compensatory mechanisms 1204 that are initially beneficial but over time make injury worse until the ESRD 1208 occurs. Compensatory mechanisms lead to elevated afferent and efferent sympathetic nerve signal level (increased signal traffic) 1207 to and from the kidney. It is the objective of this invention to block, reduce, modulate or otherwise decrease this level of stimulation.
  • the effect of the invented therapeutic intervention will be the reduction of central (coming from the brain) sympathetic stimulation 1206 to all organs and particularly blood vessels that causes vasoconstriction and elevation of blood pressure. Following that hypertension 1205 will be reduced therefore reducing continuous additional insult to the kidney and other organs.
  • FIG. 13 illustrates the physiologic mechanisms of CRF and hypertension.
  • Injured kidney 1302 sends elevated afferent nerve 1306 signals to the brain 1301 .
  • Brain in response increases sympathetic efferent signals to the kidney 1307 and to blood vessels 1311 that increase vascular resistance 1303 by vasoconstriction.
  • Vasoconstriction 1303 causes hypertension 1304 .
  • Kidney 1302 secretes renin 1310 that stimulates production of the vasoconstrictor hormone Angiotensin II 1305 that increases vasoconstriction of blood vessels 1303 and further increases hypertension 1304 .
  • Hypertension causes further mechanical damage 1312 to the kidney 1302 while sympathetically activated neurohormones 1307 and angiotensin II causes more subtle injury via the hormonal pathway 1310 .
  • Invented therapy reduces or eliminates critical pathways of the progressive disease by blocking afferent 1306 and efferent 1307 signals to and from the kidney 1302 . Both neurological 1311 and hormonal 1309 stimulus of vasoconstriction are therefore reduced resulting in the relief of hypertension 1304 . As a result, over time the progression of renal disease is slowed down, kidney function is improved and the possibility of stroke from high blood pressure is reduced.
  • FIG. 14 shows a patient 201 suffering from CRF or renal hypertension treated in accordance with the invention.
  • An implantable device 202 is implanted in the patient's body.
  • An implantable device can be an electric nerve stimulator or a chemical substance (drug) infusion device.
  • the implantable device 202 described above is equipped with the lead 204 connecting it to the renal nerve artery cuff 1401 .
  • Cuff 1401 envelopes the renal artery 203 that anatomically serves as a support structure for the renal nerve plexus. It is understood that there exist many varieties of electrode configurations such as wires, rings, needles, anchors, screws, cuffs and hooks that could all potentially be used to stimulate renal nerves.
  • the cuff configuration 1401 illustrated by FIGS. 14, 15 , 16 and 17 was selected for the preferred embodiment base on the information available to the inventors at the time of invention.
  • the lead conduit can be alternatively an electric wire or a catheter for delivery of medication or a combination of both.
  • Renal nerve conducts efferent sympathetic stimulation from the sympathetic trunk 206 to the kidney 208 .
  • Sympathetic trunk is connected to the patient's spinal cord inside the spine 207 .
  • the lead to nerve connection can be located anywhere between the kidney 208 and the posterior renal or other renal ganglia (not shown) in the region of the 10 th , 11 th and 12 th thoracic and 1 st lumbar segments of the spine 207 .
  • the stimulation lead 204 and the arterial nerve cuff 1401 can be placed using laparoscopic surgery.
  • FIG. 15 illustrates one possible embodiment of the renal nerve stimulation cuff electrode cuff.
  • the treated disease is CRF or hypertension it is the additional objective of this embodiment of the invention to selectively modulate nerve traffic in both afferent and efferent nerve fibers innervating the human kidney.
  • Using existing selective modulation techniques it is possible to stimulate only afferent or efferent fibers. Different types of fibers have different structure and respond to different levels and frequency of stimulation.
  • Anatomically renal nerve is difficult to locate in humans even during surgery.
  • the autonomic nervous system forms a plexus on the external surface renal artery.
  • Fibers contributing to the plexus arise from the celiac ganglion, the lowest splanchnic nerve, the aorticorenal ganglion and aortic plexus.
  • the plexus is distributed with branches of the renal artery to vessels of the kidney, the glomeruli and tubules.
  • the nerves from these sources fifteen or twenty in number, have a few ganglia developed upon them. They accompany the branches of the renal artery into the kidney; some filaments are distributed to the spermatic plexus and, on the right side, to the inferior vena cava. This makes isolating a renal nerve difficult.
  • the preferred embodiment of the neurostimulation shown on FIG. 15 has an innovative stimulation cuff.
  • the cuff 1401 envelopes the renal artery 203 and overlaps nerve fibers 1501 that form the renal plexus and look like a spider web.
  • Cuff has at least two isolated electrodes 1402 and 1403 needed for nerve blocking. More electrodes can be used for selective patterns of stimulation and blocking. Electrodes are connected to the lead 204 .
  • Renal artery 203 connects aorta 213 to the kidney 208 . It is subject to pulsations of pressure and therefore cyclically swells and contracts.
  • FIG. 16 further illustrates the design of the cuff 1401 .
  • Cuff envelopes the renal artery 203 .
  • Cuff is almost circumferential but has an opening 406 .
  • the cuff opens up without damaging the nerve or pinching the artery. Opening 406 also allows placement of the cuff around the artery.
  • Similar designs of nerve cuffs known as “helical” cuffs are well known, see e.g., U.S. Pat. Nos. 5,251,634; 4,649,936 and 5,634,462.
  • FIG. 17 shows the crossection of the cuff 1401 .
  • Cuff 1401 is made out of dielectric material.
  • Two electrodes 1402 and 1403 form rings to maximize the contact area with the wall of the artery 203 .
  • an invasive device is used to decrease the level of renal nerve signals that are received by the kidney or generated by the kidney and received by the brain.
  • Heart failure also called congestive heart failure (CHF) and chronic heart failure is a progressive heart disease characterized by low cardiac output, deterioration of heart muscle and fluid retention.
  • Renal failure also called chronic renal failure (CRF) is a progressive degenerative renal disease that is characterized by gradual loss of renal function that leads to the end stage renal disease (ESRD).
  • ESRD end stage renal disease
  • Hypertension is the chronic disease associated with high probability of stroke, renal failure and heart failure that is characterized by the abnormally high blood pressure.
  • a nerve in the context of this application means a separate nerve or a nerve bundle, nerve fiber, nerve plexus or nerve ganglion.
  • Renal nerve is a part of the autonomic nervous system that forms a plexus on the external surface renal artery. Fibers contributing to the plexus arise from the celiac ganglion, the lowest splanchnic nerve, the aorticorenal ganglion and aortic plexus.
  • the plexus is distributed with branches of the renal artery to blood vessels of the kidney, the glomeruli and tubules.
  • the nerves from these sources have a few ganglia developed upon them. They accompany the branches of the renal artery into the kidney; some filaments are distributed to the spermatic plexus and, on the right side, to the inferior vena cava.
  • Nerve stimulation, neurostimulation, nerve modulation and neuromodulation are equivalent and mean altering (reducing or increasing) naturally occurring level of electric signals propagating through the nerve.
  • the electric signal in the nerve is also called nerve traffic, nerve tone or nerve stimulus.
  • Nerve block, blocking or blockade is a form of neuromodulation and means the reduction or total termination of the propagation or conduction of the electric signal along the selected nerve.
  • Nerve block can be pharmacological (induced by a drug or other chemical substance) or an electric block by electrostimulation.
  • Electric nerve block can be a hyperpolarization block, cathodal, anodal or collision block.
  • Overpacing a nerve can also induce a block. Overpacing means stimulating the nerve with rapid electric pulses at a rate that exceeds the natural cycling rate of the nerve polarization and depolarization. As a result of overpacing the nerve gets fatigued, reserves of the immediately available neurotransmitter substance in the nerve become exhausted, and the nerve becomes temporarily unable to conduct signals.
  • Nerve block by the means listed above can result in the reduction of the nerve signal, in particular the renal sympathetic efferent or afferent tone that determines the electric stimulus received or generated by the kidney.
  • the technique of the controlled reduction of the nerve signal or traffic, which results in less organ stimulation, is called nerve signal modulation.
  • Nerve modulation means that the individual nerve fibers fire with a reduced frequency or that fewer of the nerve fibers comprising the renal nerve are actively conducting or firing.
  • the increase of nerve traffic or nerve activity usually involves recruitment of larger number of fibers in the nerve; alternatively less stimulation is associated with less active fibers.
  • Denervation means blocking of the renal nerve conduction or the destruction of the renal nerve.
  • Lead is a medical device used to access the nerve designated for stimulation or blocking. It is usually a tubular device that is electrically insulated and includes multiple conductors or wires. Wires conduct stimulation or blocking signals from the stimulator to the designated nerve. Wires are terminated in electrodes. Electrodes are conductive terminals and can contact the nerve directly or contact the conductive tissue in the vicinity of the nerve. Electrodes can have different geometric configurations and can be made of different materials.
  • the lead can include lumens or tubes for drug delivery to the nerve.
  • a stimulator or an electrostimulator is an electric device used to generate electric signals that are conducted by the lead to the nerve. The stimulator can be implanted in the body or external. Electric signals can be a DC current, voltage, series of pulses or AC current or voltage. Electrodes can induce an electric field that affects the nerve and results in nerve blocking.
  • Nerve cuff is a support structure that at least partially envelops the targeted nerve.

Abstract

A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.

Description

    RELATED APPLICATIONS
  • This application is related and claims priority to the following commonly-owned provisional applications: Ser. No. 60/370,190, entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the U.S. Patent and Trademark Office (USPTO) on Apr. 8, 2002; Ser. No. 60/415,575 entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the USPTO on Oct. 3, 2002, and Ser. No. 60/442,970 entitled “Treatment Of Renal Failure And Hypertension”, that was filed in the USPTO on Jan. 29, 2003. The entirety of each of these provisional applications is incorporated by reference herein.
  • FIELD OF THE INVENTION
  • This invention relates to methods and apparatus for treatment of congestive heart failure, chronic renal failure and hypertension by nerve stimulation. In particular, the invention relates to the improvement of these conditions of patients by blocking signals to the renal (kidney) nerve.
  • BACKGROUND OF THE INVENTION
  • The Heart Failure Problem:
  • Congestive Heart Failure (CHF) is a form of heart disease still increasing in frequency. According to the American Heart Association, CHF is the “Disease of the Next Millennium”. The number of patients with CHF is expected to grow even more significantly as an increasing number of the “Baby Boomers” reach 50 years of age. CHF is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function becomes impaired and results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidney and circulatory system. This reduced capacity further reduces blood flow to the kidney, which in turn further reduces the capacity of the blood. It is believed that the progressively-decreasing perfusion of the kidney is the principal non-cardiac cause perpetuating the downward spiral of the “Vicious Cycle of CHF”. Moreover, the fluid overload and associated clinical symptoms resulting from these physiologic changes are predominant causes for excessive hospital admissions, terrible quality of life and overwhelming costs to the health care system due to CHF.
  • While many different diseases may initially damage the heart, once present, CHF is split into two types: Chronic CHF and Acute (or Decompensated-Chronic) CHF. Chronic Congestive Heart Failure is a longer term, slowly progressive, degenerative disease. Over years, chronic congestive heart failure leads to cardiac insufficiency. Chronic CHF is clinically categorized by the patient's ability to exercise or perform normal activities of daily living (such as defined by the New York Heart Association Functional Class). Chronic CHF patients are usually managed on an outpatient basis, typically with drugs.
  • Chronic CHF patients may experience an abrupt, severe deterioration in heart function, termed Acute Congestive Heart Failure, resulting in the inability of the heart to maintain sufficient blood flow and pressure to keep vital organs of the body alive. These acute CHF deteriorations can occur when extra stress (such as an infection or excessive fluid overload) significantly increases the workload on the heart in a stable chronic CHF patient. In contrast to the stepwise downward progression of chronic CHF, a patient suffering acute CHF may deteriorate from even the earliest stages of CHF to severe hemodynamic collapse. In addition, Acute CHF can occur within hours or days following an Acute Myocardial Infarction (AMI), which is a sudden, irreversible injury to the heart muscle, commonly referred to as a heart attack.
  • Normal Kidney Function:
  • The kidneys are a pair of organs that lie in the back of the abdomen on each side of the vertebral column. Kidneys play an important regulatory role in maintaining the homeostatic balance of the body. The kidneys function like a complex chemical plant. The kidneys eliminate foreign chemicals from the body, regulate inorganic substances and the extracellular fluid, and function as endocrine glands, secreting hormonal substances like renin and erythropoietin.
  • The main functions of the kidney are to maintain the water balance of the body and control metabolic homeostasis. Healthy kidneys regulate the amount of fluid in the body by making the urine more or less concentrated, thus either reabsorbing or excreting more fluid, respectively. In case of renal disease, some normal and important physiological functions become detrimental to the patient's health. This process is called overcompensation. In the case of Chronic Renal Failure (CRF) patients overcompensation often manifests in hypertension (pathologically high blood pressure) that is damaging to heart and blood vessels and can result in a stroke or death.
  • The functions of the kidney can be summarized under three broad categories: a) filtering blood and excreting waste products generated by the body's metabolism; b) regulating salt, water, electrolyte and acid-base balance; and c) secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of wastes toxins in the blood and body.
  • The primary functional unit of the kidneys that is involved in urine formation is called the “nephron”. Each kidney consists of about one million nephrons. The nephron is made up of a glomerulus and its tubules, which can be separated into a number of sections: the proximal tubule, the medullary loop (loop of Henle), and the distal tubule. Each nephron is surrounded by different types of cells that have the ability to secrete several substances and hormones (such as renin and erythropoietin). Urine is formed as a result of a complex process starting with the filtration of plasma water from blood into the glomerulus. The walls of the glomerulus are freely permeable to water and small molecules but almost impermeable to proteins and large molecules. Thus, in a healthy kidney, the filtrate is virtually free of protein and has no cellular elements. The filtered fluid that eventually becomes urine flows through the tubules. The final chemical composition of the urine is determined by the secretion into and reabsorbtion of substances from the urine required to maintain homeostasis.
  • Receiving about 20% of cardiac output, the two kidneys filter about 125 ml of plasma water per minute. This is called the Glomerular Filtration Rate (GFR) and is the gold standard measurement of the kidney function. Since measurement of GFR is very cumbersome and expensive, clinically, the serum creatinine level or creatinine clearance are used as surrogates to measure kidney function. Filtration occurs because of a pressure gradient across the glomerular membrane. The pressure in the arteries of the kidney pushes plasma water into the glomerulus causing filtration. To keep the GFR relatively constant, pressure in the glomerulus is held constant by the constriction or dilatation of the afferent and efferent arterioles, the muscular walled vessels leading to and from each glomerulus.
  • Abnormal Kidney Function in CHF:
  • The kidneys maintain the water balance of the body and control metabolic homeostasis. The kidneys regulate the amount of fluid in the body by making the urine more or less concentrated, thus either reabsorbing or excreting more fluid, respectively. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of wastes toxins in the blood and body. These conditions resulting from reduced renal function or renal failure (kidney failure) are believed to increase the workload of the heart. In a CHF patient, renal failure will cause the heart to further deteriorate as the water build-up and blood toxins accumulate due to the poorly functioning kidneys and in turn, cause the heart further harm.
  • In a CHF patient, for any of the known cause of heart dysfunction, the heart will progressively fail and blood flow and pressure will drop in the patient's circulatory system. In the acute heart failure, the short-term compensations serve to maintain perfusion to critical organs, notably the brain and the heart that cannot survive prolonged reduction in blood flow. In chronic heart failure, these same responses that initially aided survival in acute heart failure can become deleterious.
  • A combination of complex mechanisms contribute to the deleterious fluid overload in CHF. As the heart fails and blood pressure drops, the kidneys cannot function owing to insufficient blood pressure for perfusion and become impaired. This impairment in renal function ultimately leads to a decrease in urine output. Without sufficient urine output, the body retains fluids and the resulting fluid overload causes peripheral edema (swelling of the legs), shortness of breath (from fluid in the lungs), and fluid in the abdomen, among other undesirable conditions in the patient.
  • In addition, the decrease in cardiac output leads to reduced renal blood flow, increased neurohormonal stimulus, and release of the hormone renin from the juxtaglomerular apparatus of the kidney. This results in avid retention of sodium and thus volume expansion. Increased rennin results in the formation of angiotensin, a potent vasoconstrictor.
  • Heart failure and the resulting reduction in blood pressure reduces the blood flow and perfusion pressure through organs in the body, other than the kidneys. As they suffer reduced blood pressure, these organs may become hypoxic causing the development of a metabolic acidosis which reduces the effectiveness of pharmacological therapy as well as increases the risk of sudden death.
  • This spiral of deterioration that physicians observe in heart failure patients is believed to be mediated, in large part, by activation of a subtle interaction between heart function and kidney function, known as the renin-angiotensin system. Disturbances in the heart's pumping function results in decreased cardiac output and diminished blood flow. The kidneys respond to the diminished blood flow as though the total blood volume was decreased, when in fact the measured volume is normal or even increased. This leads to fluid retention by the kidneys and formation of edema causing fluid overload and increased stress on the heart.
  • Systemically, CHF is associated with an abnormally elevated peripheral vascular resistance and is dominated by alterations of the circulation resulting from an intense disturbance of sympathetic nervous system function. Increased activity of the sympathetic nervous system promotes a downward vicious cycle of increased arterial vasoconstriction (increased resistance of vessels to blood flow) followed by a further reduction of cardiac output, causing even more diminished blood flow to the vital organs.
  • In CHF via the previously explained mechanism of vasoconstriction, the heart and circulatory system dramatically reduces blood flow to kidneys. During CHF, the kidneys receive a command from higher neural centers via neural pathways and hormonal messengers to retain fluid and sodium in the body. In response to stress on the heart, the neural centers command the kidneys to reduce their filtering functions. While in the short term, these commands can be beneficial, if these commands continue over hours and days they can jeopardize the persons life or make the person dependent on artificial kidney for life by causing the kidneys to cease functioning.
  • When the kidneys do not fully filter the blood, a huge amount of fluid is retained in the body resulting in bloating (fluid in tissues), and increases the workload of the heart. Fluid can penetrate into the lungs and the patient becomes short of breath. This odd and self-destructive phenomenon is most likely explained by the effects of normal compensatory mechanisms of the body that improperly perceive the chronically low blood pressure of CHF as a sign of temporary disturbance such as bleeding.
  • In an acute situation, the organism tries to protect its most vital organs, the brain and the heart, from the hazards of oxygen deprivation. Commands are issued via neural and hormonal pathways and messengers. These commands are directed toward the goal of maintaining blood pressure to the brain and heart, which are treated by the body as the most vital organs. The brain and heart cannot sustain low perfusion for any substantial period of time. A stroke or a cardiac arrest will result if the blood pressure to these organs is reduced to unacceptable levels. Other organs, such as kidneys, can withstand somewhat longer periods of ischemia without suffering long-term damage. Accordingly, the body sacrifices blood supply to these other organs in favor of the brain and the heart.
  • The hemodynamic impairment resulting from CHF activates several neurohomonal systems, such as the renin-angiotensin and aldosterone system, sympatho-adrenal system and vasopressin release. As the kidneys suffer from increased renal vasoconstriction, the filtering rate (GFR) of the blood drops and the sodium load in the circulatory system increases. Simultaneously, more renin is liberated from the juxtaglomerular of the kidney. The combined effects of reduced kidney functioning include reduced glomerular sodium load, an aldosterone-mediated increase in tubular reabsorption of sodium, and retention in the body of sodium and water. These effects lead to several signs and symptoms of the CHF condition, including an enlarged heart, increased systolic wall stress, an increased myocardial oxygen demand, and the formation of edema on the basis of fluid and sodium retention in the kidney. Accordingly, sustained reduction in renal blood flow and vasoconstriction is directly responsible for causing the fluid retention associated with CHF.
  • In view of the physiologic mechanisms described above it is positively established that the abnormal activity of the kidney is a principal non-cardiac cause of a progressive condition in a patient suffering from CHF.
  • Growing population of late stage CHF patients is an increasing concern for the society. The disease is progressive, and as of now, not curable. The limitations of drug therapy and its inability to reverse or even arrest the deterioration of CHF patients are clear. Surgical therapies are effective in some cases, but limited to the end-stage patient population because of the associated risk and cost. There is clearly a need for a new treatment that will overcome limitations of drug therapy but will be less invasive and costly than heart transplantation.
  • Similar condition existed several decades ago in the area of cardiac arrhythmias. Limitations of anti-arrhythmic drugs were overcome by the invention of heart pacemakers. Widespread use of implantable electric pacemakers resulted in prolonged productive life for millions of cardiac patients. So far, all medical devices proposed for the treatment of CHF are cardio-centric i.e., focus on the improvement of the heart function. The dramatic role played by kidneys in the deterioration of CHF patients has been overlooked by the medical device industry.
  • Neural Control of Kidneys:
  • The autonomic nervous system is recognized as an important pathway for control signals that are responsible for the regulation of body functions critical for maintaining vascular fluid balance and blood pressure. The autonomic nervous system conducts information in the form of signals from the body's biologic sensors such as baroreceptors (responding to pressure and volume of blood) and chemoreceptors (responding to chemical composition of blood) to the central nervous system via its sensory fibers. It also conducts command signals from the central nervous system that control the various innervated components of the vascular system via its motor fibers.
  • Experience with human kidney transplantation provided early evidence of the role of the nervous system in the kidney function. It was noted that after the transplant, when all the kidney nerves are totally severed, the kidney increased the excretion of water and sodium. This phenomenon was also observed in animals when the renal nerves were cut or chemically destroyed. The phenomenon was called “denervation diuresis” since the denervation acted on a kidney similar to a diuretic medication. Later the “denervation diuresis” was found to be associated with the vasodilatation the renal arterial system that led to the increase of the blood flow through the kidney. This observation was confirmed by the observation in animals that reducing blood pressure supplying the kidney could reverse the “denervation diuresis”.
  • It was also observed that after several months passed after the transplant surgery in successful cases, the “denervation diuresis” in transplant recipients stopped and the kidney function returned to normal. Originally it was believed that the “renal diuresis” is a transient phenomenon and that the nerves conducting signals from the central nervous system to the kidney are not essential for the kidney function. Later, new discoveries led to the different explanation. It is believed now that the renal nerves have a profound ability to regenerate and the reversal of the “denervation diuresis” shall be attributed to the growth of the new nerve fibers supplying kidneys with the necessary stimuli.
  • Another body of research that is of particular importance for this application was conducted in the period of 1964-1969 and focused on the role of the neural control of secretion of the hormone renin by the kidney. As was discussed previously, renin is a hormone responsible for the “vicious cycle” of vasoconstriction and water and sodium retention in heart failure patients. It was demonstrated that increase (renal nerve stimulation) or decrease (renal nerve denervation) in renal sympathetic nerve activity produced parallel increases and decreases in the renin secretion rate by the kidney, respectively.
  • In summary, it is known from clinical experience and the large body of animal research that the stimulation of the renal nerve leads to the vasoconstriction of blood vessels supplying the kidney, decreased renal blood flow, decreased removal of water and sodium from the body and increased renin secretion. These observations closely resemble the physiologic landscape of the deleterious effects of the chronic congestive heart failure. It is also known that the reduction of the sympathetic renal nerve activity, achieved by denervation, can reverse these processes.
  • It was established in animal models that the heart failure condition results in the abnormally high sympathetic stimulation of the kidney. This phenomenon was traced back to the sensory nerves conducting signals from baroreceptors to the central nervous system. Baroreceptors are the biologic sensors sensitive to blood pressure. They are present in the different locations of the vascular system. Powerful relationship exists between the baroreceptors in the carotid arteries (supplying brain with arterial blood) and the sympathetic nervous stimulus to the kidneys. When the arterial blood pressure was suddenly reduced in experimental animals with heart failure, the sympathetic tone increased. Nevertheless the normal baroreflex alone, cannot be responsible for the elevated renal nerve activity in chronic CHF patients. If exposed to the reduced level of arterial pressure for a prolonged time baroreceptors normally “reset” i.e. return to the baseline level of activity until a new disturbance is introduced. Therefore, in chronic CHF patients the components of the autonomic nervous system responsible for the control of blood pressure and the neural control of the kidney function become abnormal. The exact mechanisms that cause this abnormality are not fully understood but, its effects on the overall condition of the CHF patients are profoundly negative.
  • End Stage Renal Disease Problem:
  • There is a dramatic increase in patients with end-stage renal disease (ESRD) due to diabetic nephropathy, chronic glomerulonephritis and uncontrolled hypertension. In the US alone, 372,000 patients required dialysis in the year 2000. There were 90,000 new cases of ESRD in 1999 with the number of patients on dialysis is expected to rise to 650,000 by the year 2010. The trends in Europe and Japan are forecasted to follow a similar path. Mortality in patients with ESRD remains 10-20 times higher than that in the general population. Annual Medicare patient costs $52,868 for dialysis and $18,496 for transplantation. The total cost for Medicare patients with ESRD in 1998 was $12.04 billion.
  • The primary cause of these problems is the slow relentless progression of Chronic Renal Failure (CRF) to ESRD. CRF represents a critical period in the evolution of ESRD. The signs and symptoms of CRF are initially minor, but over the course of 2-5 years, become progressive and irreversible. Until the 1980's, there were no therapies that could significantly slow the progression of CRF to ESRD. While some progress has been made in combating the progression to and complications of ESRD in last two decades, the clinical benefits of existing interventions remain limited with no new drug or device therapies on the horizon.
  • Progression of Chronic Renal Failure:
  • It has been known for several decades that renal diseases of diverse etiology (hypotension, infection, trauma, autoimmune disease, etc.) can lead to the syndrome of CRF characterized by systemic hypertension, proteinuria (excess protein filtered from the blood into the urine) and a progressive decline in GFR ultimately resulting in ESRD. These observations suggested that CRF progresses via a common pathway of mechanisms, and that therapeutic interventions inhibiting this common pathway may be successful in slowing the rate of progression of CRF irrespective of the initiating cause.
  • To start the vicious cycle of CRF, an initial insult to the kidney causes loss of some nephrons. To maintain normal GFR, there is an activation of compensatory renal and systemic mechanisms resulting in a state of hyperfiltration in the remaining nephrons. Eventually, however, the increasing numbers of nephrons “overworked” and damaged by hyperfiltration are lost. At some point, a sufficient number of nephrons are lost so that normal GFR can no longer be maintained. These pathologic changes of CRF produce worsening systemic hypertension, thus high glomerular pressure and increased hyperfiltration. Increased glomerular hyperfiltration and permeability in CRF pushes an increased amount of protein from the blood, across the glomerulus and into the renal tubules. This protein is directly toxic to the tubules and leads to further loss of nephrons, increasing the rate of progression of CRF. This vicious cycle of CRF continues as the GFR drops, with loss of additional nephrons leading to further hyperfiltration and eventually to ESRD requiring dialysis. Clinically, hypertension and excess protein filtration have been shown to be two major determining factors in the rate of progression of CRF to ESRD.
  • Though previously clinically known, it was not until the 1980s that the physiologic link between hypertension, proteinuria, nephron loss and CRF was identified. In 1990s the role of sympathetic nervous system activity was elucidated. Afferent signals arising from the damaged kidneys due to the activation of mechanoreceptors and chemoreceptors stimulate areas of the brain responsible for blood pressure control. In response brain increases sympathetic stimulation on the systemic level resulting in the increased blood pressure primarily through vasoconstriction of blood vessels.
  • When elevated sympathetic stimulation reaches the kidney via the efferent sympathetic nerve fibers, it produces major deleterious effects in two forms:
  • A. Kidney is damaged by direct renal toxicity from the release of sympathetic neurotransmitters (such as norepinephrine) in the kidney independent of the hypertension.
  • B. Secretion of renin that activates Angiotensin II is increased leading to the increased systemic vasoconstriction and exacerbated hypertension.
  • Over time damage to the kidney leads to further increase of afferent sympathetic signals from the kidney to the brain. Elevated Angiotensin II further facilitates internal renal release of neurotransmitters. The feedback loop is therefore closed accelerating the deterioration of the kidney.
  • BRIEF DESCRIPTION OF THE INVENTION
  • A treatment of heart failure, renal failure and hypertension has been developed to arrest or slow down the progression of the disease. This treatment is expected to delay the morbid conditions and death often suffered by CHF patients and to delay the need for dialysis in renal failure. This treatment is expected to control hypertension in patients that do not respond to drugs or require multiple drugs.
  • The treatment includes a device and method that reduces the abnormally elevated sympathetic nerve signals that contribute to the progression of heart and renal disease. The desired treatment should be implemented while preserving a patient's mobility and quality of life without the risk of major surgery.
  • The treatment breaks with tradition and proposes a counterintuitive novel method and apparatus of treating heart failure, renal failure and hypertension by electrically or chemically modulating the nerves of the kidney. Elevated nerve signals to and from the kidney are a common pathway of the progression of these chronic conditions.
  • Chronic heart and renal failure is treated by reducing the sympathetic efferent or afferent nerve activity of the kidney. Efferent nerves (as opposed to afferent) are the nerves leading from the central nervous system to the organ, in this case to the kidney. Sympathetic nervous system (as opposed to parasympathetic) is the part of the autonomic nervous system that is concerned especially with preparing the body to react to situations of stress or emergency that tends to depress secretion, decrease the tone and contractility of smooth muscle, and increase heart rate. In the case of renal sympathetic activity, it is manifested in the inhibition of the production of urine and excretion of sodium. It also elevates the secretion of renin that triggers vasoconstriction. This mechanism is best illustrated by the response of the body to severe bleeding. When in experimental animals, the blood pressure is artificially reduced by bleeding, and the sympathetic inhibition of the kidney is increased to maintain blood pressure with an ultimate goal of preserving the brain from hypotension. The resulting vasoconstriction and fluid retention work in synchrony to help the body to maintain homeostasis.
  • Efferent renal nerve activity is considered postganglionic, autonomic and exclusively sympathetic. In general, efferent sympathetic nerves can cause a variety of responses in the innervated organs. Studies of sympathetic renal nerves show that they have a strong tendency to behave as a uniform population that acts as vasoconstrictors. The renal postganglionic neurons are modulated by pregangleonic (ganglion is a “knot” or agglomeration of nerve sells) nerves that originate from the brain and thoracic and upper lumbar regions of the spinal cord.
  • The pregangleonic nerves have diverse function and are likely to have high degree of redundancy. Although different pathways exist to achieve reduced efferent renal nerve activity, the simplest way is to denervate the postganglionic nerves with an electric stimulus or a chemical agent. The same desired affect could be achieved by total surgical, electric or chemical destruction (ablation) of the nerve. For two reasons this is not a preferred pathway. As was described before, renal nerves regenerate and can grow back as soon as several months after surgery. Secondarily, total irreversible denervation of the kidney can result in danger to the patient. Overdiuresis or removal of excess water from blood can result in the reduction of blood volume beyond the amount that can be rapidly replaced by fluid intake. This can result in hypovolemia and hypotension. Hypotension is especially dangerous in heart failure patients with the reduced capacity of the heart to pump blood and maintain blood pressure. In addition, the vasodilation of the renal artery resulting from the renal denervation will cause a significant increase in renal blood flow. In a healthy person, renal blood flow can amount to as much as 20% of the total cardiac output. In heart failure patients cardiac output is reduced and the renal denervation can “steal” even larger fraction of it from circulation. This, in turn, can lead to hypotension. Also, in a heart failure patient the heart has limited ability to keep up with the demand for oxygenated blood that can be caused by even modest physical effort. Therefore a heart failure patient that can sustain the increased blood flow to the kidneys while at rest can face serious complications resulting from acute hypotension, if the demand for blood flow is increased by temperature change or exercise.
  • In view of the factors described above it is desired to have means to reduce the efferent sympathetic stimulation of the kidney in CHF patients in a reversible, controlled fashion preferably based on a physiologic feedback signal that is indicative of the oxygen demand by the body, blood pressure, cardiac output of the patient or a combination of these and other physiologic parameters.
  • The treatment also breaks with tradition and proposes a counterintuitive novel method and apparatus of treating chronic renal failure (CRF) with the goal of slowing down the progression of CRF to the ESRD by electrically or chemically altering the sympathetic neural stimulation entering and exiting the kidney. The described method and apparatus can be also used to treat hypertension in patients with renal disease or abnormal renal function.
  • To control the afferent nerve signals from the kidney to the brain and block efferent nerve stimuli from entering the kidney (without systemic side effects of drug therapy), a renal nerve stimulator is implanted and attached to an electrode lead placed around or close to the renal artery. Stimulation effectively blocks or significantly reduces both efferent and afferent signals traveling between the kidney, the autonomic nervous system and the central nervous system.
  • The benefits that may be possible by controlling renal nerve signals to reduce efferent overstimulation are:
  • a. The secretion of renin by kidney should be reduced by 40-50%-translating into the proportionate reduction of systemic angiotensin II, resulting in the reduction of blood pressure in all hypertensive patients including patients refractory to drugs.
  • b. Similar to renoprotective mechanisms of ACE-I, the reduction of angiotensin II should result in slowed progression of intrarenal changes in glomerular structure and function independent of blood pressure control.
  • c. Similar to the effects of moxonidine, reduced efferent overstimulation should reduce damage by direct renal toxicity from the release of sympathetic neurotransmitters.
  • Following the reduction of the afferent sympathetic renal feedback to the brain, there is expected to be a marked reduction in the systemic efferent overstimulation. This will translate into the systemic vasodilation and reduction of hypertension independent of the renin-angiotensin II mechanism.
  • Renal nerve stimulation in hypertensive CRF patients is unlikely to cause clinically relevant episodes of hypotension. Systemic blood pressure is tightly controlled by feedbacks from baroreceptors in aorta and carotid sinuses. These mechanisms are likely to take over if the blood pressure becomes too low. In polycystic kidney disease (PKD) patients who underwent surgery for total denervation of kidneys, denervation resolved hypertension without postoperative episodes of hypotension.
  • Technique for Nerve Modulation
  • Nerve activity can be reversibly modulated in several different ways. Nerves can be stimulated with electric current or chemicals that enhance or inhibit neurotransmission. In the case of electrical stimulation, a stimulator containing a power source is typically connected to the nerve by wires or leads. Leads can terminate in electrodes, cuffs that enclose the nerve or in conductive anchors (screws or hooks) that are embedded in tissue. In the later case, the lead is designed to generate sufficient electric field to alter or induce current in the nerve without physically contacting it. The electrodes or leads can by bipolar or unipolar. There are permanent leads that are implanted for months and years to treat a chronic condition and temporary leads used to support the patient during an acute stage of the disease. The engineering aspects of design and manufacturing of nerve stimulators, pacemakers, leads, anchors and nerve cuffs are well known.
  • Proposed clinical applications of nerve stimulation include: Depression, Anxiety, Alzheimer's Disease, Obesity, and others. In all existing clinical applications except pain control, the targeted nerves are stimulated to increase the intensity of the transmitted signal. To achieve relief of hypertension and CRF signal traffic traveling to and from the kidney via renal nerves needs to be reduced. This can be achieved by known methods previously used in physiologic studies on animals. A nerve can be paced with electric pulses at high rate or at voltage that substantially exceed normal traffic. As a result, a nerve will be “overpaced”, run out of neurotransmitter substance and transmit less stimulus to the kidney. Alternatively relatively high voltage potential can be applied to the nerve to create a blockade. This method is known as “voltage clamping” of a nerve. Infusion of a small dose of a local anesthetic in the vicinity of the nerve will produce the same effect.
  • Ablation of conductive tissue pathways is another commonly used technique to control aterial or ventricular tachycardia of the heart. Ablation can be performed by introduction of a catheter into the venous system in close proximity of the sympathetic renal nerve subsequent ablation of the tissue. Catheter based ablation devices were previously used to stop electric stimulation of nerves by heating nerve tissue wit RF energy that can be delivered by a system of electrodes. RF energy thus delivered stops the nerve conduction. U.S. Pat. No. 6,292,695 describes in detail a method and apparatus for transvascular treatment of tachycardia and fibrillation with nerve stimulation and ablation. Similar catheter based apparatus can be used to ablate the renal nerve with an intent to treat CRF. The method described in this invention is applicable to irreversible ablation of the renal nerve by electric energy, cold, or chemical agents such as phenol or alcohol.
  • Thermal means may be used to cool the renal nerve and adjacent tissue to reduce the sympathetic nerve stimulation of the kidney. Specifically, the renal nerve signals may be dampened by either directly cooling the renal nerve or the kidney, to reduce their sensitivity, metabolic activity and function, or by cooling the surrounding tissue. An example of this approach is to use the cooling effect of the Peltier device. Specifically, the thermal transfer junction may be positioned adjacent the vascular wall or a renal artery to provide a cooling effect. The cooling effect may be used to dampen signals generated by the kidney. Another example of this approach is to use the fluid delivery device to deliver a cool or cold fluid (e.g. saline).
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A preferred embodiment and best mode of the invention is illustrated in the attached drawings that are described as follows:
  • FIG. 1 illustrates the role of sympathetic renal nerve stimulation in congestive heart failure (CHF).
  • FIG. 2 illustrates the preferred implanted electrostimulation embodiment of the present invention.
  • FIG. 3 illustrates stimulation of renal nerves across the wall of the renal vein.
  • FIG. 4 illustrates the drug infusion blocking embodiment with an implanted drug pump.
  • FIG. 5 illustrates the arterial pressure based control algorithm for renal nerve modulation.
  • FIG. 6 illustrates electrostimulation of the renal nerve with an anodal block.
  • FIG. 7 illustrates different nerve fibers in a nerve bundle trunk.
  • FIG. 8 illustrates renal nerve modulation by blocking electric signals at one point and stimulating the nerve at a different point.
  • FIG. 9 illustrates transvenous stimulation of the renal nerve with electric field.
  • FIG. 10 illustrates an embodiment where the stimulation lead is placed using laparoscopic surgery.
  • FIG. 11 illustrates a patient controlled stimulation embodiment.
  • FIG. 12 illustrates the progression of CRF to ESRD.
  • FIG. 13 illustrates the physiologic mechanisms of CRF.
  • FIG. 14 illustrates stimulation of renal nerves in a patient with an implanted stimulator with a renal artery cuff electrode.
  • FIG. 15 illustrates the placement of a stimulation cuff on a renal artery end nerve plexus.
  • FIG. 16 illustrates the design of the cuff electrode that wraps around an artery.
  • FIG. 17 illustrates the interface between cuff electrodes and the renal artery surface.
  • DETAILED DESCRIPTION OF THE INVENTION
  • A method and apparatus has been developed to regulate sympathetic nerve activity to the kidney to improve a patient's renal function and overall condition, and ultimately to arrest or reverse the vicious cycle of CHF disease.
  • FIG. 1 illustrates the role of sympathetic renal nerves in heart failure. Neural pathways are indicated by solid lines, hormones by interrupted lines. Baroreceptors 101 respond to low blood pressure resulting from the reduced ability of the failing heart 103 to pump blood. Unloading of baroreceptors 101 in the left ventricle of the heart 103, carotid sinus, and aortic arch (not shown) generates afferent neural signals 113 that stimulate cardio-regulatory centers in the brain 102. This stimulation results in activation of efferent pathways in the sympathetic nervous system 118. Sympathetic signals are transmitted to the spinal cord 106, sympathetic ganglia 107 and via the sympathetic efferent renal nerve 109 to the kidney 111. The increased activity of sympathetic nerves 108 also causes vasoconstriction 110 (increased resistance) of peripheral blood vessels.
  • In the kidney 111 efferent sympathetic nerve stimulation 109 causes retention of water (reduction of the amount of urine) and retention of sodium 112 an osmotic agent that is responsible for the expansion of blood volume. The sympathetic stimulation of the kidney stimulates the release of hormones renin 105 and angiotensin II. These hormones activate the complex renin-angiotensin-aldosterone system 117 leading to more deleterious hormones causing vasoconstriction 104 and heart damage 116. The sympathetic stimulation of the hypothalamus of the brain 102 results in the release of the powerful hormone vasopressin 114 that causes further vasoconstriction of blood vessels. Angiotensin II constricts blood vessels and stimulates the release of aldosterone from adrenal gland (not shown). It also increases tubular sodium reabsorption (sodium retention) in the kidney 111 and causes remodeling of cardiac myocytes therefore contributing to the further deterioration of the heart 103 and the kidney 111.
  • It can be inferred from the FIG. 1 that the renal efferent sympathetic stimulation in heart failure is caused by low blood pressure and is a primary factor responsible for the most debilitating symptom of heart failure i.e. fluid overload. It also contributes to the progression of the disease. Acting through the volume overload and peripheral vasoconstriction (together increasing load on the heart) it accelerates the enlargement of the left ventricle that in turn results in the deteriorating ability of the heart to pump blood. Drugs used to treat heat failure address these issues separately. Diuretics are used to reduce fluid overload by reducing the reabsorption of sodium and increasing the excretion of water 112. Vasodilators are used to reduce peripheral vasoconstriction 110 by reducing levels of angiotensin 117. Inotropic agents are used to increase blood pressure and de-activate the signals from baroreceptors 101. These drugs have limited affect and ultimately fail to control the progression and debilitating symptoms heart failure. The proposed invention corrects the neuro-hormonal misbalance in heart failure by directly controlling the sympathetic neural stimulation 109 of the kidney 111.
  • FIG. 2 shows a patient 201 suffering from chronic congestive heart failure treated in accordance with the invention. An implantable device 202 is implanted in the patients body. An implantable device can be an electric device similar to a pacemaker or nerve stimulator or a chemical substance infusion device. Such devices are well known in the field of medicine. Internal mechanism of the implantable device typically includes a battery 203, an electronic circuit and (in the case of a drug delivery device) a reservoir with medication.
  • An example of an implantable drug infusion device is the MiniMed 2007™ implantable insulin pump system for treatment of diabetes or the SynchroMed Infusion System used to control chronic pain, both manufactured by Medtronic Inc. The drug used in this embodiment can be a common local anesthetic such as Novocain or Lidocaine or a more long lasting equivalent anesthetic. Alternatively, a nerve toxin such as the botox can be used to block the nerve. An example of an implantable nerve stimulator is the Vagus Nerve Stimulation (VNS™) with the Cyberonics NeuroCybernetic Prosthesis (NCP®) System used for treatment of epilepsy. It is manufactured by Cyberonics Inc. The internal mechanism of the implantable device typically includes a battery, an electronic circuit and (in the case of a drug delivery device), a reservoir with medication. Neurostimulation systems from different manufacturers are virtually identical across application areas, usually varying only in the patterns of stimulating voltage pulses, style or number of electrodes used, and the programmed parameters. The basic implantable system consists of a pacemaker-like titanium case enclosing the power source and microcircuitry that are used to create and regulate the electrical impulses. An extension lead attached to this generator carries the electrical pulses to the electrode lead that is implanted or attached to the nerves or tissues to be stimulated.
  • The implantable device 202 is equipped with the lead 204 connecting it to the renal nerve 205. The lead can contain an electric wire system or a catheter for delivery of medication or both. Renal nerve conducts efferent sympathetic stimulation from the sympathetic trunk 206 to the kidney 208. Sympathetic trunk is connected to the patient's spinal cord inside the spine 207. The connection can be located between the kidney 208 and the posterior renal or other renal ganglia (not shown) in the region of the 10th, 11th and 12th thoracic and 1st lumbar segments of the spine 207.
  • The implantable device 202 is also equipped with the sensor lead 209 terminated with the sensor 210. The sensor can be a pressure sensor or an oxygen saturation sensor. The sensor 210 can be located in the left ventricle of the heart 211, right atrium of the heart or other cavity of the heart. It can also be located outside of the heart in the aorta 213, the aortic arch 212 or a carotid artery 214. If the sensor is a pressure sensor, it is used to supply the device 202 with the information necessary to safely regulate the sympathetic nerve signals to the kidney 208. A venous blood oxygen saturation signal can be used in a similar way to control the sympathetic nerve traffic based on oxygen demand. The sensor will be placed in the right atrium of the heart or in the vena cava. More than one sensor can be used in combination to supply information to the device. Sensors can be inside the vascular system (blood vessels) or outside of it. For example, a motion sensor can be used to detect activity of the person. Such sensor does not require placement outside the implanted device case and can be integrated inside the sealed case of the device 202 as a part of the internal mechanism.
  • FIG. 3 shows external renal nerve stimulator apparatus 306 connected to the electrode tip 308 by the catheter 301. A catheter is inserted via an insertion site 303 into the femoral vein 305 into the vena cava 302 and further into the renal vein 304. The tip 308 is then brought into the electric contact with the wall of the vein 304. Hooks or screws, similar to ones used to secure pacemaker leads, can be used to anchor the tip and improve the electric contact. The tip 308 can have one, two or more electrodes integrated in its design. The purpose of the electrodes is to generate the electric field sufficiently strong to influence traffic along the renal nerve 205 stimulating the kidney 208.
  • Two potential uses for the embodiment shown on FIG. 3 are the acute short-term stimulation of the renal nerve and the implanted embodiment. For short term treatment, a catheter equipped with electrodes on the tip is positioned in the renal vein. The proximal end of the catheter is left outside of the body and connected to the electro stimulation apparatus. For the implanted application, the catheter is used to position a stimulation lead, which is anchored in the vessel and left in place after the catheter is withdrawn. The lead is then connected to the implantable stimulator that is left in the body and the surgical site is closed. Patients have the benefit of mobility and lower risk of infection with the implanted stimulator-lead system.
  • Similar to the venous embodiment, an arterial system can be used. Catheter will be introduced via the femoral artery and aorta (not shown) into the renal artery 307. Arterial catheterization is more dangerous than venous but may achieve superior result by placing stimulation electrode (or electrodes) in close proximity to the renal nerve without surgery.
  • FIG. 4 shows the use of a drug infusion pump 401 to block or partially block stimulation of the kidney 208 by infiltrating tissue proximal to the renal nerve 205 with a nerve-blocking drug. Pump 401 can be an implanted drug pump. The pump is equipped with a reservoir 403 and an access port (not shown) to refill the reservoir with the drug by puncturing the skin of the patient and the port septum with an infusion needle. The pump is connected to the infusion catheter 402 that is surgically implanted in the proximity of the renal nerve 205. The drug used in this embodiment can be a common local anesthetic such as Novocain. If it is desired to block the nerve for a long time after a single bolus drug infusion, a nerve toxin such as botox (botulism toxin) can be used as a nerve-blocking drug. Other suitable nerve desensitizing agents may comprise, for example, tetrodotoxin or other inhibitor of excitable tissues.
  • FIG. 5 illustrates the use of arterial blood pressure monitoring to modulate the treatment of CHF with renal nerve blocking. The blood pressure is monitored by the computer controlled implanted device 202 (FIG. 2) using the implanted sensor 210. Alternatively the controlling device can be incorporated in the external nerve stimulator 306 (FIG. 3) and connected to a standard blood pressure measurement device (not shown). The objective of control is to avoid hypotension that can be caused by excessive vasodilation of renal arteries caused by suppression of renal sympathetic stimulus. This may cause the increase of renal blood flow dangerous for the heart failure patient with the limited heart pumping ability. The control algorithm increases or decreases the level of therapy with the goal of maintaining the blood pressure within the safe range. Similarly the oxygen content of venous or arterial blood can be measured and used to control therapy. Reduction of blood oxygen is an indicator of insufficient cardiac output in heart failure patients.
  • FIG. 6 illustrates the principles of modulating renal nerve signal with an anodal block. Renal nerve 601 conducts efferent sympathetic electric signals in the direction towards the kidney 602. Renal nerve 601 trunk is enveloped with two conductive cuff type electrodes: the anode 603 is a positive pole and the cathode 604 is a negative pole electrode. It is significant that the anode 603 is downstream of the cathode and closer to the kidney while the cathode is upstream of the anode and closer to the spine where the sympathetic nerve traffic is coming from. The electric current flowing between the electrodes opposes the normal propagation of nerve signals and creates a nerve block. Anode 603 and cathode 604 electrodes are connected to the signal generator (stimulator) 306 with wires 606. This embodiment has a practical application even if the device for renal nerve signal modulation is implanted surgically. During surgery the renal nerve is exposed and cuffs are placed that overlap the nerve. The wires and the stimulator can be fully implanted at the time of surgery. Alternatively wires or leads can cross the skin and connect to the signal generator outside of the body. An implantable stimulator can be implanted later during a separate surgery or the use of an external stimulator can be continued.
  • Clinically used spiral cuffs for connecting to a nerve are manufactured by Cyberonics Inc. (Houston, Tex.) that also manufactures a fully implantable nerve stimulator operating on batteries. See also, e.g., U.S. Pat. No. 5,251,643. Various external signal generators suitable for nerve stimulation are available from Grass-Telefactor Astro-Med Product Group (West Warwick, R.I.). Nerve cuff electrodes are well known. See, e.g., U.S. Pat. No. 6,366,815. The principle of the anodal block is based on the observation that close to an anodal electrode contact the propagation of a nerve action potential can be blocked due to hyperpolarization of the fiber membrane. See e.g., U.S. Pat. Nos. 5,814,079 and 5,800,464. If the membrane is sufficiently hyperpolarized, action potentials cannot pass the hyperpolarized zone and are annihilated.
  • As large diameter fibers need a smaller stimulus for their blocking than do small diameter fibers, a selective blockade of the large fibers is possible. See e.g., U.S. Pat. No. 5,755,750. The activity in different fibers of a nerve in an animal can be selectively blocked by applying direct electric current between an anode and a cathode attached to the nerve.
  • Antidromic pulse generating wave form for collision blocking is an alternative means of inducing a temporary electric blockade of signals traveling along nerve fibers. See e.g., U.S. Pat. No. 4,608,985. In general, nerve traffic manipulation techniques such as anodal blocking, cathodal blocking and collision blocking are sufficiently well described in scientific literature and are available to an expert in neurology. Most of blocking methods allow sufficient selectivity and reversibility so that the nerve will not be damaged in the process of blocking and that selective and gradual modulation or suppression of traffic in different functional fibers can be achieved.
  • A nerve is composed of the axons of a large number of individual nerve fibers. A large nerve, such as a renal nerve, may contain thousands of individual nerve fibers, both myelinated and non-myelinated. Practical implementation of physiological blockade of selective nerve fibers in a living organism is illustrated by the paper “Respiratory responses to selective blockade of carotid sinus baroreceptors in the dog” by Francis Hopp. Both anodal block and local anesthesia by injection of bupivacaine (a common long-acting local anaesthetic, used for surgical anaesthesia and acute pain management) were applied to the surgically isolated and exposed but intact nerve leading from baroreceptors (physiologic pressure sensors) in the carotid sinus of the heart to the brain of an animal. Anodal block was induced using simple wire electrodes. Experiments showed that by increasing anodal blocking current from 50 to 350 microamperes signal conduction in C type fibers was gradually reduced from 100% to 0% (complete block) in linear proportion to the strength of the electric current. Similarly increasing concentration of injected bupivacaine (5, 10, 20 and 100 mg/ml) resulted in gradual blocking of the carotid sinus nerve activity in a dog. These experiments confirmed that it is possible to reduce intensity of nerve stimulation (nerve traffic) in an isolated nerve in controllable, reversible and gradual was by the application of electric current or chemical blockade. In the same paper it was described that smaller C type fibers were blocked by lower electric current and higher concentration of bupivacaine than larger C type fibers.
  • Gerald DiBona in “Neural control of the kidney: functionally specific renal sympathetic nerve fibers” described the structure and role of individual nerve fibers controlling the kidney function. Approximately 96% of sympathetic renal fibers in the renal nerve are slow conducting unmyelinated C type fibers 0.4 to 2.5 micrometers in diameter. Different fibers within this range carry different signals and respond to different levels of stimulation and inhibition. It is known that lower stimulation voltage of the renal nerve created untidiuretic effect (reduced urine output) while higher level of stimulation created vasoconstriction effect. Stimulation threshold is inversely proportional to the fiber diameter; therefore it is likely that elevated signal levels in larger diameter renal nerve C fibers are responsible for the retention of fluid in heart failure. Relatively smaller diameter C fibers are responsible for vasoconstriction resulting in the reduction of renal blood flow in heart failure.
  • FIG. 7 illustrates a simplified cross-section of the renal nerve trunk 601. Trunk 601 consists of a number of individual fibers. The stimulation electrode cuff 603 envelops the nerve trunk. Larger C type fiber 705 exemplifies fibers responsible for diuresis. There are also other fibers 702 that can be for example afferent fibers. Traffic along these fibers can be blocked by the application of lower blocking voltage or lower dose of anesthetic drug. The resulting effect will be diuresis of the CHF patient (secretion of sodium and water by the kidney) and the relief of fluid overload. Smaller C fiber 704 is responsible for the regulation of renal blood flow.
  • In clinical practice, it may be desired to modulate or block selectively or preferably the larger fibers 705. This can be achieved with lower levels of stimulation. The patient can be relieved of access fluid without significantly increasing renal blood flow since traffic in smaller C fibers will not be altered. Renal blood flow can amount to as much as 20% of cardiac output. In a CHF patient with a weakened heart significant increase of renal blood flow can lead to a dangerous decrease of arterial pressure if the diseased heart fails to pump harder to keep up with an increased demand for oxygenated blood. The nerve stimulator or signal generator 306 therefore is capable of at least two levels of stimulation: first (lower) level to block or partially block signals propagating in larger C fibers that control diuresis, and second (higher) level to block signals propagating in smaller C fibers that control renal vascular resistance and blood flow to the kidney. The later method of nerve traffic modulation with higher electric current levels is useful in preventing damage to kidneys in acute clinical situations where the vasoconstriction can lead to the ischemia of a kidney, acute tubular necrosis (ATN), acute renal failure and sometimes permanent kidney damage. This type of clinical scenario is often associated with the acute heart failure when hypotension (low blood pressure) results from a severe decompensation of a chronic heart failure patient. Acute renal failure caused by low blood flow to the kidneys is the most costly complication in patients with heart failure.
  • Similar differentiated response to modulation could be elicited by applying different frequency of electric pulses (overpacing) to the renal nerve and keeping the applied voltage constant. DiBona noted that renal fibers responsible for rennin secretion responded to the lowest frequency of pulses (0.5 to 1 Hz), fibers responsible for sodium retention responded to middle range of frequencies (1 to 2 Hz) and fibers responsible for blood flow responded to the highest frequency of stimulation (2 to 5 Hz). This approach can be used when the renal nerve block is achieved by overpacing the renal nerve by applying rapid series of electric pulses to the electrodes with the intent to fatigue the nerve to the point when it stops conducting stimulation pulses.
  • One embodiment of the method of treating heart failure comprises the following steps:
      • A. Introducing one or more electrodes in the close proximity with the renal nerve,
      • B. Connecting the electrodes to an electric stimulator or generator with conductive leads or wires,
      • C. Initiating flow of electric current to the electrodes sufficient to block or reduce signal traffic in the sympathetic efferent renal nerve fibers with the intention of increasing diuresis, reducing renal secretion of renin and vasodilation of the blood vessels in the kidney to increase renal blood supply.
  • FIG. 8 shows an alternative embodiment of the invention. In this embodiment the natural efferent signal traffic 804 entering the renal nerve trunk 601 is completely blocked by the anodal block device stimulator 306 using a pair of electrodes 604 and 603. The third electrode (or pair of electrodes) 803 is situated downstream of the block. The electrode is used to stimulate or pace the kidney. Stimulation signal is transmitted from the generator 306 via the additional lead wire 805 to the electrode 803. The induced signal becomes the nerve input to the kidney. This way full control of nerve input is accomplished while the natural sympathetic tone is totally abolished.
  • FIG. 9 shows the transvenous embodiment of the invention using anodal blockade to modulate renal nerve traffic. Renal nerve 601 is located between the renal artery 901 and the renal vein 902. It follows the same direction towards the kidney. Renal artery can branch before entering the kidney but in the majority of humans there is only one renal artery. Stimulation catheter or lead 903 is introduced into the renal vein 902 and anchored to the wall of the vein using a securing device 904. The securing device can be a barb or a screw if the permanent placement of the lead 903 is desired. Electric field 904 is induced by the electric current applied by the positively charged anode 905 and cathode 906 catheter electrodes. Electrodes are connected to the stimulator (nor shown) by wires 907 and 908 that can be incorporated into the trunk of the lead 903. Electric field 904 is induced in the tissue surrounding the renal vein 902 and created the desired local polarization of the segment of the renal nerve trunk 601 situated in the close proximity of the catheter electrodes 905 and 907. Similarly catheters or leads can be designed that induce a cathodal block, a collision block or fatigue the nerve by rapidly pacing it using an induced field rather than by contacting the nerve directly.
  • FIG. 10 shows an embodiment where the stimulation lead is placed using laparoscopic surgery. This technology is common in modern surgery and uses a small video-camera and a few customized instruments to perform surgery with minimal tissue injury. The camera and instruments are inserted into the abdomen through small skin cuts allowing the surgeon to explore the whole cavity without the need of making large standard openings dividing skin and muscle.
  • After the cut is made in the umbilical area a special needle is inserted to start insufflation. A pressure regulated CO2 insufflator is connected to the needle. After satisfactory insuflation the needle is removed and a trocar is inserted through the previous small wound. This method reduces the recovery time due to its minimal tissue damage permitting the patient to return to normal activity in a shorter period of time. Although this type of procedure is known since the beginning of the 19th century, it was not until the advent of high resolution video camera that laparoscopic surgery became very popular among surgeons. Kidney surgery including removal of donor kidneys is routinely done using laparoscopic methodology. It should be easy for a skilled surgeon to place the lead 903 through a tunnel in tissue layers 1001 surrounding the renal nerve 601. This way lead electrodes 905 and 906 are placed in close proximity to the nerve and can be used to induce a block without major surgery.
  • FIG. 11 shows an implanted embodiment of the invention controlled by the patient from outside of the body. The implanted stimulation device 203 is an electric stimulation device to modulate the renal nerve signal but can be an implantable infusion pump capable of infusing a dose of an anesthetic drug on command. The implantable device 203 incorporates a magnetically activated switch such as a reed relay. The reed switch can be a single-pole, single-throw (SPST) type having normally open contacts and containing two reeds that can be magnetically actuated by an electromagnet, permanent magnet or combination of both. Such switch of extremely small size and low power requirements suitable for an implanted device is available from Coto Technology of Providence, R.I. in several configurations. Switch is normally open preventing electric or chemical blockade of the renal nerve 209. When the patient brings a magnet 1101 in close proximity to the body site where the device 202 is implanted the magnetic field 1103 acts on the magnetic switch 1102. Switch is closed and blocking of the renal nerve is activated. The resulting reduction of the sympathetic tone commands the kidney 208 to increase the production of urine. Patient can use the device when they feel the symptoms of fluid overload to remove access fluid from the body. The device 202 can be equipped with a timing circuit that is set by the external magnet. After the activation by the magnet the device can stay active (block renal nerve activity) for a predetermined duration of time to allow the kidney to make a desired amount of urine such as for an hour or several hours. Then the device will time out to avoid excessive fluid removal or adaptation of the renal nerve to the new condition.
  • FIG. 12 illustrates the progression of CRF to ESRD. Following the original injury to the kidney 1201 some nephrons 1202 are lost. Loss of nephrons lead to hyperfiltration 1203 and triggers compensatory mechanisms 1204 that are initially beneficial but over time make injury worse until the ESRD 1208 occurs. Compensatory mechanisms lead to elevated afferent and efferent sympathetic nerve signal level (increased signal traffic) 1207 to and from the kidney. It is the objective of this invention to block, reduce, modulate or otherwise decrease this level of stimulation.
  • The effect of the invented therapeutic intervention will be the reduction of central (coming from the brain) sympathetic stimulation 1206 to all organs and particularly blood vessels that causes vasoconstriction and elevation of blood pressure. Following that hypertension 1205 will be reduced therefore reducing continuous additional insult to the kidney and other organs.
  • FIG. 13 illustrates the physiologic mechanisms of CRF and hypertension. Injured kidney 1302 sends elevated afferent nerve 1306 signals to the brain 1301. Brain in response increases sympathetic efferent signals to the kidney 1307 and to blood vessels 1311 that increase vascular resistance 1303 by vasoconstriction. Vasoconstriction 1303 causes hypertension 1304. Kidney 1302 secretes renin 1310 that stimulates production of the vasoconstrictor hormone Angiotensin II 1305 that increases vasoconstriction of blood vessels 1303 and further increases hypertension 1304. Hypertension causes further mechanical damage 1312 to the kidney 1302 while sympathetically activated neurohormones 1307 and angiotensin II causes more subtle injury via the hormonal pathway 1310.
  • Invented therapy reduces or eliminates critical pathways of the progressive disease by blocking afferent 1306 and efferent 1307 signals to and from the kidney 1302. Both neurological 1311 and hormonal 1309 stimulus of vasoconstriction are therefore reduced resulting in the relief of hypertension 1304. As a result, over time the progression of renal disease is slowed down, kidney function is improved and the possibility of stroke from high blood pressure is reduced.
  • FIG. 14 shows a patient 201 suffering from CRF or renal hypertension treated in accordance with the invention. An implantable device 202 is implanted in the patient's body. An implantable device can be an electric nerve stimulator or a chemical substance (drug) infusion device. The implantable device 202 described above is equipped with the lead 204 connecting it to the renal nerve artery cuff 1401. Cuff 1401 envelopes the renal artery 203 that anatomically serves as a support structure for the renal nerve plexus. It is understood that there exist many varieties of electrode configurations such as wires, rings, needles, anchors, screws, cuffs and hooks that could all potentially be used to stimulate renal nerves. The cuff configuration 1401 illustrated by FIGS. 14, 15, 16 and 17 was selected for the preferred embodiment base on the information available to the inventors at the time of invention.
  • The lead conduit can be alternatively an electric wire or a catheter for delivery of medication or a combination of both. Renal nerve conducts efferent sympathetic stimulation from the sympathetic trunk 206 to the kidney 208. Sympathetic trunk is connected to the patient's spinal cord inside the spine 207. The lead to nerve connection can be located anywhere between the kidney 208 and the posterior renal or other renal ganglia (not shown) in the region of the 10th, 11th and 12th thoracic and 1st lumbar segments of the spine 207. The stimulation lead 204 and the arterial nerve cuff 1401, as selected for the preferred embodiment of the invention, can be placed using laparoscopic surgery.
  • FIG. 15 illustrates one possible embodiment of the renal nerve stimulation cuff electrode cuff. When the treated disease is CRF or hypertension it is the additional objective of this embodiment of the invention to selectively modulate nerve traffic in both afferent and efferent nerve fibers innervating the human kidney. Using existing selective modulation techniques it is possible to stimulate only afferent or efferent fibers. Different types of fibers have different structure and respond to different levels and frequency of stimulation. Anatomically renal nerve is difficult to locate in humans even during surgery. The autonomic nervous system forms a plexus on the external surface renal artery. Fibers contributing to the plexus arise from the celiac ganglion, the lowest splanchnic nerve, the aorticorenal ganglion and aortic plexus. The plexus is distributed with branches of the renal artery to vessels of the kidney, the glomeruli and tubules. The nerves from these sources, fifteen or twenty in number, have a few ganglia developed upon them. They accompany the branches of the renal artery into the kidney; some filaments are distributed to the spermatic plexus and, on the right side, to the inferior vena cava. This makes isolating a renal nerve difficult.
  • To overcome this anatomic limitation the preferred embodiment of the neurostimulation shown on FIG. 15 has an innovative stimulation cuff. The cuff 1401 envelopes the renal artery 203 and overlaps nerve fibers 1501 that form the renal plexus and look like a spider web. Cuff has at least two isolated electrodes 1402 and 1403 needed for nerve blocking. More electrodes can be used for selective patterns of stimulation and blocking. Electrodes are connected to the lead 204. Renal artery 203 connects aorta 213 to the kidney 208. It is subject to pulsations of pressure and therefore cyclically swells and contracts.
  • FIG. 16 further illustrates the design of the cuff 1401. Cuff envelopes the renal artery 203. Cuff is almost circumferential but has an opening 406. When the artery cyclically swells with blood pressure pulses, the cuff opens up without damaging the nerve or pinching the artery. Opening 406 also allows placement of the cuff around the artery. Similar designs of nerve cuffs known as “helical” cuffs are well known, see e.g., U.S. Pat. Nos. 5,251,634; 4,649,936 and 5,634,462.
  • FIG. 17 shows the crossection of the cuff 1401. Cuff 1401 is made out of dielectric material. Two electrodes 1402 and 1403 form rings to maximize the contact area with the wall of the artery 203.
  • Common to all the embodiments, is that an invasive device is used to decrease the level of renal nerve signals that are received by the kidney or generated by the kidney and received by the brain. The invention has been described in connection with the best mode now known to the applicant inventors. The invention is not to be limited to the disclosed embodiment. Rather, the invention covers all of various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
  • Heart failure, also called congestive heart failure (CHF) and chronic heart failure is a progressive heart disease characterized by low cardiac output, deterioration of heart muscle and fluid retention. Renal failure, also called chronic renal failure (CRF) is a progressive degenerative renal disease that is characterized by gradual loss of renal function that leads to the end stage renal disease (ESRD). ESRD requires dialysis for life. Hypertension is the chronic disease associated with high probability of stroke, renal failure and heart failure that is characterized by the abnormally high blood pressure.
  • A nerve in the context of this application means a separate nerve or a nerve bundle, nerve fiber, nerve plexus or nerve ganglion. Renal nerve is a part of the autonomic nervous system that forms a plexus on the external surface renal artery. Fibers contributing to the plexus arise from the celiac ganglion, the lowest splanchnic nerve, the aorticorenal ganglion and aortic plexus. The plexus is distributed with branches of the renal artery to blood vessels of the kidney, the glomeruli and tubules. The nerves from these sources, have a few ganglia developed upon them. They accompany the branches of the renal artery into the kidney; some filaments are distributed to the spermatic plexus and, on the right side, to the inferior vena cava.
  • Nerve stimulation, neurostimulation, nerve modulation and neuromodulation are equivalent and mean altering (reducing or increasing) naturally occurring level of electric signals propagating through the nerve. The electric signal in the nerve is also called nerve traffic, nerve tone or nerve stimulus.
  • Nerve block, blocking or blockade is a form of neuromodulation and means the reduction or total termination of the propagation or conduction of the electric signal along the selected nerve. Nerve block can be pharmacological (induced by a drug or other chemical substance) or an electric block by electrostimulation. Electric nerve block can be a hyperpolarization block, cathodal, anodal or collision block. Overpacing a nerve can also induce a block. Overpacing means stimulating the nerve with rapid electric pulses at a rate that exceeds the natural cycling rate of the nerve polarization and depolarization. As a result of overpacing the nerve gets fatigued, reserves of the immediately available neurotransmitter substance in the nerve become exhausted, and the nerve becomes temporarily unable to conduct signals. Nerve block by the means listed above can result in the reduction of the nerve signal, in particular the renal sympathetic efferent or afferent tone that determines the electric stimulus received or generated by the kidney. The technique of the controlled reduction of the nerve signal or traffic, which results in less organ stimulation, is called nerve signal modulation. Nerve modulation means that the individual nerve fibers fire with a reduced frequency or that fewer of the nerve fibers comprising the renal nerve are actively conducting or firing. The increase of nerve traffic or nerve activity usually involves recruitment of larger number of fibers in the nerve; alternatively less stimulation is associated with less active fibers. Denervation means blocking of the renal nerve conduction or the destruction of the renal nerve.
  • Lead is a medical device used to access the nerve designated for stimulation or blocking. It is usually a tubular device that is electrically insulated and includes multiple conductors or wires. Wires conduct stimulation or blocking signals from the stimulator to the designated nerve. Wires are terminated in electrodes. Electrodes are conductive terminals and can contact the nerve directly or contact the conductive tissue in the vicinity of the nerve. Electrodes can have different geometric configurations and can be made of different materials. The lead can include lumens or tubes for drug delivery to the nerve. A stimulator or an electrostimulator is an electric device used to generate electric signals that are conducted by the lead to the nerve. The stimulator can be implanted in the body or external. Electric signals can be a DC current, voltage, series of pulses or AC current or voltage. Electrodes can induce an electric field that affects the nerve and results in nerve blocking. Nerve cuff is a support structure that at least partially envelops the targeted nerve.
  • While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

Claims (53)

1-43. (canceled)
44. A method of treating cardio-renal disease, comprising:
positioning an electrode at least proximate to neural fibers that contribute to renal function of a patient; and
applying an electric field to the neural fibers via the electrode, thereby modulating at least one of urine production and blood pressure in the patient.
45. The method of claim 44 wherein positioning the electrode at least proximate to neural fibers that contribute to renal function of the patient further comprises positioning the electrode at least proximate a renal nerve of the patient between a kidney and spine of the patient.
46. The method of claim 44 wherein the electric field modulates sympathetic neural activity along at least a portion of the neural fibers.
47. The method of claim 44 wherein the electric field modulates efferent neural activity along at least a portion of the neural fibers.
48. The method of claim 44 wherein the electric field modulates afferent neural activity along at least a portion of the renal nerve.
49. The method of claim 44 wherein the electric field modulates efferent and afferent neural activity along at least a portion of the renal nerve.
50. The method of claim 44 wherein the electric field modulates renin in the patient.
51. The method of claim 44 wherein the electric field modulates vasoconstriction in the patient.
52. The method of claim 44 wherein the electrode further comprises an anode and a cathode.
53. The method of claim 52 further comprising placing the anode such that the anode is between a kidney of the patient and the cathode.
54. The method of claim 52 further comprising placing the anode and the electrode to create a cathodal nerve block.
55. The method of claim 44 further comprising placing the electrode in a renal vessel proximate to a renal nerve.
56. The method of claim 55 wherein the electrode further comprises an anode and a cathode, and wherein placing the electrode further comprises placing the anode and cathode in the renal vessel proximate to the renal nerve.
57. The method of claim 55 wherein the renal nerve has a longitudinal section, and wherein a portion of the electric field extends along the longitudinal section.
58. The method of claim 44 further comprising placing the electrode in tissue proximate to a renal nerve.
59. The method of claim 58 wherein the electrode further comprises an anode and a cathode, and wherein placing the electrode further comprises placing the anode and cathode in tissue proximate to the renal nerve.
60. The method of claim 58 wherein the renal nerve has a longitudinal section, and wherein a portion of the electric field extends along the longitudinal section.
61. The method of claim 44 wherein:
the neural fibers comprise a renal nerve having a longitudinal section; and
at least a portion of the electric field extends along the longitudinal section of the renal nerve.
62. The method of claim 44 wherein the electrode comprises an anode and a cathode, and wherein the method further comprise passing an electric current from the anode to the cathode to impede neural activity along the renal nerve.
63. The method of claim 44, further comprising sensing a physiological parameter.
64. The method of claim 63 wherein the physiological parameter is at least one of blood pressure, blood flow, and cardiac pulses.
65. The method of claim 63, further comprising modulating the electric field in response to the sensed physiological parameter.
66. The method of claim 44, wherein positioning the electrode comprises implanting the electrode in a vessel near a renal nerve of the patient by fixing the electrode to the vessel.
67. The method of claim 66, wherein implanting the electrode further comprises implanting an anode and a cathode in the vessel near the renal nerve of the patient by fixing the anode and cathode to the vessel.
68. The method of claim 44 wherein positioning the electrode comprises fixing the electrode in tissue near a renal nerve of the patient.
69. The method of claim 68 wherein fixing the electrode further comprises fixing an anode and a cathode in tissue near the renal nerve of the patient.
70. The method of claim 44 wherein positioning the electrode comprises inserting a catheter having the electrode into a vessel such that the electrode is proximate to a renal nerve of the patient.
71. The method of claim 70 wherein the electrode further comprises an anode and a cathode, and wherein inserting the catheter further comprises inserting the catheter into the vessel such that the anode and the cathode are proximate to the renal nerve of the patient.
72. The method of claim 70, further comprising:
terminating the electric field; and
removing the catheter from the patient after terminating the electric field.
73. The method of claim 44 wherein positioning the electrode comprises inserting a device having the electrode into tissue of the patient such that the electrode is adjacent to a renal nerve of the patient.
74. The method of claim 73 wherein the electrode further comprises an anode and a cathode, and wherein inserting the device further comprises inserting the device into tissue of the patient such that the anode and the cathode are adjacent to the renal nerve of the patient.
75. The method of claim 73, further comprising:
terminating the electric field; and
removing the device from the patient after terminating the electric field.
76. The method of claim 44, wherein the electric field is arranged relative to the renal nerve such that current in the electric field travels in a direction opposite to efferent signals in the renal nerve.
77. The method of claim 44, wherein the electric field is arranged relative to the renal nerve such that current in the electric field travels in a direction opposite to afferent signals in the nerve.
78. The method of claim 44, wherein the electric field is arranged relative to the renal nerve such that current in the electric field travels in a direction opposite to efferent and afferent signals in the nerve.
79. An apparatus for treating a patient, comprising:
an electrode configured to be percutaneously positioned in the patient so that the electrode is at least proximate to a renal nerve of the patient;
an energy generator operatively coupled to the electrode; and
a controller operatively coupled to the energy generator, wherein the controller is configured to generate an electric field via the energy generator and the electrode to modulate at least one of urine production and blood pressure in the patient.
80. The apparatus of claim 79 wherein the electrode is configured to be placed proximate to the renal nerve of the patient.
81. The apparatus of claim 80 wherein the electrode comprises first and second electrical contacts configured to be placed proximate to the renal nerve of the patient.
82. The apparatus of claim 79 wherein the electrode is configured to be placed in a renal vessel of the patient.
83. The apparatus of claim 79 wherein the electrode comprises first and second electrical contacts configured to be placed in the renal vessel of the patient and produce an elongated electric field having a longitudinal dimension extending along the renal vessel.
84. The apparatus of claim 79 wherein the electrode comprises first and second electrical contacts electrically coupled to the energy generator in a bipolar configuration.
85. The apparatus of claim 79 wherein the electrode comprises a first electrical contact, a second electrical contact, and a third electrical contact, and wherein the first and second electrical contacts are electrically coupled to deliver the electric field to a renal nerve of the patient.
86. The apparatus of claim 85 wherein the third electrical contact comprises a sensor for detecting a physiological parameter of the patient.
87. The apparatus of claim 86 wherein the physiological parameter is at least one of blood pressure, blood flow rate, and cardiac pulses, and wherein the energy generator further contains instructions configured to modulate the electric field according to the detected physiological parameter.
88. The apparatus of claim 85 wherein the third electrical contact is configured to deliver a pacing signal to the renal nerve of the patient.
89. The apparatus of claim 79, further comprising a sensor for detecting a physiological parameter of the patient, and wherein the instructions are configured to cause the controller to modulate the electric field according to the detected physiological parameter.
90. The apparatus of claim 79 wherein the instructions are configured to cause the controller to generate the electric field in a manner that impedes sympathetic neural activity along at least a portion of a renal nerve of the patient.
91. The apparatus of claim 79 wherein the instructions are configured to cause the controller to generate the electric field in a manner that impedes efferent neural activity along at least a portion of a renal nerve of the patient.
92. The apparatus of claim 79 wherein the instructions are configured to cause the controller to generate the electric field in a manner that impedes afferent neural activity along at least a portion of the renal nerve.
93. The apparatus of claim 79 wherein the instructions are configured to cause the controller to generate the electric field in a manner that impedes efferent and afferent neural activity along at least a portion of the renal nerve.
94. The apparatus of claim 79 wherein the instructions are configured to cause the controller to generate the electric field in a manner that modulates renin in the patient.
95. The apparatus of claim 79 wherein the instructions are configured to cause the controller to generate the electric field in a manner that modulates vasoconstriction in the patient.
US11/144,298 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients Abandoned US20050228460A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/144,298 US20050228460A1 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37019002P 2002-04-08 2002-04-08
US41557502P 2002-10-03 2002-10-03
US44297003P 2003-01-29 2003-01-29
US10/408,665 US7162303B2 (en) 2002-04-08 2003-04-08 Renal nerve stimulation method and apparatus for treatment of patients
US11/144,298 US20050228460A1 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/408,665 Continuation US7162303B2 (en) 2002-04-08 2003-04-08 Renal nerve stimulation method and apparatus for treatment of patients

Publications (1)

Publication Number Publication Date
US20050228460A1 true US20050228460A1 (en) 2005-10-13

Family

ID=40338859

Family Applications (18)

Application Number Title Priority Date Filing Date
US10/408,665 Active 2024-12-25 US7162303B2 (en) 2002-04-08 2003-04-08 Renal nerve stimulation method and apparatus for treatment of patients
US11/145,122 Active 2025-06-28 US8150518B2 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients
US11/144,173 Active 2025-05-30 US7647115B2 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients
US11/144,298 Abandoned US20050228460A1 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients
US11/688,178 Active 2025-12-28 US8131372B2 (en) 2002-04-08 2007-03-19 Renal nerve stimulation method for treatment of patients
US12/186,975 Abandoned US20090036948A1 (en) 2002-04-08 2008-08-06 Renal nerve stimulation methods for treatment of patients
US13/361,019 Abandoned US20120130345A1 (en) 2002-04-08 2012-01-30 Renal nerve stimulation method for treatment of patients
US13/617,994 Abandoned US20130013024A1 (en) 2002-04-08 2012-09-14 Renal Nerve Stimulation Method for Treatment of Patients
US13/861,178 Expired - Fee Related US8880186B2 (en) 2002-04-08 2013-04-11 Renal neuromodulation for treatment of patients with chronic heart failure
US14/086,607 Expired - Lifetime US8983595B2 (en) 2002-04-08 2013-11-21 Renal neuromodulation for treatment of patients with chronic heart failure
US14/549,071 Expired - Lifetime US9314630B2 (en) 2002-04-08 2014-11-20 Renal neuromodulation for treatment of patients
US14/846,480 Abandoned US20150374996A1 (en) 2002-04-08 2015-09-04 Implantable neural stimulation devices for reducing hypertension and associated methods
US15/069,636 Expired - Lifetime US9743983B2 (en) 2002-04-08 2016-03-14 Renal neuromodulation for treatment of patients
US15/073,387 Expired - Lifetime US9757192B2 (en) 2002-04-08 2016-03-17 Renal neuromodulation for treatment of patients
US15/095,220 Abandoned US20160325098A1 (en) 2002-04-08 2016-04-11 Renal Nerve Stimulation Method for Treatment of Patients
US15/476,867 Expired - Fee Related US9907611B2 (en) 2002-04-08 2017-03-31 Renal neuromodulation for treatment of patients
US15/878,746 Expired - Lifetime US10179028B2 (en) 2002-04-08 2018-01-24 Methods for treating patients via renal neuromodulation
US16/211,112 Abandoned US20190183568A1 (en) 2002-04-08 2018-12-05 Method for treating hypertensive patients via renal neuromodulation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/408,665 Active 2024-12-25 US7162303B2 (en) 2002-04-08 2003-04-08 Renal nerve stimulation method and apparatus for treatment of patients
US11/145,122 Active 2025-06-28 US8150518B2 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients
US11/144,173 Active 2025-05-30 US7647115B2 (en) 2002-04-08 2005-06-03 Renal nerve stimulation method and apparatus for treatment of patients

Family Applications After (14)

Application Number Title Priority Date Filing Date
US11/688,178 Active 2025-12-28 US8131372B2 (en) 2002-04-08 2007-03-19 Renal nerve stimulation method for treatment of patients
US12/186,975 Abandoned US20090036948A1 (en) 2002-04-08 2008-08-06 Renal nerve stimulation methods for treatment of patients
US13/361,019 Abandoned US20120130345A1 (en) 2002-04-08 2012-01-30 Renal nerve stimulation method for treatment of patients
US13/617,994 Abandoned US20130013024A1 (en) 2002-04-08 2012-09-14 Renal Nerve Stimulation Method for Treatment of Patients
US13/861,178 Expired - Fee Related US8880186B2 (en) 2002-04-08 2013-04-11 Renal neuromodulation for treatment of patients with chronic heart failure
US14/086,607 Expired - Lifetime US8983595B2 (en) 2002-04-08 2013-11-21 Renal neuromodulation for treatment of patients with chronic heart failure
US14/549,071 Expired - Lifetime US9314630B2 (en) 2002-04-08 2014-11-20 Renal neuromodulation for treatment of patients
US14/846,480 Abandoned US20150374996A1 (en) 2002-04-08 2015-09-04 Implantable neural stimulation devices for reducing hypertension and associated methods
US15/069,636 Expired - Lifetime US9743983B2 (en) 2002-04-08 2016-03-14 Renal neuromodulation for treatment of patients
US15/073,387 Expired - Lifetime US9757192B2 (en) 2002-04-08 2016-03-17 Renal neuromodulation for treatment of patients
US15/095,220 Abandoned US20160325098A1 (en) 2002-04-08 2016-04-11 Renal Nerve Stimulation Method for Treatment of Patients
US15/476,867 Expired - Fee Related US9907611B2 (en) 2002-04-08 2017-03-31 Renal neuromodulation for treatment of patients
US15/878,746 Expired - Lifetime US10179028B2 (en) 2002-04-08 2018-01-24 Methods for treating patients via renal neuromodulation
US16/211,112 Abandoned US20190183568A1 (en) 2002-04-08 2018-12-05 Method for treating hypertensive patients via renal neuromodulation

Country Status (1)

Country Link
US (18) US7162303B2 (en)

Cited By (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070106337A1 (en) * 2005-11-10 2007-05-10 Electrocore, Inc. Methods And Apparatus For Treating Disorders Through Neurological And/Or Muscular Intervention
US20070112327A1 (en) * 2005-11-03 2007-05-17 Yun Anthony J Methods and compositions for treating a renal disease condition in a subject
US20070208382A1 (en) * 2006-03-03 2007-09-06 Yun Joonkyoo A Methods and compositions for treating a renal associated condition in a subject
US20070265687A1 (en) * 2002-04-08 2007-11-15 Ardian, Inc. Apparatuses for renal neuromodulation
US20080119907A1 (en) * 2006-11-22 2008-05-22 Cardiac Pacemakers, Inc. Renal function modulation via application of electrical energy stimulation
US20090036948A1 (en) * 2002-04-08 2009-02-05 Ardian, Inc. Renal nerve stimulation methods for treatment of patients
US20090076409A1 (en) * 2006-06-28 2009-03-19 Ardian, Inc. Methods and systems for thermally-induced renal neuromodulation
US20100010567A1 (en) * 2005-07-22 2010-01-14 The Foundry, Llc Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US7711430B2 (en) 2006-02-10 2010-05-04 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US7717948B2 (en) 2002-04-08 2010-05-18 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7725188B2 (en) 2006-02-10 2010-05-25 Electrocore Llc Electrical stimulation treatment of hypotension
US20100137860A1 (en) * 2002-04-08 2010-06-03 Ardian, Inc. Apparatus for performing a non-continuous circumferential treatment of a body lumen
US7747324B2 (en) 2005-11-10 2010-06-29 Electrocore Llc Electrical stimulation treatment of bronchial constriction
US20100168731A1 (en) * 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100168739A1 (en) * 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100179620A1 (en) * 2009-01-14 2010-07-15 Ramesh Wariar System and method for promoting diuresis and natriuresis by the application of electric fields to the kidney
US20100268307A1 (en) * 2002-04-08 2010-10-21 Ardian,Inc. Methods for intravascularly-induced neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US20110112400A1 (en) * 2009-11-06 2011-05-12 Ardian, Inc. High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation
US20110202098A1 (en) * 2002-04-08 2011-08-18 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20110200171A1 (en) * 2010-01-19 2011-08-18 Ardian, Inc. Methods and apparatus for renal neuromodulation via stereotactic radiotherapy
US20110208173A1 (en) * 2010-02-24 2011-08-25 Medtronic Vascular, Inc. Methods for Treating sleep apnea via renal Denervation
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8612022B1 (en) 2012-09-13 2013-12-17 Invatec S.P.A. Neuromodulation catheters and associated systems and methods
US8620423B2 (en) 2002-04-08 2013-12-31 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermal modulation of nerves contributing to renal function
US8626300B2 (en) 2002-04-08 2014-01-07 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US8725249B2 (en) 2008-12-09 2014-05-13 Nephera Ltd. Stimulation of the urinary system
US8728075B2 (en) 2010-04-26 2014-05-20 Medtronic Ardian Luxembourg S.A.R.L. Multi-directional deflectable catheter apparatuses, systems, and methods for renal neuromodulation
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US8771252B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US8805512B1 (en) 2011-08-30 2014-08-12 Valencia Technologies Corporation Implantable electroacupuncture device and method for reducing hypertension
US8808345B2 (en) 2008-12-31 2014-08-19 Medtronic Ardian Luxembourg S.A.R.L. Handle assemblies for intravascular treatment devices and associated systems and methods
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US8840537B2 (en) 2005-11-10 2014-09-23 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8880185B2 (en) 2010-06-11 2014-11-04 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US8888773B2 (en) 2012-05-11 2014-11-18 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8923970B2 (en) 2008-12-09 2014-12-30 Nephera Ltd. Stimulation of the urinary system
US8938297B2 (en) 2011-09-23 2015-01-20 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating cardiovascular disease
US8942816B2 (en) 2012-03-06 2015-01-27 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating dyslipidemia
US8939970B2 (en) 2004-09-10 2015-01-27 Vessix Vascular, Inc. Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US8942808B2 (en) 2012-03-12 2015-01-27 Valencia Technologies Corporation Stimulation paradigm to improve blood pressure dipping in an implantable electroacupuncture device
US8945107B2 (en) 2010-10-26 2015-02-03 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US8951296B2 (en) 2012-06-29 2015-02-10 Medtronic Ardian Luxembourg S.A.R.L. Devices and methods for photodynamically modulating neural function in a human
US8954143B2 (en) 2012-03-06 2015-02-10 Valencia Technologies Corporation Radial feed through packaging for an implantable electroacupuncture device
US8954165B2 (en) 2012-01-25 2015-02-10 Nevro Corporation Lead anchors and associated systems and methods
US8956352B2 (en) 2010-10-25 2015-02-17 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods
US8965511B2 (en) 2011-08-30 2015-02-24 Valencia Technologies Corporation Implantable electroacupuncture system and method for reducing hypertension
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US8996125B2 (en) 2011-09-23 2015-03-31 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating cardiovascular disease
US9017317B2 (en) 2012-12-06 2015-04-28 Medtronic Ardian Luxembourg S.A.R.L. Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9028472B2 (en) 2011-12-23 2015-05-12 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9044575B2 (en) 2012-10-22 2015-06-02 Medtronic Adrian Luxembourg S.a.r.l. Catheters with enhanced flexibility and associated devices, systems, and methods
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9060754B2 (en) 2010-10-26 2015-06-23 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9066845B2 (en) 2012-03-06 2015-06-30 Valencia Technologies Corporation Electrode configuration for an implantable electroacupuncture device
US9066720B2 (en) 2010-10-25 2015-06-30 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US9066726B2 (en) 2013-03-15 2015-06-30 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode apposition judgment using pressure elements
US9078801B2 (en) 2012-03-06 2015-07-14 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating erectile dysfunction
US9079000B2 (en) 2011-10-18 2015-07-14 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9084610B2 (en) 2010-10-21 2015-07-21 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses, systems, and methods for renal neuromodulation
US9089716B2 (en) 2012-03-12 2015-07-28 Valencia Technologies Corporation Circuits and methods for using a high impedance, thin, coin-cell type battery in an implantable electroacupuncture device
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9095321B2 (en) 2012-11-21 2015-08-04 Medtronic Ardian Luxembourg S.A.R.L. Cryotherapeutic devices having integral multi-helical balloons and methods of making the same
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9125666B2 (en) 2003-09-12 2015-09-08 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation of atherosclerotic material
US9125667B2 (en) 2004-09-10 2015-09-08 Vessix Vascular, Inc. System for inducing desirable temperature effects on body tissue
US9138578B2 (en) 2013-09-10 2015-09-22 Medtronic Ardian Luxembourg S.A.R.L. Endovascular catheters with tuned control members and associated systems and methods
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9155590B2 (en) 2010-03-03 2015-10-13 Medtronic Ablation Frontiers, Llc Variable-output radiofrequency ablation power supply
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
US9173696B2 (en) 2012-09-17 2015-11-03 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
US9173811B2 (en) 2011-09-29 2015-11-03 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating depression and similar mental conditions
US9179974B2 (en) 2013-03-15 2015-11-10 Medtronic Ardian Luxembourg S.A.R.L. Helical push wire electrode
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
US9192766B2 (en) 2011-12-02 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and devices for treatment of polycystic kidney disease
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US9192715B2 (en) 2002-04-08 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal nerve blocking
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9198828B2 (en) 2011-09-29 2015-12-01 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating depression, bipolar disorder and anxiety
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9241752B2 (en) 2012-04-27 2016-01-26 Medtronic Ardian Luxembourg S.A.R.L. Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods
US9265935B2 (en) 2013-06-28 2016-02-23 Nevro Corporation Neurological stimulation lead anchors and associated systems and methods
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9277955B2 (en) 2010-04-09 2016-03-08 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9297845B2 (en) 2013-03-15 2016-03-29 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9314399B2 (en) 2012-03-06 2016-04-19 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating dyslipidemia and obesity
US9327100B2 (en) 2008-11-14 2016-05-03 Vessix Vascular, Inc. Selective drug delivery in a lumen
US9327123B2 (en) 2011-11-07 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Endovascular nerve monitoring devices and associated systems and methods
US9327122B2 (en) 2002-04-08 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9326816B2 (en) 2013-08-30 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods
US9327134B2 (en) 2012-03-12 2016-05-03 Valencia Technologies Corporation Implantable electroacupuncture device and method
US9339332B2 (en) 2013-08-30 2016-05-17 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with nerve monitoring features for transmitting digital neural signals and associated systems and methods
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9364390B2 (en) 2012-03-06 2016-06-14 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating obesity
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9399115B2 (en) 2012-10-22 2016-07-26 Medtronic Ardian Luxembourg S.A.R.L. Catheters with enhanced flexibility and associated devices, systems, and methods
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9433786B2 (en) 2012-03-06 2016-09-06 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating Parkinson's disease and essential tremor
US9439726B2 (en) 2002-04-08 2016-09-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9486355B2 (en) 2005-05-03 2016-11-08 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US9510777B2 (en) 2012-03-08 2016-12-06 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US9579149B2 (en) 2014-03-13 2017-02-28 Medtronic Ardian Luxembourg S.A.R.L. Low profile catheter assemblies and associated systems and methods
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
US9616234B2 (en) 2002-05-03 2017-04-11 Trustees Of Boston University System and method for neuro-stimulation
US9629679B2 (en) 2002-04-08 2017-04-25 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal denervation
US9649156B2 (en) 2010-12-15 2017-05-16 Boston Scientific Scimed, Inc. Bipolar off-wall electrode device for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US9713483B2 (en) 1995-10-13 2017-07-25 Medtronic Vascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US9724512B2 (en) 2012-09-28 2017-08-08 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating parkinson's disease and essential tremor through application of stimului at or near an acupoint on the chorea line
US9744333B2 (en) 2012-10-19 2017-08-29 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems and methods
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9757196B2 (en) 2011-09-28 2017-09-12 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
US9808300B2 (en) 2006-05-02 2017-11-07 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US9827421B2 (en) 2012-03-12 2017-11-28 Valencia Technologies Corporation Methods and systems for treating a chronic low back pain condition using an implantable electroacupuncture device
US9827039B2 (en) 2013-03-15 2017-11-28 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9833283B2 (en) 2013-07-01 2017-12-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US9848950B2 (en) 2012-04-27 2017-12-26 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized disease treatment by ablation
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
US9883909B2 (en) 2012-03-08 2018-02-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
US9895194B2 (en) 2013-09-04 2018-02-20 Boston Scientific Scimed, Inc. Radio frequency (RF) balloon catheter having flushing and cooling capability
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US9919144B2 (en) 2011-04-08 2018-03-20 Medtronic Adrian Luxembourg S.a.r.l. Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
US9943365B2 (en) 2013-06-21 2018-04-17 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9943354B2 (en) 2012-04-27 2018-04-17 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized inhibition of inflammation by ablation
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9962223B2 (en) 2013-10-15 2018-05-08 Boston Scientific Scimed, Inc. Medical device balloon
US9974593B2 (en) 2012-03-08 2018-05-22 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the treatment of sexual dysfunction
US9974607B2 (en) 2006-10-18 2018-05-22 Vessix Vascular, Inc. Inducing desirable temperature effects on body tissue
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10004550B2 (en) 2010-08-05 2018-06-26 Medtronic Ardian Luxembourg S.A.R.L. Cryoablation apparatuses, systems, and methods for renal neuromodulation
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US10166069B2 (en) 2014-01-27 2019-01-01 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters having jacketed neuromodulation elements and related devices, systems, and methods
US10182865B2 (en) 2010-10-25 2019-01-22 Medtronic Ardian Luxembourg S.A.R.L. Microwave catheter apparatuses, systems, and methods for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10231784B2 (en) 2016-10-28 2019-03-19 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics
US10258791B2 (en) 2012-04-27 2019-04-16 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
US10292754B2 (en) 2010-11-17 2019-05-21 Medtronic Ardian Luxembourg S.A.R.L. Therapeutic renal neuromodulation for treating dyspnea and associated systems and methods
US10321946B2 (en) 2012-08-24 2019-06-18 Boston Scientific Scimed, Inc. Renal nerve modulation devices with weeping RF ablation balloons
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10342592B2 (en) 2012-03-07 2019-07-09 Medtronic Ardian Luxembourg S.A.R.L. Selective modulation of renal nerves
US10368775B2 (en) 2014-10-01 2019-08-06 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for evaluating neuromodulation therapy via hemodynamic responses
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US10413357B2 (en) 2013-07-11 2019-09-17 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US10433902B2 (en) 2013-10-23 2019-10-08 Medtronic Ardian Luxembourg S.A.R.L. Current control methods and systems
US10463424B2 (en) 2014-03-11 2019-11-05 Medtronic Ardian Luxembourg S.A.R.L. Catheters with independent radial-expansion members and associated devices, systems, and methods
US10492842B2 (en) 2014-03-07 2019-12-03 Medtronic Ardian Luxembourg S.A.R.L. Monitoring and controlling internally administered cryotherapy
US10543037B2 (en) 2013-03-15 2020-01-28 Medtronic Ardian Luxembourg S.A.R.L. Controlled neuromodulation systems and methods of use
US10548663B2 (en) 2013-05-18 2020-02-04 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices, systems, and methods
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10588682B2 (en) 2011-04-25 2020-03-17 Medtronic Ardian Luxembourg S.A.R.L. Apparatus and methods related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls
US10610292B2 (en) 2014-04-25 2020-04-07 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology
US10646713B2 (en) 2017-02-22 2020-05-12 Medtronic Ardian Luxembourg S.A.R.L. Systems, devices, and associated methods for treating patients via renal neuromodulation to reduce a risk of developing cognitive impairment
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
US10660703B2 (en) 2012-05-08 2020-05-26 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US10667736B2 (en) 2014-12-17 2020-06-02 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing sympathetic nervous system tone for neuromodulation therapy
US10695124B2 (en) 2013-07-22 2020-06-30 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US10709490B2 (en) 2014-05-07 2020-07-14 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods
US10722300B2 (en) 2013-08-22 2020-07-28 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
US10736692B2 (en) 2016-04-28 2020-08-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the treatment of cancer
US10736690B2 (en) 2014-04-24 2020-08-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters and associated systems and methods
US10737123B2 (en) 2012-03-08 2020-08-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the management of pain
US10835305B2 (en) 2012-10-10 2020-11-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
US10905490B2 (en) 2012-04-27 2021-02-02 Medtronic Ardian Luxembourg S.A.R.L. Cryotherapeutic devices for renal neuromodulation and associated systems and methods
US10945788B2 (en) 2017-07-05 2021-03-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating depression in patients via renal neuromodulation
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
US10952790B2 (en) 2013-09-13 2021-03-23 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US10959669B2 (en) 2018-01-24 2021-03-30 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing the efficacy of neuromodulation therapy
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US11013549B2 (en) 2012-03-08 2021-05-25 Medtronic Ardian Luxembourg S.A.R.L. Gastrointestinal neuromodulation and associated systems and methods
US11013554B2 (en) 2014-11-14 2021-05-25 Medtronic Ardian Lexembourg S.A.R.L. Catheter apparatuses for modulation of nerves in communication with pulmonary system and associated systems and methods
US11116564B2 (en) 2017-07-05 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating anxiety disorders in patients via renal neuromodulation
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
US11154712B2 (en) 2014-08-28 2021-10-26 Medtronic Ardian Luxembourg S.A.R.L. Methods for assessing efficacy of renal neuromodulation and associated systems and devices
US11154547B2 (en) 2016-06-29 2021-10-26 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
US11160982B2 (en) 2017-07-05 2021-11-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating post-traumatic stress disorder in patients via renal neuromodulation
US11202671B2 (en) 2014-01-06 2021-12-21 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US11213678B2 (en) 2013-09-09 2022-01-04 Medtronic Ardian Luxembourg S.A.R.L. Method of manufacturing a medical device for neuromodulation
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US11253189B2 (en) 2018-01-24 2022-02-22 Medtronic Ardian Luxembourg S.A.R.L. Systems, devices, and methods for evaluating neuromodulation therapy via detection of magnetic fields
US11304749B2 (en) 2017-11-17 2022-04-19 Medtronic Ardian Luxembourg S.A.R.L. Systems, devices, and associated methods for neuromodulation with enhanced nerve targeting
US11382513B2 (en) 2016-11-08 2022-07-12 Palo Alto Investors Methods and compositions for treating a condition in a subject
US11478298B2 (en) 2018-01-24 2022-10-25 Medtronic Ardian Luxembourg S.A.R.L. Controlled irrigation for neuromodulation systems and associated methods
US11633120B2 (en) 2018-09-04 2023-04-25 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing efficacy of renal neuromodulation therapy
US11707629B2 (en) 2009-05-28 2023-07-25 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US11723710B2 (en) 2016-11-17 2023-08-15 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US11813456B2 (en) 2015-11-30 2023-11-14 Palo Alto Investors LP Methods of enhancing homeostatic capacity in a subject by increasing homeostatic system component responsiveness, and devices for use in practicing the same
US11890393B2 (en) 2018-07-02 2024-02-06 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap
US11931096B2 (en) 2021-06-14 2024-03-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient

Families Citing this family (439)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US8016823B2 (en) 2003-01-18 2011-09-13 Tsunami Medtech, Llc Medical instrument and method of use
US6702811B2 (en) 1999-04-05 2004-03-09 Medtronic, Inc. Ablation catheter assembly with radially decreasing helix and method of use
AU2619301A (en) * 1999-10-25 2001-06-06 Therus Corporation Use of focused ultrasound for vascular sealing
US6626855B1 (en) * 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
US7565205B2 (en) * 2000-02-17 2009-07-21 Standen Ltd. Treating a tumor or the like with electric fields at different orientations
US6616624B1 (en) * 2000-10-30 2003-09-09 Cvrx, Inc. Systems and method for controlling renovascular perfusion
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US8974446B2 (en) 2001-10-11 2015-03-10 St. Jude Medical, Inc. Ultrasound ablation apparatus with discrete staggered ablation zones
US20130178829A1 (en) * 2001-10-23 2013-07-11 Autonomic Technologies, Inc. Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system
US8444636B2 (en) 2001-12-07 2013-05-21 Tsunami Medtech, Llc Medical instrument and method of use
JP2005515819A (en) * 2002-02-01 2005-06-02 ザ クリーブランド クリニック ファウンデイション A transmission device that stimulates the sympathetic nerve chain
US7702386B2 (en) * 2002-03-22 2010-04-20 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US8036745B2 (en) * 2004-06-10 2011-10-11 Bio Control Medical (B.C.M.) Ltd. Parasympathetic pacing therapy during and following a medical procedure, clinical trauma or pathology
US20040082859A1 (en) 2002-07-01 2004-04-29 Alan Schaer Method and apparatus employing ultrasound energy to treat body sphincters
US7189204B2 (en) 2002-12-04 2007-03-13 Cardiac Pacemakers, Inc. Sleep detection using an adjustable threshold
AU2004212004B2 (en) 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US7221979B2 (en) * 2003-04-30 2007-05-22 Medtronic, Inc. Methods and apparatus for the regulation of hormone release
US7738952B2 (en) * 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
US8002553B2 (en) 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
EP1670547B1 (en) 2003-08-18 2008-11-12 Cardiac Pacemakers, Inc. Patient monitoring system
US7887493B2 (en) * 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US8606356B2 (en) 2003-09-18 2013-12-10 Cardiac Pacemakers, Inc. Autonomic arousal detection system and method
US7418292B2 (en) * 2003-10-01 2008-08-26 Medtronic, Inc. Device and method for attenuating an immune response
US8579892B2 (en) 2003-10-07 2013-11-12 Tsunami Medtech, Llc Medical system and method of use
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US9020595B2 (en) 2003-12-24 2015-04-28 Cardiac Pacemakers, Inc. Baroreflex activation therapy with conditional shut off
US7509166B2 (en) * 2003-12-24 2009-03-24 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US7706884B2 (en) 2003-12-24 2010-04-27 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US8200331B2 (en) 2004-11-04 2012-06-12 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US20100016929A1 (en) * 2004-01-22 2010-01-21 Arthur Prochazka Method and system for controlled nerve ablation
WO2005070494A1 (en) * 2004-01-22 2005-08-04 Rehabtronics Inc. Method of routing electrical current to bodily tissues via implanted passive conductors
US7082331B1 (en) 2004-04-21 2006-07-25 Pacesetter, Inc. System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device
US7454250B1 (en) 2004-04-21 2008-11-18 Pacesetter, Inc. System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device
US7245971B2 (en) * 2004-04-21 2007-07-17 Pacesetter, Inc. System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device
EP1750799A2 (en) * 2004-05-04 2007-02-14 The Cleveland Clinic Foundation Methods of treating medical conditions by neuromodulation of the sympathetic nervous system
US7747323B2 (en) 2004-06-08 2010-06-29 Cardiac Pacemakers, Inc. Adaptive baroreflex stimulation therapy for disordered breathing
EP2583717B1 (en) * 2004-07-28 2019-02-20 Medtronic Ardian Luxembourg S.à.r.l. Methods and devices for renal nerve blocking
CA2575458C (en) * 2004-07-28 2015-06-02 Ardian, Inc. Methods and devices for renal nerve blocking
EP1804902A4 (en) * 2004-09-10 2008-04-16 Cleveland Clinic Foundation Intraluminal electrode assembly
EP1804905B1 (en) * 2004-10-05 2016-02-17 Medtronic Ardian Luxembourg S.à.r.l. Apparatus for renal neuromodulation
US9510930B2 (en) 2008-10-22 2016-12-06 Contego Medical, Llc Angioplasty device with embolic filter
US9707071B2 (en) 2004-11-24 2017-07-18 Contego Medical Llc Percutaneous transluminal angioplasty device with integral embolic filter
US20060116720A1 (en) * 2004-12-01 2006-06-01 Penny Knoblich Method and apparatus for improving renal function
US8219189B2 (en) * 2004-12-01 2012-07-10 Penny Knoblich Method and apparatus for improving renal function
CN101076290B (en) 2004-12-09 2011-11-23 铸造品股份有限公司 Aortic valve repair
US20070060954A1 (en) * 2005-02-25 2007-03-15 Tracy Cameron Method of using spinal cord stimulation to treat neurological disorders or conditions
US7660628B2 (en) 2005-03-23 2010-02-09 Cardiac Pacemakers, Inc. System to provide myocardial and neural stimulation
EP2438877B1 (en) 2005-03-28 2016-02-17 Vessix Vascular, Inc. Intraluminal electrical tissue characterization and tuned RF energy for selective treatment of atheroma and other target tissues
US7493161B2 (en) 2005-05-10 2009-02-17 Cardiac Pacemakers, Inc. System and method to deliver therapy in presence of another therapy
US7499748B2 (en) * 2005-04-11 2009-03-03 Cardiac Pacemakers, Inc. Transvascular neural stimulation device
US7881782B2 (en) * 2005-04-20 2011-02-01 Cardiac Pacemakers, Inc. Neural stimulation system to prevent simultaneous energy discharges
US7644714B2 (en) 2005-05-27 2010-01-12 Apnex Medical, Inc. Devices and methods for treating sleep disorders
US7584004B2 (en) * 2005-06-13 2009-09-01 Cardiac Pacemakers, Inc. Vascularly stabilized peripheral nerve cuff assembly
CA2608397A1 (en) 2005-06-28 2007-01-04 Bioness Development, Llc Improvements to an implant, system and method using implanted passive conductors for routing electrical current
JP2009500086A (en) 2005-07-01 2009-01-08 ハンセン メディカル,インク. Robotic guide catheter system
US20070194658A1 (en) * 2005-07-13 2007-08-23 Jimin Zhang Systems and methods for performing acoustic hemostasis of deep bleeding trauma in limbs
US7927284B2 (en) * 2005-09-16 2011-04-19 Cardiac Pacemakers, Inc. Quantifying hemodynamic response to drug therapy using implantable sensor
US20070073354A1 (en) * 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US20070213616A1 (en) * 2005-10-20 2007-09-13 Thomas Anderson Systems and methods for arteriotomy localization
US10406366B2 (en) * 2006-11-17 2019-09-10 Respicardia, Inc. Transvenous phrenic nerve stimulation system
EP2371416B1 (en) 2005-11-18 2018-08-22 Respicardia, Inc. System to modulate phrenic nerve to prevent sleep apnea
US7519253B2 (en) 2005-11-18 2009-04-14 Omni Sciences, Inc. Broadband or mid-infrared fiber light sources
US7570999B2 (en) 2005-12-20 2009-08-04 Cardiac Pacemakers, Inc. Implantable device for treating epilepsy and cardiac rhythm disorders
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
EP1981584B1 (en) * 2006-02-03 2015-05-13 Interventional Autonomics Corporation Intravascular device for neuromodulation
US20070225781A1 (en) * 2006-03-21 2007-09-27 Nidus Medical, Llc Apparatus and methods for altering temperature in a region within the body
US20080004673A1 (en) * 2006-04-03 2008-01-03 Cvrx, Inc. Implantable extravascular electrostimulation system having a resilient cuff
US8401650B2 (en) * 2008-04-10 2013-03-19 Electrocore Llc Methods and apparatus for electrical treatment using balloon and electrode
EP2021846B1 (en) 2006-05-19 2017-05-03 Koninklijke Philips N.V. Ablation device with optimized input power profile
US7647101B2 (en) * 2006-06-09 2010-01-12 Cardiac Pacemakers, Inc. Physical conditioning system, device and method
US20070299476A1 (en) * 2006-06-23 2007-12-27 Euljoon Park Sympathetic afferent activation for adjusting autonomic tone
US20080046054A1 (en) * 2006-06-23 2008-02-21 Cvrx, Inc. Implantable electrode assembly utilizing a belt mechanism for sutureless attachment
US7761168B2 (en) * 2006-07-13 2010-07-20 Yossi Gross Peltier unidirectional and selective nerve stimulation
US8135478B2 (en) * 2006-07-13 2012-03-13 Rainbow Medical Ltd Peltier unidirectional and selective nerve stimulation
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US7801604B2 (en) * 2006-08-29 2010-09-21 Cardiac Pacemakers, Inc. Controlled titration of neurostimulation therapy
US8457734B2 (en) 2006-08-29 2013-06-04 Cardiac Pacemakers, Inc. System and method for neural stimulation
WO2008048471A2 (en) 2006-10-13 2008-04-24 Apnex Medical, Inc. Obstructive sleep apnea treatment devices, systems and methods
US8855771B2 (en) 2011-01-28 2014-10-07 Cyberonics, Inc. Screening devices and methods for obstructive sleep apnea therapy
US9205262B2 (en) 2011-05-12 2015-12-08 Cyberonics, Inc. Devices and methods for sleep apnea treatment
US9744354B2 (en) 2008-12-31 2017-08-29 Cyberonics, Inc. Obstructive sleep apnea treatment devices, systems and methods
US9186511B2 (en) 2006-10-13 2015-11-17 Cyberonics, Inc. Obstructive sleep apnea treatment devices, systems and methods
US9913982B2 (en) 2011-01-28 2018-03-13 Cyberonics, Inc. Obstructive sleep apnea treatment devices, systems and methods
EP2094352A4 (en) 2006-12-06 2010-05-19 Cleveland Clinic Foundation Method and system for treating acute heart failure by neuromodulation
US7744618B2 (en) 2006-12-07 2010-06-29 Cardiac Pacemakers, Inc. Device and method for modulating renal function
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
EP2136863A2 (en) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
MX2009010000A (en) * 2007-03-19 2010-03-17 Insuline Medical Ltd Drug delivery device.
US20080243204A1 (en) * 2007-03-28 2008-10-02 University Of Florida Research Foundation, Inc. Variational parameter neurostimulation paradigm for treatment of neurologic disease
WO2008128070A2 (en) 2007-04-11 2008-10-23 The Cleveland Clinic Foundation Method and apparatus for renal neuromodulation
US8496653B2 (en) * 2007-04-23 2013-07-30 Boston Scientific Scimed, Inc. Thrombus removal
US8209033B2 (en) * 2007-05-14 2012-06-26 Cardiac Pacemakers, Inc. Method and apparatus for regulating blood volume using volume receptor stimulation
US8271080B2 (en) 2007-05-23 2012-09-18 Cardiac Pacemakers, Inc. Decongestive therapy titration for heart failure patients using implantable sensor
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
ATE556667T1 (en) 2007-08-23 2012-05-15 Aegea Medical Inc UTERUS THERAPY DEVICE
AU2015200960A1 (en) * 2007-10-11 2015-03-19 Milux Holding Sa System and method for thermal treatment of hypertension, hypotension or aneurysm
HUE057333T2 (en) * 2007-10-11 2022-05-28 Implantica Patent Ltd System for thermal treatment of hypertension, hypotension or aneurysm
US20090105799A1 (en) * 2007-10-23 2009-04-23 Flowmedica, Inc. Renal assessment systems and methods
US7986992B2 (en) * 2007-11-16 2011-07-26 Ruse Technologies, Llc Apparatus and method for treating atrial fibrillation and atrial tachycardia
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8170658B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US20090149799A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for chemical modulation of neural activity
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8170660B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8160695B2 (en) * 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US7949398B1 (en) * 2007-12-27 2011-05-24 Pacesetter, Inc. Acquiring nerve activity from carotid body and/or sinus
US7848816B1 (en) 2007-12-27 2010-12-07 Pacesetter, Inc. Acquiring nerve activity from carotid body and/or sinus
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
WO2009108810A2 (en) * 2008-02-26 2009-09-03 Ruse Technologies, Llc Apparatus and method for treating atrial fibrillation and atrial tachycardia
US7925352B2 (en) * 2008-03-27 2011-04-12 Synecor Llc System and method for transvascularly stimulating contents of the carotid sheath
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8721632B2 (en) 2008-09-09 2014-05-13 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US8713026B2 (en) * 2008-06-13 2014-04-29 Sandisk Technologies Inc. Method for playing digital media files with a digital media player using a plurality of playlists
US20090326602A1 (en) * 2008-06-27 2009-12-31 Arkady Glukhovsky Treatment of indications using electrical stimulation
US8768469B2 (en) 2008-08-08 2014-07-01 Enteromedics Inc. Systems for regulation of blood pressure and heart rate
WO2010019481A1 (en) 2008-08-11 2010-02-18 Conceptx Medical, Inc. Systems and methods for treating dyspnea, including via electrical afferent signal blocking
US8463376B2 (en) 2008-08-12 2013-06-11 Guy P. Curtis System and method for transvascular activation of cardiac nerves with automatic restart
US8408421B2 (en) * 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
CN102209497A (en) * 2008-09-22 2011-10-05 明诺医学股份有限公司 Inducing desirable temperature effects on body tissue using alternate energy sources
EP2331201B1 (en) 2008-10-01 2020-04-29 Inspire Medical Systems, Inc. System for treating sleep apnea transvenously
US20100114244A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Electrical renal autonomic blockade
US8386053B2 (en) * 2008-10-31 2013-02-26 Medtronic, Inc. Subclavian ansae stimulation
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
MX2011004817A (en) 2008-11-07 2011-07-28 Insuline Medical Ltd Device and method for drug delivery.
US7910193B2 (en) * 2008-11-10 2011-03-22 Mkp Structural Design Associates, Inc. Three-dimensional auxetic structures and applications thereof
JP5726084B2 (en) * 2008-11-11 2015-05-27 シファメド・ホールディングス・エルエルシー Thin electrode assembly
US9795442B2 (en) 2008-11-11 2017-10-24 Shifamed Holdings, Llc Ablation catheters
US20100125288A1 (en) * 2008-11-17 2010-05-20 G&L Consulting, Llc Method and apparatus for reducing renal blood pressure
EP3184045B1 (en) 2008-11-19 2023-12-06 Inspire Medical Systems, Inc. System treating sleep disordered breathing
WO2010067360A2 (en) 2008-12-09 2010-06-17 Nephera Ltd. Stimulation of the urinary system
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
EP2376011B1 (en) * 2009-01-09 2019-07-03 ReCor Medical, Inc. Apparatus for treatment of mitral valve insufficiency
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
WO2010088533A1 (en) * 2009-01-30 2010-08-05 Medtronic, Inc. Closed-loop neurostimulation to treat pulmonary edema
US11284931B2 (en) 2009-02-03 2022-03-29 Tsunami Medtech, Llc Medical systems and methods for ablating and absorbing tissue
US8480581B2 (en) * 2009-03-24 2013-07-09 Cardiac Pacemakers, Inc. Systems and methods for anemia detection, monitoring, and treatment
JP2012521864A (en) 2009-03-31 2012-09-20 インスパイア・メディカル・システムズ・インコーポレイテッド Percutaneous access method in a system for treating sleep-related abnormal breathing
BRPI1015460A2 (en) * 2009-04-22 2020-08-18 Mercator Medsystems, Inc. guanetidine for use in the treatment of hypertension and hypertension treatment system
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
US20100305664A1 (en) * 2009-06-01 2010-12-02 Wingeier Brett M Methods and Devices for Adrenal Stimulation
EP2445568B1 (en) * 2009-06-24 2020-09-23 Kalila Medical, Inc. Steerable medical delivery devices
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
US8517962B2 (en) * 2009-10-12 2013-08-27 Kona Medical, Inc. Energetic modulation of nerves
US8986231B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
US8295912B2 (en) 2009-10-12 2012-10-23 Kona Medical, Inc. Method and system to inhibit a function of a nerve traveling with an artery
BR112012008538A2 (en) * 2009-10-12 2016-04-05 Kona Medical Inc energy modulation of nerves
US20110118600A1 (en) * 2009-11-16 2011-05-19 Michael Gertner External Autonomic Modulation
US20160059044A1 (en) 2009-10-12 2016-03-03 Kona Medical, Inc. Energy delivery to intraparenchymal regions of the kidney to treat hypertension
US8469904B2 (en) 2009-10-12 2013-06-25 Kona Medical, Inc. Energetic modulation of nerves
US9119951B2 (en) 2009-10-12 2015-09-01 Kona Medical, Inc. Energetic modulation of nerves
US20110092880A1 (en) * 2009-10-12 2011-04-21 Michael Gertner Energetic modulation of nerves
US8986211B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
US9174065B2 (en) 2009-10-12 2015-11-03 Kona Medical, Inc. Energetic modulation of nerves
WO2011049716A1 (en) * 2009-10-19 2011-04-28 Cardiac Pacemakers, Inc. Cardiorenal electrical stimulation system
CN102596320B (en) 2009-10-30 2016-09-07 瑞蔻医药有限公司 Method and apparatus by percutaneous ultrasound ripple Renal denervation treatment hypertension
WO2011053772A1 (en) * 2009-10-30 2011-05-05 Sound Interventions, Inc. Method and apparatus for non-invasive treatment of hypertension through ultrasound renal denervation
US8900223B2 (en) * 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
WO2011060339A1 (en) 2009-11-13 2011-05-19 St. Jude Medical, Inc. Assembly of staggered ablation elements
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US8696698B2 (en) 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US9161801B2 (en) * 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
US20110264116A1 (en) * 2009-12-31 2011-10-27 Gordon Kocur Compressive Denervation Apparatus for Innervated Renal Vasculature
WO2011084863A2 (en) 2010-01-07 2011-07-14 Cheetah Omni, Llc Fiber lasers and mid-infrared light sources in methods and systems for selective biological tissue processing and spectroscopy
CN102892454B (en) 2010-01-26 2016-01-20 迈克尔·A·埃文斯 For the method for denervation, device and medicament
CA2793737A1 (en) 2010-03-24 2011-09-29 Shifamed Holdings, Llc Intravascular tissue disruption
JP5760079B2 (en) 2010-04-14 2015-08-05 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Device for delivering denervation therapy to the renal arteries
US8364272B2 (en) 2010-04-30 2013-01-29 Medtronic, Inc. Brain stimulation programming
US10086202B2 (en) 2010-05-11 2018-10-02 Cardiac Pacemakers, Inc. Patient control of therapy suspension
JP5774683B2 (en) 2010-05-11 2015-09-09 カーディアック ペースメイカーズ, インコーポレイテッド Implantable medical device with means to automatically recover from interrupted therapy
US9655677B2 (en) 2010-05-12 2017-05-23 Shifamed Holdings, Llc Ablation catheters including a balloon and electrodes
WO2011143468A2 (en) 2010-05-12 2011-11-17 Shifamed, Llc Low profile electrode assembly
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
WO2012027734A1 (en) * 2010-08-27 2012-03-01 G&L Consulting, Llc System and method for electric diuresis
WO2012149511A2 (en) 2011-04-28 2012-11-01 Synecor Llc Neuromodulation systems and methods for treating acute heart failure syndromes
US20120059211A1 (en) * 2010-09-03 2012-03-08 Ronald Weinstock Method of diagnosing and treatment of hypertension
CN103200893A (en) * 2010-09-07 2013-07-10 波士顿科学西美德公司 Self-powered ablation catheter for renal denervation
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
US9028417B2 (en) 2010-10-18 2015-05-12 CardioSonic Ltd. Ultrasound emission element
US8585601B2 (en) 2010-10-18 2013-11-19 CardioSonic Ltd. Ultrasound transducer
US9566456B2 (en) 2010-10-18 2017-02-14 CardioSonic Ltd. Ultrasound transceiver and cooling thereof
JP2013543423A (en) 2010-10-18 2013-12-05 カーディオソニック リミテッド Tissue treatment
ES2912362T3 (en) 2010-11-09 2022-05-25 Aegea Medical Inc Method of placement and apparatus for delivering steam to the uterus
AU2011329669B2 (en) * 2010-11-19 2016-07-28 Boston Scientific Scimed, Inc. Renal nerve detection and ablation apparatus and method
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US10016233B2 (en) 2010-12-06 2018-07-10 Biosense Webster (Israel) Ltd. Treatment of atrial fibrillation using high-frequency pacing and ablation of renal nerves
EP2658605B1 (en) 2010-12-28 2016-07-27 Cibiem, Inc. Endovascular carotid body ablation catheter for sympathetic rebalancing of patient
US9744349B2 (en) 2011-02-10 2017-08-29 Respicardia, Inc. Medical lead and implantation
EP2675525A1 (en) 2011-02-18 2013-12-25 ReCor Medical, Inc. Apparatus for effecting renal denervation using ultrasound
WO2012135224A1 (en) * 2011-03-27 2012-10-04 Medtronic Ardian Luxembourg Sarl Systems and methods for local drug delivery to kidneys
US8663190B2 (en) 2011-04-22 2014-03-04 Ablative Solutions, Inc. Expandable catheter system for peri-ostial injection and muscle and nerve fiber ablation
US9237925B2 (en) 2011-04-22 2016-01-19 Ablative Solutions, Inc. Expandable catheter system for peri-ostial injection and muscle and nerve fiber ablation
US9526572B2 (en) 2011-04-26 2016-12-27 Aperiam Medical, Inc. Method and device for treatment of hypertension and other maladies
WO2012151396A2 (en) 2011-05-03 2012-11-08 Shifamed Holdings, Llc Steerable delivery sheaths
US20120323233A1 (en) 2011-05-09 2012-12-20 Cyberheart, Inc. Renovascular treatment device, system, and method for radiosurgically alleviating hypertension
US20120290053A1 (en) * 2011-05-11 2012-11-15 St. Jude Medical, Inc. Renal nerve stimulation lead, delivery system, and method
US20120290024A1 (en) * 2011-05-11 2012-11-15 St. Jude Medical, Inc. Transvenous renal nerve modulation for treatment of hypertension, cardiovascular disorders, and chronic renal diseases
US8909316B2 (en) 2011-05-18 2014-12-09 St. Jude Medical, Cardiology Division, Inc. Apparatus and method of assessing transvascular denervation
WO2012170258A1 (en) * 2011-06-07 2012-12-13 Curtis Guy P System and method for transvascular activation of cardiac nerves with automatic restart
US9028470B2 (en) * 2011-06-17 2015-05-12 University Of Utah Research Foundation Image-guided renal nerve ablation
US20130072995A1 (en) 2011-07-11 2013-03-21 Terrance Ransbury Catheter system for acute neuromodulation
US9446240B2 (en) 2011-07-11 2016-09-20 Interventional Autonomics Corporation System and method for neuromodulation
EP2766086A4 (en) 2011-07-11 2015-09-30 Interventional Autonomics Corp System and method for neuromodulation
CN103987334A (en) 2011-07-12 2014-08-13 沃夫医药公司 Renal nerve denervation via the renal pelvis
EP2741813B1 (en) 2011-08-11 2022-03-09 Inspire Medical Systems, Inc. System for selecting a stimulation protocol based on sensed respiratory effort
US9056185B2 (en) 2011-08-24 2015-06-16 Ablative Solutions, Inc. Expandable catheter system for fluid injection into and deep to the wall of a blood vessel
US20130053792A1 (en) 2011-08-24 2013-02-28 Ablative Solutions, Inc. Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
US9278196B2 (en) 2011-08-24 2016-03-08 Ablative Solutions, Inc. Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
US8702619B2 (en) 2011-08-26 2014-04-22 Symap Holding Limited Mapping sympathetic nerve distribution for renal ablation and catheters for same
US9820811B2 (en) 2011-08-26 2017-11-21 Symap Medical (Suzhou), Ltd System and method for mapping the functional nerves innervating the wall of arteries, 3-D mapping and catheters for same
US9014821B2 (en) 2011-08-26 2015-04-21 Symap Holding Limited System and method for locating and identifying the functional nerves innervating the wall of arteries and catheters for same
US8934992B2 (en) 2011-09-01 2015-01-13 Inspire Medical Systems, Inc. Nerve cuff
US9089668B2 (en) 2011-09-28 2015-07-28 Surefire Medical, Inc. Flow directional infusion device
US9427579B2 (en) 2011-09-29 2016-08-30 Pacesetter, Inc. System and method for performing renal denervation verification
AU2012313968A1 (en) 2011-09-30 2014-05-01 Adi Mashiach Apparatus and method for extending implant life using a dual power scheme
CN104135960B (en) 2011-10-07 2017-06-06 埃杰亚医疗公司 A kind of uterine therapy device
CA2887597C (en) 2011-10-19 2018-01-09 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
KR102067583B1 (en) 2011-12-09 2020-01-17 메타벤션, 인크. Therapeutic neuromodulation of the hepatic system
US9649064B2 (en) 2012-01-26 2017-05-16 Autonomix Medical, Inc. Controlled sympathectomy and micro-ablation systems and methods
US10470684B2 (en) 2012-01-26 2019-11-12 Autonomix Medical, Inc. Controlled sympathectomy and micro-ablation systems and methods
WO2013116380A1 (en) 2012-01-30 2013-08-08 Vytronus, Inc. Tissue necrosis methods and apparatus
US9089341B2 (en) 2012-02-28 2015-07-28 Surefire Medical, Inc. Renal nerve neuromodulation device
AU2013202803C1 (en) * 2012-03-07 2016-06-23 Reshape Lifesciences, Inc. Devices for regulation of blood pressure and heart rate
WO2013134543A1 (en) * 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg Sarl Immune system neuromodulation and associated systems and methods
EP2822646B1 (en) 2012-03-09 2023-10-18 Mayo Foundation For Medical Education And Research Modulating afferent signals to treat medical conditions
US8934988B2 (en) 2012-03-16 2015-01-13 St. Jude Medical Ab Ablation stent with meander structure
EP2830522A4 (en) 2012-03-28 2016-03-30 Cibiem Inc Carotid body modulation planning and assessment
US9439598B2 (en) 2012-04-12 2016-09-13 NeuroMedic, Inc. Mapping and ablation of nerves within arteries and tissues
US8961550B2 (en) 2012-04-17 2015-02-24 Indian Wells Medical, Inc. Steerable endoluminal punch
US10357304B2 (en) 2012-04-18 2019-07-23 CardioSonic Ltd. Tissue treatment
US9113929B2 (en) 2012-04-19 2015-08-25 St. Jude Medical, Cardiology Division, Inc. Non-electric field renal denervation electrode
CN107693114A (en) 2012-04-24 2018-02-16 西比姆公司 The catheter in blood vessel and method extractd for carotid body
US20130289650A1 (en) * 2012-04-25 2013-10-31 Pacesetter, Inc. Neuromodulation for Hypertension Control
US20130296443A1 (en) * 2012-05-02 2013-11-07 Enigma Medical, Inc. System and method of trans-venous pre-aortic ganglion ablation
US20130331813A1 (en) * 2012-05-02 2013-12-12 Enigma Medical, Inc. System and method of trans-abdominal pre-aortic ganglion ablation
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
CA3158197A1 (en) 2012-05-29 2013-12-05 Autonomix Medical, Inc. Endoscopic sympathectomy systems and methods
US11357447B2 (en) 2012-05-31 2022-06-14 Sonivie Ltd. Method and/or apparatus for measuring renal denervation effectiveness
WO2013181660A1 (en) 2012-06-01 2013-12-05 Cibiem, Inc. Methods and devices for cryogenic carotid body ablation
US9398930B2 (en) 2012-06-01 2016-07-26 Cibiem, Inc. Percutaneous methods and devices for carotid body ablation
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2866669A4 (en) 2012-06-30 2016-04-20 Cibiem Inc Carotid body ablation via directed energy
US9955946B2 (en) 2014-03-12 2018-05-01 Cibiem, Inc. Carotid body ablation with a transvenous ultrasound imaging and ablation catheter
US9381063B2 (en) 2012-07-13 2016-07-05 Magnetecs Inc. Method and apparatus for magnetically guided catheter for renal denervation employing MOSFET sensor array
JP2014018508A (en) * 2012-07-20 2014-02-03 Tohoku Univ Automatic nerve control device and renal sympathetic nerve control device
US8682450B2 (en) 2012-07-31 2014-03-25 Pacesetter, Inc. Systems and methods for controlling neurostimulation of acupuncture sites using an implantable cardiac rhythm management device
US9849025B2 (en) 2012-09-07 2017-12-26 Yale University Brain cooling system
WO2014047355A1 (en) 2012-09-19 2014-03-27 Denervx LLC Cooled microwave denervation
US9526827B2 (en) 2012-10-29 2016-12-27 Ablative Solutions, Inc. Peri-vascular tissue ablation catheter with support structures
US10226278B2 (en) 2012-10-29 2019-03-12 Ablative Solutions, Inc. Method for painless renal denervation using a peri-vascular tissue ablation catheter with support structures
US8740849B1 (en) 2012-10-29 2014-06-03 Ablative Solutions, Inc. Peri-vascular tissue ablation catheter with support structures
US10945787B2 (en) 2012-10-29 2021-03-16 Ablative Solutions, Inc. Peri-vascular tissue ablation catheters
US10736656B2 (en) 2012-10-29 2020-08-11 Ablative Solutions Method for painless renal denervation using a peri-vascular tissue ablation catheter with support structures
US10881458B2 (en) 2012-10-29 2021-01-05 Ablative Solutions, Inc. Peri-vascular tissue ablation catheters
US9301795B2 (en) 2012-10-29 2016-04-05 Ablative Solutions, Inc. Transvascular catheter for extravascular delivery
US9554849B2 (en) 2012-10-29 2017-01-31 Ablative Solutions, Inc. Transvascular method of treating hypertension
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
CN104902836B (en) 2012-11-05 2017-08-08 毕达哥拉斯医疗有限公司 Controlled tissue melts
EP2931361B1 (en) 2012-12-14 2023-07-05 Case Western Reserve University Population based encoding of neural information
AU2014207265B2 (en) 2013-01-21 2017-04-20 Cala Health, Inc. Devices and methods for controlling tremor
CN109044528B (en) * 2013-01-31 2021-11-02 迪格玛医疗有限公司 Methods and systems for reducing neural activity in an organ of a subject
US20140228875A1 (en) 2013-02-08 2014-08-14 Nidus Medical, Llc Surgical device with integrated visualization and cauterization
US8880167B2 (en) * 2013-02-13 2014-11-04 Flint Hills Scientific, Llc Selective recruitment and activation of fiber types in nerves for the control of undesirable brain state changes
US9179997B2 (en) 2013-03-06 2015-11-10 St. Jude Medical, Cardiology Division, Inc. Thermochromic polyvinyl alcohol based hydrogel artery
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
WO2014143611A1 (en) * 2013-03-11 2014-09-18 Ohio State Innovation Foundation Systems for treating post-traumatic stress disorder
WO2014164435A1 (en) * 2013-03-11 2014-10-09 Ohio State Innovation Foundation Systems for treating anxiety and anxiety-associated disorders
US10716914B2 (en) 2013-03-12 2020-07-21 St. Jude Medical, Cardiology Division, Inc. Catheter system
EP2777741A3 (en) 2013-03-12 2015-01-21 St. Jude Medical, Cardiology Division, Inc. Catheter system
EP2777740A3 (en) 2013-03-12 2015-01-21 St. Jude Medical, Cardiology Division, Inc. Catheter system
US9510902B2 (en) 2013-03-13 2016-12-06 St. Jude Medical, Cardiology Division, Inc. Ablation catheters and systems including rotational monitoring means
WO2014159273A1 (en) 2013-03-14 2014-10-02 Recor Medical, Inc. Methods of plating or coating ultrasound transducers
CN106178294B (en) 2013-03-14 2018-11-20 瑞蔻医药有限公司 A kind of endovascular ablation system based on ultrasound
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US8876813B2 (en) 2013-03-14 2014-11-04 St. Jude Medical, Inc. Methods, systems, and apparatus for neural signal detection
US9131982B2 (en) 2013-03-14 2015-09-15 St. Jude Medical, Cardiology Division, Inc. Mediguide-enabled renal denervation system for ensuring wall contact and mapping lesion locations
WO2014150441A2 (en) 2013-03-15 2014-09-25 St. Jude Medical, Cardiology Division, Inc. Ablation system, methods, and controllers
US9974477B2 (en) 2013-03-15 2018-05-22 St. Jude Medical, Cardiology Division, Inc. Quantification of renal denervation via alterations in renal blood flow pre/post ablation
US9186212B2 (en) 2013-03-15 2015-11-17 St. Jude Medical, Cardiology Division, Inc. Feedback systems and methods utilizing two or more sites along denervation catheter
US9987070B2 (en) 2013-03-15 2018-06-05 St. Jude Medical, Cardiology Division, Inc. Ablation system, methods, and controllers
US9179973B2 (en) 2013-03-15 2015-11-10 St. Jude Medical, Cardiology Division, Inc. Feedback systems and methods for renal denervation utilizing balloon catheter
US10349824B2 (en) 2013-04-08 2019-07-16 Apama Medical, Inc. Tissue mapping and visualization systems
CN110141177B (en) 2013-04-08 2021-11-23 阿帕玛医疗公司 Ablation catheter
US10098694B2 (en) 2013-04-08 2018-10-16 Apama Medical, Inc. Tissue ablation and monitoring thereof
US10350002B2 (en) 2013-04-25 2019-07-16 St. Jude Medical, Cardiology Division, Inc. Electrode assembly for catheter system
US9731122B2 (en) 2013-04-29 2017-08-15 Rainbow Medical Ltd. Electroosmotic tissue treatment
US10010364B2 (en) 2013-05-02 2018-07-03 Halcyon Medical, Inc. Devices and methods for detection and treatment of the aorticorenal ganglion
WO2014188430A2 (en) 2013-05-23 2014-11-27 CardioSonic Ltd. Devices and methods for renal denervation and assessment thereof
US9872728B2 (en) 2013-06-28 2018-01-23 St. Jude Medical, Cardiology Division, Inc. Apparatuses and methods for affixing electrodes to an intravascular balloon
US20150011991A1 (en) 2013-07-03 2015-01-08 St. Jude Medical, Cardiology Division, Inc. Electrode Assembly For Catheter System
US20150031946A1 (en) 2013-07-24 2015-01-29 Nidus Medical, Llc Direct vision cryosurgical probe and methods of use
EP3030167A4 (en) 2013-08-07 2017-03-22 Cibiem, Inc. Carotid body ablation via directed energy
US9687288B2 (en) 2013-09-30 2017-06-27 Arrinex, Inc. Apparatus and methods for treating rhinitis
US10183165B2 (en) 2013-10-09 2019-01-22 GiMer Medical Co., Ltd. Method of reducing renal hypertension and computer-readable medium
US10639476B2 (en) 2013-10-09 2020-05-05 GiMer Medical Co., Ltd. Electronic stimulation device, method of treatment and electronic stimulation system
US10632310B2 (en) 2013-10-09 2020-04-28 GiMer Medical Co., Ltd. Electronic stimulation device, method of treatment and electronic stimulation system
USD774043S1 (en) 2013-10-23 2016-12-13 St. Jude Medical, Cardiology Division, Inc. Display screen with graphical user interface for ablation generator
USD914883S1 (en) 2013-10-23 2021-03-30 St. Jude Medical, Cardiology Division, Inc. Ablation generator
USD747491S1 (en) 2013-10-23 2016-01-12 St. Jude Medical, Cardiology Division, Inc. Ablation generator
US10856936B2 (en) 2013-10-23 2020-12-08 St. Jude Medical, Cardiology Division, Inc. Electrode assembly for catheter system including thermoplastic-based struts
US10034705B2 (en) 2013-10-24 2018-07-31 St. Jude Medical, Cardiology Division, Inc. High strength electrode assembly for catheter system including novel electrode
WO2015061052A1 (en) 2013-10-24 2015-04-30 St. Jude Medical, Cardiology Division, Inc. Flexible catheter shaft and method of manufacture
WO2015061034A1 (en) 2013-10-24 2015-04-30 St. Jude Medical, Cardiology Division, Inc. Flexible catheter shaft and method of manufacture
US10390881B2 (en) 2013-10-25 2019-08-27 Denervx LLC Cooled microwave denervation catheter with insertion feature
US9931046B2 (en) 2013-10-25 2018-04-03 Ablative Solutions, Inc. Intravascular catheter with peri-vascular nerve activity sensors
US10517666B2 (en) 2013-10-25 2019-12-31 Ablative Solutions, Inc. Apparatus for effective ablation and nerve sensing associated with denervation
US9949652B2 (en) 2013-10-25 2018-04-24 Ablative Solutions, Inc. Apparatus for effective ablation and nerve sensing associated with denervation
EP3062722B1 (en) 2013-10-28 2019-03-20 St. Jude Medical, Cardiology Division, Inc. Electrode assembly for catheter system including interlinked struts
US9861433B2 (en) 2013-11-05 2018-01-09 St. Jude Medical, Cardiology Division, Inc. Helical-shaped ablation catheter and methods of use
EA201691073A1 (en) 2013-12-05 2016-12-30 РФЕМБ ХОЛДИНГС, ЭлЭлСи CANCER IMMUNOTHERAPY USING RADIO-FREQUENCY ELECTRICAL BREAKDOWN MEMBRANE (RF-EMB)
US10286190B2 (en) 2013-12-11 2019-05-14 Cook Medical Technologies Llc Balloon catheter with dynamic vessel engaging member
US9511228B2 (en) * 2014-01-14 2016-12-06 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation
US20150209107A1 (en) 2014-01-24 2015-07-30 Denervx LLC Cooled microwave denervation catheter configuration
EP3104768B1 (en) 2014-02-11 2023-07-26 Cyberonics, Inc. Systems for detecting and treating obstructive sleep apnea
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9889031B1 (en) 2014-03-25 2018-02-13 Surefire Medical, Inc. Method of gastric artery embolization
US20170112564A1 (en) * 2014-04-01 2017-04-27 Mayo Foundation For Medical Education And Research Methods and materials for treating hypertension
US20170065327A1 (en) * 2014-04-01 2017-03-09 Mayo Foundation For Medical Education And Research Methods and materials for treating elevated sympathetic nerve activity conditions
WO2015159296A1 (en) 2014-04-17 2015-10-22 Digma Medical Ltd. Methods and systems for blocking neural activity in an organ of a subject, preferably in the small intestine or the duodenum
EP2937053A1 (en) 2014-04-24 2015-10-28 St. Jude Medical, Cardiology Division, Inc. Ablation systems including pulse rate detector and feedback mechanism and methods of use
US10478249B2 (en) 2014-05-07 2019-11-19 Pythagoras Medical Ltd. Controlled tissue ablation techniques
WO2015179666A1 (en) 2014-05-22 2015-11-26 Aegea Medical Inc. Systems and methods for performing endometrial ablation
US10179019B2 (en) 2014-05-22 2019-01-15 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
CA2946791C (en) 2014-05-22 2023-09-19 CARDIONOMIC, Inc. Catheter and catheter system for electrical neuromodulation
CN114768093A (en) 2014-06-02 2022-07-22 卡拉健康公司 Systems and methods for peripheral nerve stimulation to treat tremor
US9763743B2 (en) 2014-07-25 2017-09-19 Arrinex, Inc. Apparatus and method for treating rhinitis
AU2015315658B2 (en) 2014-09-08 2019-05-23 CARDIONOMIC, Inc. Catheter and electrode systems for electrical neuromodulation
EP3194017A1 (en) 2014-09-08 2017-07-26 Cardionomic, Inc. Methods for electrical neuromodulation of the heart
US10925579B2 (en) 2014-11-05 2021-02-23 Otsuka Medical Devices Co., Ltd. Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery
EP3610917A1 (en) 2015-01-05 2020-02-19 Cardionomic, Inc. Cardiac modulation facilitation methods and systems
US10292805B2 (en) 2015-01-23 2019-05-21 Contego Medical, Llc Interventional device having an integrated embolic filter and associated methods
WO2016123608A2 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
CN113908438A (en) 2015-03-19 2022-01-11 启迪医疗仪器公司 Stimulation for treating sleep disordered breathing
WO2016160694A1 (en) 2015-03-27 2016-10-06 Shifamed Holdings, Llc Steerable medical devices, systems, and methods of use
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
EP3285849A4 (en) 2015-04-24 2018-12-26 Shifamed Holdings, LLC Steerable medical devices, systems, and methods of use
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
CN112914514A (en) 2015-06-10 2021-06-08 卡拉健康公司 System and method for peripheral nerve stimulation to treat tremor with a detachable treatment and monitoring unit
US9616221B2 (en) 2015-07-08 2017-04-11 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
US11547480B2 (en) * 2015-07-21 2023-01-10 Koninklijke Philips N.V. System for stimulating renal nerves
WO2017053847A1 (en) 2015-09-23 2017-03-30 Cala Health, Inc. Systems and methods for peripheral nerve stimulation in the finger or hand to treat hand tremors
US10207110B1 (en) 2015-10-13 2019-02-19 Axon Therapies, Inc. Devices and methods for treatment of heart failure via electrical modulation of a splanchnic nerve
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US9724515B2 (en) 2015-10-29 2017-08-08 Rainbow Medical Ltd. Electrical substance clearance from the brain for treatment of Alzheimer's disease
US10898716B2 (en) 2015-10-29 2021-01-26 Rainbow Medical Ltd. Electrical substance clearance from the brain
WO2017083257A1 (en) 2015-11-09 2017-05-18 Shifamed Holdings, Llc Steering assemblies for medical devices, and methods of use
WO2017087549A1 (en) 2015-11-16 2017-05-26 Apama Medical, Inc. Energy delivery devices
US9950156B2 (en) 2016-09-13 2018-04-24 Rainbow Medical Ltd. Disc therapy
US9770591B2 (en) 2015-12-29 2017-09-26 Rainbow Medical Ltd. Disc therapy
US11484706B2 (en) 2015-12-29 2022-11-01 Discure Technologies Ltd Disc therapy
US10518085B2 (en) 2015-12-29 2019-12-31 Rainbow Medical Ltd. Disc therapy
US11612426B2 (en) 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
IL286747B1 (en) 2016-01-21 2024-01-01 Cala Health Inc Wearable device for treating urinary symptoms
JP7125349B2 (en) 2016-02-11 2022-08-24 アリネックス, インコーポレイテッド Method and device for image-guided posterior nasal nerve ablation
CN114983553A (en) 2016-02-19 2022-09-02 埃杰亚医疗公司 Method and apparatus for determining the integrity of a body cavity
CN109310863A (en) 2016-03-09 2019-02-05 卡迪诺米克公司 Cardiac contractility neural stimulation system and method
US10420939B2 (en) 2016-03-31 2019-09-24 The Cleveland Clinic Foundation Nerve stimulation to promote neuroregeneration
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
US10524859B2 (en) 2016-06-07 2020-01-07 Metavention, Inc. Therapeutic tissue modulation devices and methods
CN109600988B (en) 2016-06-15 2021-08-31 阿里内克斯股份有限公司 Device and method for treating the outer surface of the nasal cavity
WO2017223264A1 (en) 2016-06-23 2017-12-28 St. Jude Medical, Cardiology Division, Inc. Catheter system and electrode assembly for intraprocedural evaluation of renal denervation
CN109689151A (en) 2016-07-08 2019-04-26 卡拉健康公司 With lucky N number of electrode and the system and method for improving the dry N number of nerve of electrode stimulating
US11154354B2 (en) 2016-07-29 2021-10-26 Axon Therapies, Inc. Devices, systems, and methods for treatment of heart failure by splanchnic nerve ablation
CN110139688B (en) 2016-08-14 2022-03-18 迪格玛医疗有限公司 Device and method for nerve ablation in the wall of the gastrointestinal tract
US10575904B1 (en) 2016-08-14 2020-03-03 Digma Medical Ltd. Apparatus and method for selective submucosal ablation
US10583286B2 (en) 2016-08-23 2020-03-10 Boston Scientific Neuromodulation Corporation Methods and devices for neuromodulation of the adrenal gland
US10441788B2 (en) * 2016-08-23 2019-10-15 Boston Scientific Neuromodulation Corporation Methods and devices for neuromodulation of the adrenal gland
CA3033662A1 (en) * 2016-08-25 2018-03-01 Cala Health, Inc. Systems and methods for treating cardiac dysfunction through peripheral nerve stimulation
US11400263B1 (en) 2016-09-19 2022-08-02 Trisalus Life Sciences, Inc. System and method for selective pressure-controlled therapeutic delivery
US10780250B1 (en) 2016-09-19 2020-09-22 Surefire Medical, Inc. System and method for selective pressure-controlled therapeutic delivery
US11253312B2 (en) 2016-10-17 2022-02-22 Arrinex, Inc. Integrated nasal nerve detector ablation-apparatus, nasal nerve locator, and methods of use
US10806942B2 (en) 2016-11-10 2020-10-20 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues
AU2017254920B2 (en) * 2016-11-10 2019-04-04 Gimer Medical Co. Ltd. Method of reducing renal hypertension and computer-readable medium
EP3538208A1 (en) * 2016-11-14 2019-09-18 Boston Scientific Neuromodulation Corporation System for controlling spinal cord stimulation to treat hypertension
US10569086B2 (en) 2017-01-11 2020-02-25 Rainbow Medical Ltd. Electrical microglial cell activation
EP3582850A4 (en) 2017-02-17 2021-01-06 The University of British Columbia Apparatus and methods for maintaining physiological functions
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US20200094080A1 (en) 2017-03-20 2020-03-26 Sonivie Ltd. Method for treating heart failure by improving ejection fraction of a patient
US11331480B2 (en) 2017-04-03 2022-05-17 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
JP7300999B2 (en) 2017-04-28 2023-06-30 アリネックス, インコーポレイテッド Systems and methods for locating blood vessels in the treatment of rhinitis
US10758722B2 (en) 2017-05-03 2020-09-01 Rainbow Medical Ltd. Electrical treatment of Parkinson's disease
EP3974021B1 (en) 2017-06-30 2023-06-14 ONWARD Medical N.V. A system for neuromodulation
JP7162050B2 (en) 2017-08-11 2022-10-27 インスパイア・メディカル・システムズ・インコーポレイテッド cuff electrode
CN109420252B (en) * 2017-08-22 2023-10-31 精能医学股份有限公司 Electrical stimulation apparatus, method of generating electrical signal, and computer-readable storage medium
WO2019055434A1 (en) 2017-09-13 2019-03-21 CARDIONOMIC, Inc. Neurostimulation systems and methods for affecting cardiac contractility
CN107890568A (en) * 2017-10-31 2018-04-10 华仁药业股份有限公司 The hemofiltration replacement liquid and its preparation technology of a kind of less harmful
US11166676B2 (en) * 2017-12-11 2021-11-09 Marina I. Adrianzen Fonseca Real-time kidney monitoring medical device
US10561461B2 (en) 2017-12-17 2020-02-18 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
US11857778B2 (en) 2018-01-17 2024-01-02 Cala Health, Inc. Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation
US11751939B2 (en) 2018-01-26 2023-09-12 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
EP3765141A1 (en) 2018-03-14 2021-01-20 Rainbow Medical Ltd. Electrical substance clearance from the brain
EP3758793A4 (en) 2018-03-29 2021-12-08 Nevro Corp. Leads having sidewall openings, and associated systems and methods
JP2021528151A (en) * 2018-06-19 2021-10-21 サーマキル,インコーポレイテッド Systems and methods for thermal blockade of nerves
US10849685B2 (en) 2018-07-18 2020-12-01 Ablative Solutions, Inc. Peri-vascular tissue access catheter with locking handle
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
CA3107959A1 (en) 2018-08-13 2020-02-20 CARDIONOMIC, Inc. Systems and methods for affecting cardiac contractility and/or relaxation
WO2020070727A2 (en) 2018-10-06 2020-04-09 Symap Medical (Suzhou), Limited System and method for mapping the functional nerves innervating the wall of arteries, 3-d mapping and catheters for same
US11338117B2 (en) 2018-10-08 2022-05-24 Trisalus Life Sciences, Inc. Implantable dual pathway therapeutic agent delivery port
US10675477B2 (en) 2018-10-26 2020-06-09 Ruse Technologies, Llc Implantable cardioverter defibrillators using high power amplifiers with impedance tracking lowpass filters
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
EP3653260A1 (en) 2018-11-13 2020-05-20 GTX medical B.V. Sensor in clothing of limbs or footwear
EP3897818A1 (en) * 2018-12-20 2021-10-27 Galvani Bioelectronics Limited Nerve stimulation system
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
JP2022531658A (en) 2019-05-06 2022-07-08 カーディオノミック,インク. Systems and methods for noise reduction of physiological signals during electrical neural regulation
EP4241836A3 (en) 2019-06-20 2023-11-29 Axon Therapies, Inc. Devices for endovascular ablation of a splanchnic nerve
US11065461B2 (en) 2019-07-08 2021-07-20 Bioness Inc. Implantable power adapter
US11123197B2 (en) 2019-09-03 2021-09-21 Rainbow Medical Ltd. Hydropneumatic artificial intervertebral disc
US10881858B1 (en) 2019-09-18 2021-01-05 Rainbow Medical Ltd. Electrical substance clearance from the brain
US11890468B1 (en) 2019-10-03 2024-02-06 Cala Health, Inc. Neurostimulation systems with event pattern detection and classification
DE19211698T1 (en) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
RU2728093C1 (en) * 2019-12-31 2020-07-28 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method for predicting the effectiveness of nephroprotection in selecting the patients with resistant arterial hypertension associated with type 2 diabetes mellitus for the sympathetic renal denervation of renal arteries
US11413090B2 (en) 2020-01-17 2022-08-16 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
CN112494159B (en) * 2020-11-27 2022-02-11 广州通泽医疗科技有限公司 Electric signal transmission device for preventing electrode from falling off
TWI777339B (en) * 2020-12-28 2022-09-11 財團法人工業技術研究院 Electrical stimulation device and method
US11298530B1 (en) 2021-05-03 2022-04-12 Discure Technologies Ltd. Synergistic therapies for intervertebral disc degeneration
EP4108197A1 (en) 2021-06-24 2022-12-28 Gradient Denervation Technologies Systems for treating tissue
RU2767134C1 (en) * 2021-06-30 2022-03-16 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Method for predicting the long-term antihypertensive efficacy of renal denervation in patients with resistant arterial hypertension
US11344721B1 (en) 2021-08-16 2022-05-31 Rainbow Medical Ltd. Cartilage treatment
WO2023031053A1 (en) * 2021-08-30 2023-03-09 Implantica Patent Ltd Treatment of hypertension
US11413455B1 (en) 2022-02-08 2022-08-16 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
CN114469310B (en) * 2022-03-25 2022-07-29 天津市鹰泰利安康医疗科技有限责任公司 Electrode control system for irreversible electroporation equipment

Citations (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276996A (en) * 1940-11-30 1942-03-17 A J Ginsberg Non-radio-interfering therapeutic apparatus
US2276995A (en) * 1938-01-22 1942-03-17 A J Ginsberg Electrotherapy
US3127895A (en) * 1962-07-02 1964-04-07 Dynapower System Corp Therapeutic pulse generation and control circuit
US3563246A (en) * 1967-04-24 1971-02-16 Intelectron Corp Method and apparatus for improving neural performance in human subjects by electrotherapy
US3650277A (en) * 1969-02-24 1972-03-21 Lkb Medical Ab Apparatus for influencing the systemic blood pressure in a patient by carotid sinus nerve stimulation
US3794022A (en) * 1972-06-30 1974-02-26 E Nawracaj Dual oscillator, variable pulse duration electrotherapeutic device
US3800802A (en) * 1972-01-07 1974-04-02 Int Medical Electronics Ltd Short-wave therapy apparatus
US3803463A (en) * 1972-07-10 1974-04-09 J Cover Weapon for immobilization and capture
US3952751A (en) * 1975-01-08 1976-04-27 W. Denis Kendall High-performance electrotherapeutic apparatus
US4011861A (en) * 1974-04-03 1977-03-15 Case Western Reserve University Implantable electric terminal for organic tissue
US4071033A (en) * 1976-12-20 1978-01-31 Nawracaj Edward P Electrotherapeutic device with modulated dual signals
US4141365A (en) * 1977-02-24 1979-02-27 The Johns Hopkins University Epidural lead electrode and insertion needle
US4315503A (en) * 1976-11-17 1982-02-16 Electro-Biology, Inc. Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment
US4379462A (en) * 1980-10-29 1983-04-12 Neuromed, Inc. Multi-electrode catheter assembly for spinal cord stimulation
US4649936A (en) * 1984-10-11 1987-03-17 Case Western Reserve University Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking
US4816016A (en) * 1984-03-16 1989-03-28 Pudenz-Schulte Medical Research Corp. Subcutaneous infusion reservoir and pump system
US4981146A (en) * 1988-04-21 1991-01-01 Maven Labs, Inc. Nausea control device
US4998532A (en) * 1986-05-23 1991-03-12 Lti Biomedical, Inc. Portable electro-therapy system
US5006119A (en) * 1989-05-25 1991-04-09 Engineering & Research Associates, Inc. Hollow core coaxial catheter
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5193048A (en) * 1990-04-27 1993-03-09 Kaufman Dennis R Stun gun with low battery indicator and shutoff timer
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5203326A (en) * 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5282785A (en) * 1990-06-15 1994-02-01 Cortrak Medical, Inc. Drug delivery apparatus and method
US5282468A (en) * 1990-06-07 1994-02-01 Medtronic, Inc. Implantable neural electrode
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5397338A (en) * 1993-03-29 1995-03-14 Maven Labs, Inc. Electrotherapy device
US5397308A (en) * 1993-10-22 1995-03-14 Scimed Life Systems, Inc. Balloon inflation measurement apparatus
US5400784A (en) * 1993-10-15 1995-03-28 Case Western Reserve University Slowly penetrating inter-fascicular nerve cuff electrode and method of using
US5498238A (en) * 1990-06-15 1996-03-12 Cortrak Medical, Inc. Simultaneous angioplasty and phoretic drug delivery
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5704908A (en) * 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US5711326A (en) * 1995-08-25 1998-01-27 Whirlpool Corporation Dishwasher accumulator soil removal grating for a filter system
US5713847A (en) * 1994-02-09 1998-02-03 The University Of Iowa Research Foundation Human drug delivery device for tinnitus
US5723001A (en) * 1994-06-09 1998-03-03 Electropharmacology, Inc. Apparatus and method for therapeutically treating human body tissue with electromagnetic radiation
US5728396A (en) * 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US5861021A (en) * 1996-06-17 1999-01-19 Urologix Inc Microwave thermal therapy of cardiac tissue
US5865787A (en) * 1992-10-06 1999-02-02 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery
US5871449A (en) * 1996-12-27 1999-02-16 Brown; David Lloyd Device and method for locating inflamed plaque in an artery
US6010613A (en) * 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6026326A (en) * 1997-01-13 2000-02-15 Medtronic, Inc. Apparatus and method for treating chronic constipation
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6192889B1 (en) * 1998-05-05 2001-02-27 Woodside Biomedical, Inc. Method of suppression and prevention of the gag reflex
US6205361B1 (en) * 1998-02-10 2001-03-20 Advanced Bionics Corporation Implantable expandable multicontact electrodes
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6347247B1 (en) * 1998-05-08 2002-02-12 Genetronics Inc. Electrically induced vessel vasodilation
US20020026228A1 (en) * 1999-11-30 2002-02-28 Patrick Schauerte Electrode for intravascular stimulation, cardioversion and/or defibrillation
US20020026222A1 (en) * 1999-11-30 2002-02-28 Biotronik Mess- Und Therapiegeraete Gmbh & Co Device for regulating heart rate and heart pumping force
US6353763B1 (en) * 1998-01-15 2002-03-05 Regenesis Biomedical, Inc. Pulsed electromagnetic energy treatment apparatus and method
US6356787B1 (en) * 2000-02-24 2002-03-12 Electro Core Techniques, Llc Method of treating facial blushing by electrical stimulation of the sympathetic nerve chain
US6356786B1 (en) * 2000-01-20 2002-03-12 Electrocore Techniques, Llc Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain
US20020032468A1 (en) * 1996-04-30 2002-03-14 Hill Michael R.S. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US20020038137A1 (en) * 1999-04-30 2002-03-28 Medtronic, Inc. Therapeutic treatment of disorders based on timing information
US20030004549A1 (en) * 2000-10-26 2003-01-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US20030009145A1 (en) * 2001-03-23 2003-01-09 Struijker-Boudier Harry A.J. Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6508774B1 (en) * 1999-03-09 2003-01-21 Transurgical, Inc. Hifu applications with feedback control
US6516211B1 (en) * 1997-05-23 2003-02-04 Transurgical, Inc. MRI-guided therapeutic unit and methods
US6514226B1 (en) * 2000-02-10 2003-02-04 Chf Solutions, Inc. Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney
US6522932B1 (en) * 1998-02-10 2003-02-18 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and tools for use therewith
US6522926B1 (en) * 2000-09-27 2003-02-18 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US6524607B1 (en) * 1995-06-09 2003-02-25 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US20030040774A1 (en) * 2001-08-21 2003-02-27 Terry Reese S. Treatment of congestive heart failure and autonomic cardiovascular drive disorders
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US6534081B2 (en) * 1997-07-02 2003-03-18 Euro-Celtique S.A. Prolonged anesthesia in joints and body spaces
US6536949B1 (en) * 2000-03-07 2003-03-25 Richard R. Heuser Catheter for thermal evaluation of arteriosclerotic plaque
US20030060858A1 (en) * 2000-09-27 2003-03-27 Kieval Robert S. Stimulus regimens for cardiovascular reflex control
US20030060857A1 (en) * 2000-09-27 2003-03-27 Perrson Bruce J. Electrode designs and methods of use for cardiovascular reflex control devices
US20030060848A1 (en) * 2001-09-26 2003-03-27 Kieval Robert S. Mapping methods for cardiovascular reflex control devices
US6672312B2 (en) * 2001-01-31 2004-01-06 Transurgical, Inc. Pulmonary vein ablation with myocardial tissue locating
US6676657B2 (en) * 2000-12-07 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services Endoluminal radiofrequency cauterization system
US20040010303A1 (en) * 2001-09-26 2004-01-15 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US6681136B2 (en) * 2000-12-04 2004-01-20 Science Medicus, Inc. Device and method to modulate blood pressure by electrical waveforms
US6684105B2 (en) * 2001-08-31 2004-01-27 Biocontrol Medical, Ltd. Treatment of disorders by unidirectional nerve stimulation
US20040019364A1 (en) * 2000-09-27 2004-01-29 Cvrx, Inc. Devices and methods for cardiovascular reflex control via coupled electrodes
US20040019371A1 (en) * 2001-02-08 2004-01-29 Ali Jaafar Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6692738B2 (en) * 2000-01-27 2004-02-17 The General Hospital Corporation Delivery of therapeutic biologicals from implantable tissue matrices
US6697670B2 (en) * 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US20050010263A1 (en) * 2001-07-27 2005-01-13 Patrick Schauerte Neurostimulation unit for immobilizing the heart during cardiosurgical operations
US6845267B2 (en) * 2000-09-28 2005-01-18 Advanced Bionics Corporation Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system
US20050038409A1 (en) * 2001-11-29 2005-02-17 Jerome Segal Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20050049542A1 (en) * 2003-08-25 2005-03-03 Sigg Daniel C. Electroporation catheter with sensing capabilities
US20050065574A1 (en) * 2002-02-01 2005-03-24 Ali Rezai Methods of affecting hypothalamic-related conditions
US20050065562A1 (en) * 2000-01-20 2005-03-24 Rezai Ali R Electrical stimulation of the sympathetic nerve chain
US20060004430A1 (en) * 2004-06-30 2006-01-05 Cvrx, Inc. Connection structures for extra-vascular electrode lead body
US20060004417A1 (en) * 2004-06-30 2006-01-05 Cvrx, Inc. Baroreflex activation for arrhythmia treatment
US6994706B2 (en) * 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US6994700B2 (en) * 2002-09-20 2006-02-07 Flowmedica, Inc. Apparatus and method for inserting an intra-aorta catheter through a delivery sheath
US20060030814A1 (en) * 2002-09-20 2006-02-09 Flowmedica, Inc. Method and apparatus for selective drug infusion via an intra-aortic flow diverter delivery catheter
US20060036218A1 (en) * 2002-09-20 2006-02-16 Flowmedica, Inc. Method and apparatus for selective material delivery via an intra-renal catheter

Family Cites Families (438)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US252462A (en) * 1882-01-17 Nut-lock
US1025756A (en) 1909-12-11 1912-05-07 Ofenbaugesellschaft Mit Beschraenkter Haftung Latch mechanism.
US2130758A (en) 1935-06-01 1938-09-20 E J Rose Mfg Company Of Califo Electrode for diathermy treatment and the like
US3181535A (en) 1957-10-04 1965-05-04 Diapulse Mfg Corp Of America Athermapeutic apparatus
US3043310A (en) 1959-04-24 1962-07-10 Diapulse Mfg Corp Of America Treatment head for athermapeutic apparatus
US3270746A (en) 1963-08-26 1966-09-06 Dynapower Systems Corp High-performance electrotherapeutic treatment head
US3329149A (en) 1964-10-28 1967-07-04 Dynapower Systems Corp Of Cali Supporting arm for electrotherapeutic treatment head
US3572208A (en) 1968-12-30 1971-03-23 Honeywell Inc Pneumatic annunciation system
US3522811A (en) 1969-02-13 1970-08-04 Medtronic Inc Implantable nerve stimulator and method of use
US3670737A (en) 1970-07-02 1972-06-20 Diapulse Corp Of America Ultra-short wave athermapeutic apparatus
US3760812A (en) 1971-03-19 1973-09-25 Univ Minnesota Implantable spiral wound stimulation electrodes
US3774620A (en) 1971-06-14 1973-11-27 Nemectron Gmbh Electromedicinal apparatus for interference current therapy
US3895639A (en) 1971-09-07 1975-07-22 Rodler Ing Hans Apparatus for producing an interference signal at a selected location
US3897789A (en) 1973-09-13 1975-08-05 Stanley J Blanchard Acupuncture apparatus
US3894532A (en) 1974-01-17 1975-07-15 Acupulse Inc Instruments for transcutaneous and subcutaneous investigation and treatment
US3911930A (en) 1974-03-01 1975-10-14 Stimulation Tech Method and structure of preventing and treating ileus, and reducing acute pain by electrical pulse stimulation
US4055190A (en) 1974-12-19 1977-10-25 Michio Tany Electrical therapeutic apparatus
US4026300A (en) 1975-03-14 1977-05-31 Liberty Mutual Method and apparatus for interfacing to nerves
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4105017A (en) 1976-11-17 1978-08-08 Electro-Biology, Inc. Modification of the growth repair and maintenance behavior of living tissue and cells by a specific and selective change in electrical environment
US4266532A (en) 1976-11-17 1981-05-12 Electro-Biology, Inc. Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4305115A (en) 1979-03-14 1981-12-08 Harry H. Leveen Electrostatic shield
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4405305A (en) 1980-10-27 1983-09-20 University Of Utah Research Foundation Subcutaneous peritoneal injection catheter
CS226514B1 (en) 1981-01-28 1984-04-16 Petr Ing Csc Slovak Apparatus for stimulating live tissues
US4454883A (en) 1982-02-16 1984-06-19 Therafield Holdings Limited Electrotherapeutic apparatus
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4467808A (en) 1982-09-17 1984-08-28 Biolectron, Inc. Method for preventing and treating osteoporosis in a living body by using electrical stimulation non-invasively
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
FR2541902B1 (en) 1983-03-04 1986-02-07 Cofrem International Sa THERMAL THERAPEUTIC APPARATUS
DE3483160D1 (en) 1983-09-14 1990-10-11 Jacob Zabara NEUROCYBERNETIC PROSTHESIS.
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4587975A (en) 1984-07-02 1986-05-13 Cardiac Pacemakers, Inc. Dimension sensitive angioplasty catheter
US4674482A (en) 1984-09-12 1987-06-23 Irt, Inc. Pulse electro-magnetic field therapy device with auto bias circuit
US4608985A (en) 1984-10-11 1986-09-02 Case Western Reserve University Antidromic pulse generating wave form for collision blocking
US4602624A (en) 1984-10-11 1986-07-29 Case Western Reserve University Implantable cuff, method of manufacture, and method of installation
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4709698A (en) 1986-05-14 1987-12-01 Thomas J. Fogarty Heatable dilation catheter
US5014699A (en) 1986-05-23 1991-05-14 Trustees Of The University Of Pennsylvania Electromagnetic method and apparatus for healing living tissue
US4715852A (en) 1986-07-21 1987-12-29 Eaton Corporation Implanted medication infusion device
US4774967A (en) 1986-09-09 1988-10-04 American Biointerface Corporation Method and apparatus for mammalian nerve regeneration
US4791931A (en) 1987-08-13 1988-12-20 Pacesetter Infusion, Ltd. Demand pacemaker using an artificial baroreceptor reflex
US4852573A (en) 1987-12-04 1989-08-01 Kennedy Philip R Implantable neural electrode
DE68925030T2 (en) 1988-01-21 1996-07-25 Massachusetts Inst Technology MOLECULE TRANSPORT THROUGH FABRICS WITH THE USE OF ELECTROPORATION.
US4890623A (en) 1988-03-14 1990-01-02 C. R. Bard, Inc. Biopotential sensing device and method for making
US4955377A (en) 1988-10-28 1990-09-11 Lennox Charles D Device and method for heating tissue in a patient's body
US5094242A (en) 1988-11-07 1992-03-10 Regents Of The University Of California Implantable nerve stimulation device
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5458631A (en) 1989-01-06 1995-10-17 Xavier; Ravi Implantable catheter with electrical pulse nerve stimulators and drug delivery system
AU4945490A (en) 1989-01-06 1990-08-01 Angioplasty Systems Inc. Electrosurgical catheter for resolving atherosclerotic plaque
US5779698A (en) 1989-01-18 1998-07-14 Applied Medical Resources Corporation Angioplasty catheter system and method for making same
US5125928A (en) 1989-04-13 1992-06-30 Everest Medical Corporation Ablation catheter with selectively deployable electrodes
US4976711A (en) 1989-04-13 1990-12-11 Everest Medical Corporation Ablation catheter with selectively deployable electrodes
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
RU1785710C (en) 1989-10-06 1993-01-07 Vremennyj Nauchnyj Kollektiv O Microwave resonant therapeutic device
US4979511A (en) 1989-11-03 1990-12-25 Cyberonics, Inc. Strain relief tether for implantable electrode
US5851206A (en) 1990-03-13 1998-12-22 The Regents Of The University Of California Method and apparatus for endovascular thermal thrombosis and thermal cancer treatment
US5184617A (en) 1990-06-05 1993-02-09 Staodyn, Inc. Output pulse compensation for therapeutic-type electronic devices
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5058584A (en) 1990-08-30 1991-10-22 Medtronic, Inc. Method and apparatus for epidural burst stimulation for angina pectoris
US5111815A (en) 1990-10-15 1992-05-12 Cardiac Pacemakers, Inc. Method and apparatus for cardioverter/pacer utilizing neurosensing
EP0491979A1 (en) 1990-12-22 1992-07-01 Peter Dr. Ing. Osypka Pacemaker catheter with two poles
US5324255A (en) 1991-01-11 1994-06-28 Baxter International Inc. Angioplasty and ablative devices having onboard ultrasound components and devices and methods for utilizing ultrasound to treat or prevent vasopasm
US5263480A (en) 1991-02-01 1993-11-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5425364A (en) 1991-02-15 1995-06-20 Cardiac Pathways Corporation Flexible strip assembly without feedthrough holes and device utilizing the same
US5269303A (en) 1991-02-22 1993-12-14 Cyberonics, Inc. Treatment of dementia by nerve stimulation
US5251634A (en) 1991-05-03 1993-10-12 Cyberonics, Inc. Helical nerve electrode
US5215086A (en) 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5335657A (en) 1991-05-03 1994-08-09 Cyberonics, Inc. Therapeutic treatment of sleep disorder by nerve stimulation
WO1992020291A1 (en) 1991-05-24 1992-11-26 Applied Medical Resources, Inc. Articulating tissue cutter assembly
US5458568A (en) 1991-05-24 1995-10-17 Cortrak Medical, Inc. Porous balloon for selective dilatation and drug delivery
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5213098A (en) 1991-07-26 1993-05-25 Medtronic, Inc. Post-extrasystolic potentiation stimulation with physiologic sensor feedback
US5222494A (en) 1991-07-31 1993-06-29 Cyberonics, Inc. Implantable tissue stimulator output stabilization system
US5231988A (en) 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
EP0606390A4 (en) 1991-10-03 1994-12-07 Gen Hospital Corp Apparatus and method for vasodilation.
US5215089A (en) 1991-10-21 1993-06-01 Cyberonics, Inc. Electrode assembly for nerve stimulation
DE69233091T2 (en) 1991-11-08 2004-05-06 Boston Scientific Ltd., St. Michael ABLATION ELECTRODE WITH INSULATED TEMPERATURE MEASURING ELEMENT
US5304206A (en) 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5193539A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5358514A (en) 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
US5193540A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5697882A (en) 1992-01-07 1997-12-16 Arthrocare Corporation System and method for electrosurgical cutting and ablation
AU682146B2 (en) 1992-03-09 1997-09-25 St. George's Hospital Medical School Image neurography and diffusion anisotropy imaging
US5300068A (en) * 1992-04-21 1994-04-05 St. Jude Medical, Inc. Electrosurgical apparatus
US5370680A (en) 1992-05-27 1994-12-06 Magnetic Resonance Therapeutics, Inc. Athermapeutic apparatus employing electro-magnetic fields
JP3493196B2 (en) 1992-06-24 2004-02-03 サイベロニクス,インク. Treatment of neuropsychiatric disorders by nerve stimulation
US5772590A (en) 1992-06-30 1998-06-30 Cordis Webster, Inc. Cardiovascular catheter with laterally stable basket-shaped electrode array with puller wire
US5507724A (en) 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
US5542916A (en) 1992-08-12 1996-08-06 Vidamed, Inc. Dual-channel RF power delivery system
US5484400A (en) 1992-08-12 1996-01-16 Vidamed, Inc. Dual channel RF delivery system
DE4229693A1 (en) 1992-09-05 1994-03-10 Achim Dr Hansjuergens Electrotherapeutic device
US5618563A (en) * 1992-09-10 1997-04-08 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5478303A (en) 1992-09-18 1995-12-26 Foley-Nolan; Darragh Electromagnetic apparatus for use in therapy
US5338662A (en) 1992-09-21 1994-08-16 Bio-Preserve Medical Corporation Organ perfusion device
US5553611A (en) 1994-01-06 1996-09-10 Endocardial Solutions, Inc. Endocardial measurement method
WO1994007446A1 (en) 1992-10-05 1994-04-14 Boston Scientific Corporation Device and method for heating tissue
US5807306A (en) 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
US5334193A (en) 1992-11-13 1994-08-02 American Cardiac Ablation Co., Inc. Fluid cooled ablation catheter
US5441483A (en) 1992-11-16 1995-08-15 Avitall; Boaz Catheter deflection control
CA2109980A1 (en) 1992-12-01 1994-06-02 Mir A. Imran Steerable catheter with adjustable bend location and/or radius and method
US5256141A (en) 1992-12-22 1993-10-26 Nelson Gencheff Biological material deployment method and apparatus
US5317155A (en) 1992-12-29 1994-05-31 The Electrogesic Corporation Corona discharge apparatus
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5792187A (en) 1993-02-22 1998-08-11 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
FR2704151B1 (en) * 1993-04-21 1995-07-13 Klotz Antoine Olivier Electronic device intended for the adrenergic stimulation of the sympathetic system relating to the venous media.
WO1994024298A1 (en) 1993-04-21 1994-10-27 Institut Pasteur Biocompatible implant for the expression and secretion in vivo of a therapeutical compound
US6517811B2 (en) 1993-05-06 2003-02-11 Research Corporation Technologies, Inc. Compounds for cancer imaging and therapy
US5584863A (en) 1993-06-24 1996-12-17 Electropharmacology, Inc. Pulsed radio frequency electrotherapeutic system
US5860974A (en) 1993-07-01 1999-01-19 Boston Scientific Corporation Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft
DE69432148T2 (en) 1993-07-01 2003-10-16 Boston Scient Ltd CATHETER FOR IMAGE DISPLAY, DISPLAY OF ELECTRICAL SIGNALS AND ABLATION
US5507791A (en) * 1993-08-31 1996-04-16 Sit'ko; Sergei P. Microwave resonance therapy
US5582609A (en) 1993-10-14 1996-12-10 Ep Technologies, Inc. Systems and methods for forming large lesions in body tissue using curvilinear electrode elements
US5470352A (en) 1993-10-29 1995-11-28 Northeastern University Balloon angioplasty device
US5433739A (en) 1993-11-02 1995-07-18 Sluijter; Menno E. Method and apparatus for heating an intervertebral disc for relief of back pain
US5571147A (en) 1993-11-02 1996-11-05 Sluijter; Menno E. Thermal denervation of an intervertebral disc for relief of back pain
US5599345A (en) 1993-11-08 1997-02-04 Zomed International, Inc. RF treatment apparatus
US5730127A (en) 1993-12-03 1998-03-24 Avitall; Boaz Mapping and ablation catheter system
JPH07157424A (en) 1993-12-03 1995-06-20 Lintec Corp Gel formulation for local anesthesia
US5458626A (en) 1993-12-27 1995-10-17 Krause; Horst E. Method of electrical nerve stimulation for acceleration of tissue healing
US6858024B1 (en) 1994-02-14 2005-02-22 Scimed Life Systems, Inc. Guide catheter having selected flexural modulus segments
GB9407135D0 (en) 1994-04-11 1994-06-01 Aberdeen University And Plasma Treatment of osteoporosis
US5505201A (en) 1994-04-20 1996-04-09 Case Western Reserve University Implantable helical spiral cuff electrode
US5505700A (en) 1994-06-14 1996-04-09 Cordis Corporation Electro-osmotic infusion catheter
US6009877A (en) 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
US6056744A (en) 1994-06-24 2000-05-02 Conway Stuart Medical, Inc. Sphincter treatment apparatus
US6405732B1 (en) 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
JP3578460B2 (en) 1994-06-27 2004-10-20 ボストン サイエンティフィック リミテッド Systems and methods for sensing body temperature
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5810802A (en) 1994-08-08 1998-09-22 E.P. Technologies, Inc. Systems and methods for controlling tissue ablation using multiple temperature sensing elements
US5454782A (en) 1994-08-11 1995-10-03 Perkins; Rodney C. Translumenal circumferential energy delivery device
WO1996004957A1 (en) 1994-08-17 1996-02-22 Electropharmacology, Inc. Electrotherapeutic system
US5531778A (en) 1994-09-20 1996-07-02 Cyberonics, Inc. Circumneural electrode assembly
US5540734A (en) 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
WO1996011723A1 (en) 1994-10-17 1996-04-25 Australasian Medical Technology Limited Devices and methods for implementation of pulsed electromagnetic field therapy
US5722401A (en) 1994-10-19 1998-03-03 Cardiac Pathways Corporation Endocardial mapping and/or ablation catheter probe
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
CA2204789C (en) 1994-11-10 2002-11-12 Paul Ashton Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5571150A (en) 1994-12-19 1996-11-05 Cyberonics, Inc. Treatment of patients in coma by nerve stimulation
US5569198A (en) 1995-01-23 1996-10-29 Cortrak Medical Inc. Microporous catheter
ATE308930T1 (en) 1995-05-04 2005-11-15 Sherwood Serv Ag THERMO-SURGERY SYSTEM WITH COLD ELECTRIC TIP
US5540730A (en) 1995-06-06 1996-07-30 Cyberonics, Inc. Treatment of motility disorders by nerve stimulation
US6149620A (en) * 1995-11-22 2000-11-21 Arthrocare Corporation System and methods for electrosurgical tissue treatment in the presence of electrically conductive fluid
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6322558B1 (en) 1995-06-09 2001-11-27 Engineering & Research Associates, Inc. Apparatus and method for predicting ablation depth
US5983131A (en) 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
US5672174A (en) 1995-08-15 1997-09-30 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method
EP0955883B1 (en) 1995-09-20 2002-07-31 Texas Heart Institute Detecting thermal discrepancies in vessel walls
US6615071B1 (en) 1995-09-20 2003-09-02 Board Of Regents, The University Of Texas System Method and apparatus for detecting vulnerable atherosclerotic plaque
US5700282A (en) 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
DE69633411T2 (en) 1995-10-13 2005-10-20 Transvascular, Inc., Menlo Park METHOD AND DEVICE FOR PREVENTING ARTERIAL ATTRACTIONS AND / OR FOR CARRYING OUT OTHER TRANSVASCULAR INTERVENTIONS
US5755750A (en) 1995-11-13 1998-05-26 University Of Florida Method and apparatus for selectively inhibiting activity in nerve fibers
US6073048A (en) 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
CN2291164Y (en) * 1996-12-23 1998-09-16 祝强 Instrument for bringing high blood pressure down
AU733341B2 (en) * 1996-02-02 2001-05-10 Transvascular, Inc. A device, system and method for interstitial transvascular intervention
WO1997029802A2 (en) * 1996-02-20 1997-08-21 Advanced Bionics Corporation Improved implantable microstimulator and systems employing the same
US5913876A (en) 1996-02-20 1999-06-22 Cardiothoracic Systems, Inc. Method and apparatus for using vagus nerve stimulation in surgery
US6036687A (en) 1996-03-05 2000-03-14 Vnus Medical Technologies, Inc. Method and apparatus for treating venous insufficiency
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
US5690681A (en) 1996-03-29 1997-11-25 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US6449507B1 (en) 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US6006134A (en) 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US5690691A (en) 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5938690A (en) 1996-06-07 1999-08-17 Advanced Neuromodulation Systems, Inc. Pain management system and method
US5824026A (en) 1996-06-12 1998-10-20 The Spectranetics Corporation Catheter for delivery of electric energy and a process for manufacturing same
US5944710A (en) 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US20020040204A1 (en) * 1996-06-24 2002-04-04 Dev Nagendu B. Electroporation-enhanced inhibition of vascular neointimal hyperplasia
US6246912B1 (en) 1996-06-27 2001-06-12 Sherwood Services Ag Modulated high frequency tissue modification
US5983141A (en) 1996-06-27 1999-11-09 Radionics, Inc. Method and apparatus for altering neural tissue function
US6245026B1 (en) 1996-07-29 2001-06-12 Farallon Medsystems, Inc. Thermography catheter
US5924997A (en) 1996-07-29 1999-07-20 Campbell; Thomas Henderson Catheter and method for the thermal mapping of hot spots in vascular lesions of the human body
US6058328A (en) 1996-08-06 2000-05-02 Pacesetter, Inc. Implantable stimulation device having means for operating in a preemptive pacing mode to prevent tachyarrhythmias and method thereof
US6135999A (en) 1997-02-12 2000-10-24 Oratec Internationals, Inc. Concave probe for arthroscopic surgery
US5906636A (en) 1996-09-20 1999-05-25 Texas Heart Institute Heat treatment of inflamed tissue
US5800464A (en) 1996-10-03 1998-09-01 Medtronic, Inc. System for providing hyperpolarization of cardiac to enhance cardiac function
US5814079A (en) 1996-10-04 1998-09-29 Medtronic, Inc. Cardiac arrhythmia management by application of adnodal stimulation for hyperpolarization of myocardial cells
US5893885A (en) 1996-11-01 1999-04-13 Cordis Webster, Inc. Multi-electrode ablation catheter
US6091995A (en) 1996-11-08 2000-07-18 Surx, Inc. Devices, methods, and systems for shrinking tissues
US5954719A (en) 1996-12-11 1999-09-21 Irvine Biomedical, Inc. System for operating a RF ablation generator
ATE274974T1 (en) * 1997-01-13 2004-09-15 Neurodan As IMPLANTABLE ELECTRODE FOR NERVE STIMULATION
JP2001513679A (en) 1997-02-26 2001-09-04 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ Battery powered patient subcutaneous insertion device
US5954761A (en) 1997-03-25 1999-09-21 Intermedics Inc. Implantable endocardial lead assembly having a stent
JP4157168B2 (en) 1997-03-27 2008-09-24 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ Implantable device system for monitoring and / or acting on body parameters
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US7027869B2 (en) 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US5948007A (en) 1997-04-30 1999-09-07 Medtronic, Inc. Dual channel implantation neurostimulation techniques
US6024740A (en) 1997-07-08 2000-02-15 The Regents Of The University Of California Circumferential ablation device assembly
US5971983A (en) 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
US6161048A (en) 1997-06-26 2000-12-12 Radionics, Inc. Method and system for neural tissue modification
WO1999000060A1 (en) 1997-06-26 1999-01-07 Advanced Coronary Intervention Electrosurgical catheter for resolving obstructions by radio frequency ablation
US6117101A (en) 1997-07-08 2000-09-12 The Regents Of The University Of California Circumferential ablation device assembly
US6869431B2 (en) 1997-07-08 2005-03-22 Atrionix, Inc. Medical device with sensor cooperating with expandable member
AU3458197A (en) 1997-07-16 1999-02-10 Impulse Dynamics N.V. Smooth muscle controller
US6258084B1 (en) 1997-09-11 2001-07-10 Vnus Medical Technologies, Inc. Method for applying energy to biological tissue including the use of tumescent tissue compression
US6917834B2 (en) 1997-12-03 2005-07-12 Boston Scientific Scimed, Inc. Devices and methods for creating lesions in endocardial and surrounding tissue to isolate focal arrhythmia substrates
WO1999033407A1 (en) 1997-12-31 1999-07-08 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6146380A (en) 1998-01-09 2000-11-14 Radionics, Inc. Bent tip electrical surgical probe
US6251130B1 (en) 1998-03-24 2001-06-26 Innercool Therapies, Inc. Device for applications of selective organ cooling
US6415187B1 (en) 1998-02-10 2002-07-02 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and insertion needle for use therewith
US6273886B1 (en) 1998-02-19 2001-08-14 Curon Medical, Inc. Integrated tissue heating and cooling apparatus
US6258087B1 (en) 1998-02-19 2001-07-10 Curon Medical, Inc. Expandable electrode assemblies for forming lesions to treat dysfunction in sphincters and adjoining tissue regions
US6142993A (en) 1998-02-27 2000-11-07 Ep Technologies, Inc. Collapsible spline structure using a balloon as an expanding actuator
US6086527A (en) 1998-04-02 2000-07-11 Scimed Life Systems, Inc. System for treating congestive heart failure
US6314325B1 (en) 1998-04-07 2001-11-06 William R. Fitz Nerve hyperpolarization method and apparatus for pain relief
US6219577B1 (en) * 1998-04-14 2001-04-17 Global Vascular Concepts, Inc. Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
NZ507185A (en) 1998-04-14 2002-09-27 Gmp Drug Delivery Inc Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
US5916154A (en) 1998-04-22 1999-06-29 Nellcor Puritan Bennett Method of enhancing performance in pulse oximetry via electrical stimulation
US6269269B1 (en) 1998-04-23 2001-07-31 Medtronic Inc. Method and apparatus for synchronized treatment of obstructive sleep apnea
US6058331A (en) * 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
US5928272A (en) 1998-05-02 1999-07-27 Cyberonics, Inc. Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity
US7198635B2 (en) 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
WO1999065561A1 (en) 1998-06-19 1999-12-23 Cordis Webster, Inc. Method and apparatus for transvascular treatment of tachycardia and fibrillation
US6322559B1 (en) 1998-07-06 2001-11-27 Vnus Medical Technologies, Inc. Electrode catheter having coil structure
EP2428249B1 (en) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7599736B2 (en) 2001-07-23 2009-10-06 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
US6304787B1 (en) 1998-08-26 2001-10-16 Advanced Bionics Corporation Cochlear electrode array having current-focusing and tissue-treating features
US6123702A (en) 1998-09-10 2000-09-26 Scimed Life Systems, Inc. Systems and methods for controlling power in an electrosurgical probe
US6123718A (en) 1998-11-02 2000-09-26 Polymerex Medical Corp. Balloon catheter
US7313444B2 (en) 1998-11-20 2007-12-25 Pacesetter, Inc. Self-anchoring coronary sinus lead
US20070066972A1 (en) 2001-11-29 2007-03-22 Medwaves, Inc. Ablation catheter apparatus with one or more electrodes
US6077227A (en) 1998-12-28 2000-06-20 Medtronic, Inc. Method for manufacture and implant of an implantable blood vessel cuff
US7122019B1 (en) 2000-11-28 2006-10-17 Flowmedica Inc. Intra-aortic renal drug delivery catheter
US7481803B2 (en) 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US7780628B1 (en) 1999-01-11 2010-08-24 Angiodynamics, Inc. Apparatus and methods for treating congestive heart disease
US7329236B2 (en) 1999-01-11 2008-02-12 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6749598B1 (en) 1999-01-11 2004-06-15 Flowmedica, Inc. Apparatus and methods for treating congestive heart disease
US6461314B1 (en) 1999-02-02 2002-10-08 Transurgical, Inc. Intrabody hifu applicator
ES2240078T3 (en) 1999-03-09 2005-10-16 Thermage, Inc. APPARATUS FOR TREATMENT OF FABRICS.
US6464687B1 (en) 1999-03-09 2002-10-15 Ball Semiconductor, Inc. Implantable drug delivery system
US6678558B1 (en) 1999-03-25 2004-01-13 Genetronics, Inc. Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US6325797B1 (en) 1999-04-05 2001-12-04 Medtronic, Inc. Ablation catheter and method for isolating a pulmonary vein
US6738663B2 (en) 1999-04-09 2004-05-18 Oncostim, A Minnesota Corporation Implantable device and method for the electrical treatment of cancer
US6366808B1 (en) * 2000-03-13 2002-04-02 Edward A. Schroeppel Implantable device and method for the electrical treatment of cancer
US6317615B1 (en) 1999-04-19 2001-11-13 Cardiac Pacemakers, Inc. Method and system for reducing arterial restenosis in the presence of an intravascular stent
US6939346B2 (en) 1999-04-21 2005-09-06 Oratec Interventions, Inc. Method and apparatus for controlling a temperature-controlled probe
US6341236B1 (en) 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
AU4696100A (en) 1999-05-04 2000-11-17 Curon Medical, Inc. Electrodes for creating lesions in tissue regions at or near a sphincter
US6178352B1 (en) 1999-05-07 2001-01-23 Woodside Biomedical, Inc. Method of blood pressure moderation
US6304777B1 (en) 1999-05-26 2001-10-16 Impulse Dynamics N.V. Induction of cardioplegia applied electrical signals
US6442424B1 (en) 1999-05-26 2002-08-27 Impulse Dynamics N.V. Local cardiac motion control using applied electrical signals
US7171263B2 (en) 1999-06-04 2007-01-30 Impulse Dynamics Nv Drug delivery device
WO2001000273A1 (en) 1999-06-25 2001-01-04 Emory University Devices and methods for vagus nerve stimulation
US6272383B1 (en) 1999-06-28 2001-08-07 Woodside Biomedical, Inc. Electro-acupuncture method using an electrical stimulator
US7053063B2 (en) 1999-07-21 2006-05-30 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes in tissue
US6927049B2 (en) 1999-07-21 2005-08-09 The Regents Of The University Of California Cell viability detection using electrical measurements
US6300108B1 (en) 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6326177B1 (en) 1999-08-04 2001-12-04 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Method and apparatus for intracellular electro-manipulation
US6450942B1 (en) 1999-08-20 2002-09-17 Cardiorest International Ltd. Method for reducing heart loads in mammals
US6599256B1 (en) 1999-09-10 2003-07-29 Transurgical, Inc. Occlusion of tubular anatomical structures by energy application
US7510536B2 (en) 1999-09-17 2009-03-31 University Of Washington Ultrasound guided high intensity focused ultrasound treatment of nerves
EP1244392A1 (en) 1999-09-28 2002-10-02 Novasys Medical, Inc. Treatment of tissue by application of energy and drugs
US6272377B1 (en) 1999-10-01 2001-08-07 Cardiac Pacemakers, Inc. Cardiac rhythm management system with arrhythmia prediction and prevention
US6473644B1 (en) 1999-10-13 2002-10-29 Cyberonics, Inc. Method to enhance cardiac capillary growth in heart failure patients
US6287304B1 (en) 1999-10-15 2001-09-11 Neothermia Corporation Interstitial cauterization of tissue volumes with electrosurgically deployed electrodes
US6669655B1 (en) 1999-10-20 2003-12-30 Transurgical, Inc. Sonic element and catheter incorporating same
WO2001033172A1 (en) 1999-10-29 2001-05-10 Universität Zürich Method of volumetric blood flow measurement
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6542781B1 (en) 1999-11-22 2003-04-01 Scimed Life Systems, Inc. Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue
US6711444B2 (en) 1999-11-22 2004-03-23 Scimed Life Systems, Inc. Methods of deploying helical diagnostic and therapeutic element supporting structures within the body
US6592567B1 (en) 1999-12-07 2003-07-15 Chf Solutions, Inc. Kidney perfusion catheter
US6415183B1 (en) 1999-12-09 2002-07-02 Cardiac Pacemakers, Inc. Method and apparatus for diaphragmatic pacing
US20030150464A1 (en) 1999-12-17 2003-08-14 Casscells S. Ward Inducing apoptosis of atrial myocytes to treat atrial fibrillation
US6328699B1 (en) 2000-01-11 2001-12-11 Cedars-Sinai Medical Center Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure
US20060085046A1 (en) * 2000-01-20 2006-04-20 Ali Rezai Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system
US6438423B1 (en) 2000-01-20 2002-08-20 Electrocore Technique, Llc Method of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain
US7565205B2 (en) 2000-02-17 2009-07-21 Standen Ltd. Treating a tumor or the like with electric fields at different orientations
US6868289B2 (en) 2002-10-02 2005-03-15 Standen Ltd. Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
US6770070B1 (en) 2000-03-17 2004-08-03 Rita Medical Systems, Inc. Lung treatment apparatus and method
EP1265674B1 (en) 2000-03-24 2008-09-17 ProRhythm, Inc. Apparatus for intrabody thermal treatment
US6287608B1 (en) 2000-04-11 2001-09-11 Intellicardia, Inc. Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney by infusion of a vasodilator
US20010044596A1 (en) 2000-05-10 2001-11-22 Ali Jaafar Apparatus and method for treatment of vascular restenosis by electroporation
WO2001087172A1 (en) 2000-05-12 2001-11-22 Cardima, Inc. Multi-channel rf energy delivery with coagulum reduction
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2001095820A1 (en) 2000-06-13 2001-12-20 Atrionix, Inc. Surgical ablation probe for forming a circumferential lesion
EP1299035B1 (en) 2000-07-13 2013-02-13 ReCor Medical, Inc. Thermal treatment apparatus with focussed energy application
EP2277586B1 (en) 2000-07-26 2013-06-26 Boston Scientific Neuromodulation Corporation Regarcheable spinal cord stimulator system
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
US6862479B1 (en) 2000-08-30 2005-03-01 Advanced Bionics Corporation Spinal cord stimulation as a therapy for sexual dysfunction
ES2289619T3 (en) 2000-09-07 2008-02-01 Covidien Ag APPARATUS FOR THE TREATMENT OF INTERVERTEBRAL DISCS.
US6405079B1 (en) 2000-09-22 2002-06-11 Mehdi M. Ansarinia Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions
US7840271B2 (en) 2000-09-27 2010-11-23 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US7623926B2 (en) 2000-09-27 2009-11-24 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US7306591B2 (en) 2000-10-02 2007-12-11 Novasys Medical, Inc. Apparatus and methods for treating female urinary incontinence
US6640120B1 (en) 2000-10-05 2003-10-28 Scimed Life Systems, Inc. Probe assembly for mapping and ablating pulmonary vein tissue and method of using same
US7104987B2 (en) 2000-10-17 2006-09-12 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US8417334B2 (en) 2000-10-26 2013-04-09 Medtronic, Inc. Method and apparatus for electrically stimulating the nervous system to improve ventricular dysfunction, heart failure, and other cardiac conditions
US6616624B1 (en) 2000-10-30 2003-09-09 Cvrx, Inc. Systems and method for controlling renovascular perfusion
US7081114B2 (en) 2000-11-29 2006-07-25 St. Jude Medical, Atrial Fibrillation Division, Inc. Electrophysiology/ablation catheter having lariat configuration of variable radius
US6666845B2 (en) * 2001-01-04 2003-12-23 Advanced Neuromodulation Systems, Inc. Implantable infusion pump
WO2002053207A2 (en) 2001-01-04 2002-07-11 Advanced Neuromodulation Systems, Inc. Implantable infusion pump
WO2002054941A2 (en) 2001-01-11 2002-07-18 Rita Medical Systems Inc Bone-treatment instrument and method
US6600954B2 (en) 2001-01-25 2003-07-29 Biocontrol Medical Bcm Ltd. Method and apparatus for selective control of nerve fibers
US6564096B2 (en) 2001-02-28 2003-05-13 Robert A. Mest Method and system for treatment of tachycardia and fibrillation
AU2002250250A1 (en) 2001-03-01 2002-09-19 Three Arch Partners Intravascular device for treatment of hypertension
US6620151B2 (en) 2001-03-01 2003-09-16 Advanced Neuromodulation Systems, Inc. Non-constant pressure infusion pump
US20020177846A1 (en) 2001-03-06 2002-11-28 Mulier Peter M.J. Vaporous delivery of thermal energy to tissue sites
US6786904B2 (en) 2002-01-10 2004-09-07 Triton Biosystems, Inc. Method and device to treat vulnerable plaque
WO2002085448A2 (en) 2001-04-20 2002-10-31 The Board Of Regents Of The University Of Oklahoma Cardiac neuromodulation and methods of using same
AU2002258990A1 (en) 2001-04-23 2002-11-05 Transurgical, Inc. Improvements in ablation therapy
US6972016B2 (en) 2001-05-01 2005-12-06 Cardima, Inc. Helically shaped electrophysiology catheter
WO2002096512A1 (en) 2001-05-29 2002-12-05 Medtronic, Inc. Closed-loop neuromodulation for prevention and treatment of cardiac conditions
US7127284B2 (en) 2001-06-11 2006-10-24 Mercator Medsystems, Inc. Electroporation microneedle and methods for its use
US20060116736A1 (en) * 2001-07-23 2006-06-01 Dilorenzo Daniel J Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity
US20060167498A1 (en) 2001-07-23 2006-07-27 Dilorenzo Daniel J Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease
US6600956B2 (en) 2001-08-21 2003-07-29 Cyberonics, Inc. Circumneural electrode assembly
US20030050635A1 (en) 2001-08-22 2003-03-13 Csaba Truckai Embolization systems and techniques for treating tumors
CA2458610C (en) 2001-08-31 2011-08-16 Cyto Pulse Sciences, Inc. Non-linear amplitude dielectrophoresis waveform for cell fusion
WO2003028802A2 (en) 2001-10-01 2003-04-10 Am Discovery, Incorporated Devices for treating atrial fibrilation
US8974446B2 (en) 2001-10-11 2015-03-10 St. Jude Medical, Inc. Ultrasound ablation apparatus with discrete staggered ablation zones
US20030125790A1 (en) 2001-12-27 2003-07-03 Vitaly Fastovsky Deployment device, system and method for medical implantation
US20060189941A1 (en) 2002-01-22 2006-08-24 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US7155284B1 (en) 2002-01-24 2006-12-26 Advanced Bionics Corporation Treatment of hypertension
JP2005515819A (en) 2002-02-01 2005-06-02 ザ クリーブランド クリニック ファウンデイション A transmission device that stimulates the sympathetic nerve chain
WO2003066153A2 (en) 2002-02-01 2003-08-14 The Cleveland Clinic Foundation Neural stimulation delivery device with independently moveable delivery structures
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
JP2005519680A (en) 2002-03-14 2005-07-07 ブレインズゲート リミティド Blood pressure control technology
US6736835B2 (en) 2002-03-21 2004-05-18 Depuy Acromed, Inc. Early intervention spinal treatment methods and devices for use therein
AU2003220599A1 (en) 2002-03-27 2003-10-13 Cvrx, Inc. Devices and methods for cardiovascular reflex control via coupled electrodes
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US20070129761A1 (en) * 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US8347891B2 (en) * 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20070135875A1 (en) * 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US8774913B2 (en) * 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US7191015B2 (en) 2002-04-11 2007-03-13 Medtronic Vascular, Inc. Devices and methods for transluminal or transthoracic interstitial electrode placement
JP4499427B2 (en) 2002-04-16 2010-07-07 サイト パルス サイエンシズ、インコーポレイテッド A method of treating biomaterials by moving electric fields and reversing electrode polarity.
US20030199767A1 (en) 2002-04-19 2003-10-23 Cespedes Eduardo Ignacio Methods and apparatus for the identification and stabilization of vulnerable plaque
US20030236443A1 (en) 2002-04-19 2003-12-25 Cespedes Eduardo Ignacio Methods and apparatus for the identification and stabilization of vulnerable plaque
US20030199747A1 (en) 2002-04-19 2003-10-23 Michlitsch Kenneth J. Methods and apparatus for the identification and stabilization of vulnerable plaque
US20030199768A1 (en) 2002-04-19 2003-10-23 Cespedes Eduardo Ignacio Methods and apparatus for the identification and stabilization of vulnerable plaque
US20030204161A1 (en) 2002-04-25 2003-10-30 Bozidar Ferek-Petric Implantable electroporation therapy device and method for using same
US6748953B2 (en) 2002-06-11 2004-06-15 Scimed Life Systems, Inc. Method for thermal treatment of type II endoleaks in arterial aneurysms
US20040193228A1 (en) 2003-03-31 2004-09-30 Gerber Martin T. Method, system and device for treating various disorders of the pelvic floor by electrical stimulation of the left and right pudendal nerves
WO2004107965A2 (en) 2002-09-20 2004-12-16 Flowmedica, Inc. Systems and methods for performing bi-lateral interventions or diagnosis in branched body lumens
EP1585572A4 (en) 2002-09-20 2010-02-24 Flowmedica Inc Method and apparatus for intra aortic substance delivery to a branch vessel
US7993325B2 (en) * 2002-09-20 2011-08-09 Angio Dynamics, Inc. Renal infusion systems and methods
US7150741B2 (en) 2002-09-20 2006-12-19 Advanced Neuromodulation Systems, Inc. Programmable dose control module
US7063679B2 (en) 2002-09-20 2006-06-20 Flowmedica, Inc. Intra-aortic renal delivery catheter
US7585836B2 (en) 2004-05-14 2009-09-08 Goodson Iv Harry Burt Bi-lateral local renal delivery for treating congestive heart failure and for BNP therapy
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
EP1551499A1 (en) 2002-10-04 2005-07-13 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
US20040162590A1 (en) 2002-12-19 2004-08-19 Whitehurst Todd K. Fully implantable miniature neurostimulator for intercostal nerve stimulation as a therapy for angina pectoris
AU2004204674A1 (en) 2003-01-03 2004-07-29 Advanced Neuromodulation Systems, Inc. System and method for stimulation of a person's brain stem
US7167750B2 (en) 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7837676B2 (en) 2003-02-20 2010-11-23 Recor Medical, Inc. Cardiac ablation devices
US7004911B1 (en) 2003-02-24 2006-02-28 Hosheng Tu Optical thermal mapping for detecting vulnerable plaque
US6923808B2 (en) 2003-02-24 2005-08-02 Boston Scientific Scimed, Inc. Probes having helical and loop shaped inflatable therapeutic elements
EP1599240A4 (en) 2003-02-24 2007-06-06 Plc Medical Systems Inc A method and catheter system applicable to acute renal failure
US7097643B2 (en) 2003-03-03 2006-08-29 Sinus Rhythm Technologies, Inc. Electrical block positioning devices and methods of use therefor
US20040176699A1 (en) 2003-03-03 2004-09-09 Volcano Therapeutics, Inc. Thermography catheter with improved wall contact
US7517342B2 (en) 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
US7221979B2 (en) 2003-04-30 2007-05-22 Medtronic, Inc. Methods and apparatus for the regulation of hormone release
JP2006526464A (en) 2003-06-05 2006-11-24 フローメディカ,インコーポレイテッド System and method for performing bilateral intervention or diagnosis in a branched body lumen
US7738952B2 (en) 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
US20060167437A1 (en) 2003-06-17 2006-07-27 Flowmedica, Inc. Method and apparatus for intra aortic substance delivery to a branch vessel
US20060269531A1 (en) 2003-07-18 2006-11-30 Eastern Virginia Medical School Apparatus for generating electrical pulses and methods of using the same
WO2005016165A1 (en) 2003-08-05 2005-02-24 Flowmedica, Inc. System and method for prevention of radiocontrast induced nephropathy
JP2007504910A (en) 2003-09-12 2007-03-08 ミノウ・メディカル・エルエルシイ Selectable biased reshaping and / or excision of atherosclerotic material
US7502650B2 (en) 2003-09-22 2009-03-10 Cvrx, Inc. Baroreceptor activation for epilepsy control
US7435248B2 (en) 2003-09-26 2008-10-14 Boston Scientific Scimed, Inc. Medical probes for creating and diagnosing circumferential lesions within or around the ostium of a vessel
US20050153885A1 (en) 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US7186209B2 (en) 2003-10-09 2007-03-06 Jacobson Jerry I Cardioelectromagnetic treatment
US7416549B2 (en) 2003-10-10 2008-08-26 Boston Scientific Scimed, Inc. Multi-zone bipolar ablation probe assembly
US7480532B2 (en) 2003-10-22 2009-01-20 Cvrx, Inc. Baroreflex activation for pain control, sedation and sleep
US7783353B2 (en) 2003-12-24 2010-08-24 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity and circadian rhythm
US20080015659A1 (en) 2003-12-24 2008-01-17 Yi Zhang Neurostimulation systems and methods for cardiac conditions
ES2729378T3 (en) 2003-12-24 2019-11-04 Univ California Tissue ablation with irreversible electroporation
US8396560B2 (en) 2004-11-18 2013-03-12 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
JP2007526817A (en) 2004-03-02 2007-09-20 シーブイアールエックス, インコーポレイテッド Activation of baroreflex from outside
WO2005091910A2 (en) 2004-03-04 2005-10-06 Flowmedica, Inc. Sheath for use in peripheral interventions
US20050209548A1 (en) 2004-03-19 2005-09-22 Dev Sukhendu B Electroporation-mediated intravascular delivery
EP1750799A2 (en) 2004-05-04 2007-02-14 The Cleveland Clinic Foundation Methods of treating medical conditions by neuromodulation of the sympathetic nervous system
US8412348B2 (en) 2004-05-06 2013-04-02 Boston Scientific Neuromodulation Corporation Intravascular self-anchoring integrated tubular electrode body
US20050261672A1 (en) 2004-05-18 2005-11-24 Mark Deem Systems and methods for selective denervation of heart dysrhythmias
WO2005123183A2 (en) 2004-06-11 2005-12-29 University Of South Florida Electroporation device and method for delivery to ocular tissue
US20060067972A1 (en) * 2004-06-23 2006-03-30 Flowmedica, Inc. Devices for renal-based heart failure treatment
FR2873385B1 (en) 2004-07-23 2006-10-27 Centre Nat Rech Scient Cnrse MONITORING AND CONTROL OF ELECTROPORATION
US7373204B2 (en) * 2004-08-19 2008-05-13 Lifestim, Inc. Implantable device and method for treatment of hypertension
US20060085054A1 (en) 2004-09-09 2006-04-20 Zikorus Arthur W Methods and apparatus for treatment of hollow anatomical structures
EP1804902A4 (en) 2004-09-10 2008-04-16 Cleveland Clinic Foundation Intraluminal electrode assembly
US20060069323A1 (en) * 2004-09-24 2006-03-30 Flowmedica, Inc. Systems and methods for bi-lateral guidewire cannulation of branched body lumens
US20060074453A1 (en) * 2004-10-04 2006-04-06 Cvrx, Inc. Baroreflex activation and cardiac resychronization for heart failure treatment
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp Methods and compositions for treatment of free radical injury
US7524318B2 (en) 2004-10-28 2009-04-28 Boston Scientific Scimed, Inc. Ablation probe with flared electrodes
US20070083239A1 (en) 2005-09-23 2007-04-12 Denise Demarais Methods and apparatus for inducing, monitoring and controlling renal neuromodulation
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
WO2006052905A2 (en) 2004-11-08 2006-05-18 Cardima, Inc. System and method for performing ablation and other medical procedures using an electrode array with flex circuit
US8332047B2 (en) 2004-11-18 2012-12-11 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US20060116720A1 (en) 2004-12-01 2006-06-01 Penny Knoblich Method and apparatus for improving renal function
EP1835964B1 (en) 2004-12-21 2016-03-09 EBR Systems, Inc. Leadless cardiac system for pacing and arrhythmia treatment
EP3666328B1 (en) 2004-12-27 2022-04-06 Novocure GmbH Treating a tumor or the like with electric fields at different orientations
US9833618B2 (en) 2005-02-04 2017-12-05 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US7548780B2 (en) 2005-02-22 2009-06-16 Cardiac Pacemakers, Inc. Cell therapy and neural stimulation for cardiac repair
EP2438877B1 (en) 2005-03-28 2016-02-17 Vessix Vascular, Inc. Intraluminal electrical tissue characterization and tuned RF energy for selective treatment of atheroma and other target tissues
US7499748B2 (en) 2005-04-11 2009-03-03 Cardiac Pacemakers, Inc. Transvascular neural stimulation device
US8834461B2 (en) 2005-07-11 2014-09-16 Medtronic Ablation Frontiers Llc Low power tissue ablation system
US20070021803A1 (en) 2005-07-22 2007-01-25 The Foundry Inc. Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20070156200A1 (en) 2005-12-29 2007-07-05 Lilian Kornet System and method for regulating blood pressure and electrolyte balance
US8571650B2 (en) 2006-03-03 2013-10-29 Palo Alto Investors Methods and compositions for treating a renal associated condition in a subject
US20080004673A1 (en) 2006-04-03 2008-01-03 Cvrx, Inc. Implantable extravascular electrostimulation system having a resilient cuff
US20070282376A1 (en) 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US7647101B2 (en) 2006-06-09 2010-01-12 Cardiac Pacemakers, Inc. Physical conditioning system, device and method
CN101610735B (en) 2006-06-28 2015-07-01 美敦力Af卢森堡公司 Methods and systems for thermally-induced renal neuromodulation
US20080039904A1 (en) 2006-08-08 2008-02-14 Cherik Bulkes Intravascular implant system
US20080091255A1 (en) 2006-10-11 2008-04-17 Cardiac Pacemakers Implantable neurostimulator for modulating cardiovascular function
EP2954868A1 (en) 2006-10-18 2015-12-16 Vessix Vascular, Inc. Tuned rf energy and electrical tissue characterization for selective treatment of target tissues
WO2008128070A2 (en) 2007-04-11 2008-10-23 The Cleveland Clinic Foundation Method and apparatus for renal neuromodulation
US8630704B2 (en) 2007-06-25 2014-01-14 Cardiac Pacemakers, Inc. Neural stimulation with respiratory rhythm management
JP2010021134A (en) 2008-06-11 2010-01-28 Sumitomo Chemical Co Ltd Method for manufacturing lithium complex metal oxide
US20100168739A1 (en) 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8808345B2 (en) 2008-12-31 2014-08-19 Medtronic Ardian Luxembourg S.A.R.L. Handle assemblies for intravascular treatment devices and associated systems and methods
US8350846B2 (en) 2009-01-28 2013-01-08 International Business Machines Corporation Updating ray traced acceleration data structures between frames based on changing perspective
US20110112400A1 (en) 2009-11-06 2011-05-12 Ardian, Inc. High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation
EP2525715A4 (en) 2010-01-19 2014-06-04 Medtronic Ardian Luxembourg S R L Methods and apparatus for renal neuromodulation via stereotactic radiotherapy
US8870863B2 (en) 2010-04-26 2014-10-28 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses, systems, and methods for renal neuromodulation
US20130218029A1 (en) * 2012-02-16 2013-08-22 Pacesetter, Inc. System and method for assessing renal artery nerve density

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276995A (en) * 1938-01-22 1942-03-17 A J Ginsberg Electrotherapy
US2276996A (en) * 1940-11-30 1942-03-17 A J Ginsberg Non-radio-interfering therapeutic apparatus
US3127895A (en) * 1962-07-02 1964-04-07 Dynapower System Corp Therapeutic pulse generation and control circuit
US3563246A (en) * 1967-04-24 1971-02-16 Intelectron Corp Method and apparatus for improving neural performance in human subjects by electrotherapy
US3650277A (en) * 1969-02-24 1972-03-21 Lkb Medical Ab Apparatus for influencing the systemic blood pressure in a patient by carotid sinus nerve stimulation
US3800802A (en) * 1972-01-07 1974-04-02 Int Medical Electronics Ltd Short-wave therapy apparatus
US3794022A (en) * 1972-06-30 1974-02-26 E Nawracaj Dual oscillator, variable pulse duration electrotherapeutic device
US3803463A (en) * 1972-07-10 1974-04-09 J Cover Weapon for immobilization and capture
US4011861A (en) * 1974-04-03 1977-03-15 Case Western Reserve University Implantable electric terminal for organic tissue
US3952751A (en) * 1975-01-08 1976-04-27 W. Denis Kendall High-performance electrotherapeutic apparatus
US4315503A (en) * 1976-11-17 1982-02-16 Electro-Biology, Inc. Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment
US4071033A (en) * 1976-12-20 1978-01-31 Nawracaj Edward P Electrotherapeutic device with modulated dual signals
US4141365A (en) * 1977-02-24 1979-02-27 The Johns Hopkins University Epidural lead electrode and insertion needle
US4379462A (en) * 1980-10-29 1983-04-12 Neuromed, Inc. Multi-electrode catheter assembly for spinal cord stimulation
US4816016A (en) * 1984-03-16 1989-03-28 Pudenz-Schulte Medical Research Corp. Subcutaneous infusion reservoir and pump system
US4649936A (en) * 1984-10-11 1987-03-17 Case Western Reserve University Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking
US4998532A (en) * 1986-05-23 1991-03-12 Lti Biomedical, Inc. Portable electro-therapy system
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US4981146A (en) * 1988-04-21 1991-01-01 Maven Labs, Inc. Nausea control device
US5006119A (en) * 1989-05-25 1991-04-09 Engineering & Research Associates, Inc. Hollow core coaxial catheter
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5193048A (en) * 1990-04-27 1993-03-09 Kaufman Dennis R Stun gun with low battery indicator and shutoff timer
US5282468A (en) * 1990-06-07 1994-02-01 Medtronic, Inc. Implantable neural electrode
US5282785A (en) * 1990-06-15 1994-02-01 Cortrak Medical, Inc. Drug delivery apparatus and method
US5498238A (en) * 1990-06-15 1996-03-12 Cortrak Medical, Inc. Simultaneous angioplasty and phoretic drug delivery
US5286254A (en) * 1990-06-15 1994-02-15 Cortrak Medical, Inc. Drug delivery apparatus and method
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5203326A (en) * 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5865787A (en) * 1992-10-06 1999-02-02 Cortrak Medical, Inc. Simultaneous cardiac pacing and local drug delivery
US5397338A (en) * 1993-03-29 1995-03-14 Maven Labs, Inc. Electrotherapy device
US5400784A (en) * 1993-10-15 1995-03-28 Case Western Reserve University Slowly penetrating inter-fascicular nerve cuff electrode and method of using
US5397308A (en) * 1993-10-22 1995-03-14 Scimed Life Systems, Inc. Balloon inflation measurement apparatus
US5713847A (en) * 1994-02-09 1998-02-03 The University Of Iowa Research Foundation Human drug delivery device for tinnitus
US5723001A (en) * 1994-06-09 1998-03-03 Electropharmacology, Inc. Apparatus and method for therapeutically treating human body tissue with electromagnetic radiation
US6524607B1 (en) * 1995-06-09 2003-02-25 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5711326A (en) * 1995-08-25 1998-01-27 Whirlpool Corporation Dishwasher accumulator soil removal grating for a filter system
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US6010613A (en) * 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US5728396A (en) * 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US20020032468A1 (en) * 1996-04-30 2002-03-14 Hill Michael R.S. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US5861021A (en) * 1996-06-17 1999-01-19 Urologix Inc Microwave thermal therapy of cardiac tissue
US5704908A (en) * 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
US5871449A (en) * 1996-12-27 1999-02-16 Brown; David Lloyd Device and method for locating inflamed plaque in an artery
US6026326A (en) * 1997-01-13 2000-02-15 Medtronic, Inc. Apparatus and method for treating chronic constipation
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6516211B1 (en) * 1997-05-23 2003-02-04 Transurgical, Inc. MRI-guided therapeutic unit and methods
US6534081B2 (en) * 1997-07-02 2003-03-18 Euro-Celtique S.A. Prolonged anesthesia in joints and body spaces
US6353763B1 (en) * 1998-01-15 2002-03-05 Regenesis Biomedical, Inc. Pulsed electromagnetic energy treatment apparatus and method
US6205361B1 (en) * 1998-02-10 2001-03-20 Advanced Bionics Corporation Implantable expandable multicontact electrodes
US6522932B1 (en) * 1998-02-10 2003-02-18 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and tools for use therewith
US6192889B1 (en) * 1998-05-05 2001-02-27 Woodside Biomedical, Inc. Method of suppression and prevention of the gag reflex
US6347247B1 (en) * 1998-05-08 2002-02-12 Genetronics Inc. Electrically induced vessel vasodilation
US6865416B2 (en) * 1998-05-08 2005-03-08 Genetronics, Inc. Electrically induced vessel vasodilation
US6508774B1 (en) * 1999-03-09 2003-01-21 Transurgical, Inc. Hifu applications with feedback control
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US20020038137A1 (en) * 1999-04-30 2002-03-28 Medtronic, Inc. Therapeutic treatment of disorders based on timing information
US20020026222A1 (en) * 1999-11-30 2002-02-28 Biotronik Mess- Und Therapiegeraete Gmbh & Co Device for regulating heart rate and heart pumping force
US20020026228A1 (en) * 1999-11-30 2002-02-28 Patrick Schauerte Electrode for intravascular stimulation, cardioversion and/or defibrillation
US6690971B2 (en) * 1999-11-30 2004-02-10 Biotronik Mess - Und Therapiegeraete Gmbh & Co. Ingenieurbuero Berlin Device for regulating heart rate and heart pumping force
US20050065562A1 (en) * 2000-01-20 2005-03-24 Rezai Ali R Electrical stimulation of the sympathetic nerve chain
US20050065573A1 (en) * 2000-01-20 2005-03-24 Rezai Ali R. Electrical stimulation of the sympathetic nerve chain
US6356786B1 (en) * 2000-01-20 2002-03-12 Electrocore Techniques, Llc Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain
US6692738B2 (en) * 2000-01-27 2004-02-17 The General Hospital Corporation Delivery of therapeutic biologicals from implantable tissue matrices
US6514226B1 (en) * 2000-02-10 2003-02-04 Chf Solutions, Inc. Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney
US6356787B1 (en) * 2000-02-24 2002-03-12 Electro Core Techniques, Llc Method of treating facial blushing by electrical stimulation of the sympathetic nerve chain
US6536949B1 (en) * 2000-03-07 2003-03-25 Richard R. Heuser Catheter for thermal evaluation of arteriosclerotic plaque
US20040019364A1 (en) * 2000-09-27 2004-01-29 Cvrx, Inc. Devices and methods for cardiovascular reflex control via coupled electrodes
US20030060857A1 (en) * 2000-09-27 2003-03-27 Perrson Bruce J. Electrode designs and methods of use for cardiovascular reflex control devices
US6985774B2 (en) * 2000-09-27 2006-01-10 Cvrx, Inc. Stimulus regimens for cardiovascular reflex control
US20030060858A1 (en) * 2000-09-27 2003-03-27 Kieval Robert S. Stimulus regimens for cardiovascular reflex control
US6522926B1 (en) * 2000-09-27 2003-02-18 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US6845267B2 (en) * 2000-09-28 2005-01-18 Advanced Bionics Corporation Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation
US20030004549A1 (en) * 2000-10-26 2003-01-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US6681136B2 (en) * 2000-12-04 2004-01-20 Science Medicus, Inc. Device and method to modulate blood pressure by electrical waveforms
US6676657B2 (en) * 2000-12-07 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services Endoluminal radiofrequency cauterization system
US6672312B2 (en) * 2001-01-31 2004-01-06 Transurgical, Inc. Pulmonary vein ablation with myocardial tissue locating
US20040019371A1 (en) * 2001-02-08 2004-01-29 Ali Jaafar Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US20030009145A1 (en) * 2001-03-23 2003-01-09 Struijker-Boudier Harry A.J. Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20050010263A1 (en) * 2001-07-27 2005-01-13 Patrick Schauerte Neurostimulation unit for immobilizing the heart during cardiosurgical operations
US6994706B2 (en) * 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US6697670B2 (en) * 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US20030040774A1 (en) * 2001-08-21 2003-02-27 Terry Reese S. Treatment of congestive heart failure and autonomic cardiovascular drive disorders
US6684105B2 (en) * 2001-08-31 2004-01-27 Biocontrol Medical, Ltd. Treatment of disorders by unidirectional nerve stimulation
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US20040010303A1 (en) * 2001-09-26 2004-01-15 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US6850801B2 (en) * 2001-09-26 2005-02-01 Cvrx, Inc. Mapping methods for cardiovascular reflex control devices
US20030060848A1 (en) * 2001-09-26 2003-03-27 Kieval Robert S. Mapping methods for cardiovascular reflex control devices
US20050038409A1 (en) * 2001-11-29 2005-02-17 Jerome Segal Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20050065574A1 (en) * 2002-02-01 2005-03-24 Ali Rezai Methods of affecting hypothalamic-related conditions
US6994700B2 (en) * 2002-09-20 2006-02-07 Flowmedica, Inc. Apparatus and method for inserting an intra-aorta catheter through a delivery sheath
US20060030814A1 (en) * 2002-09-20 2006-02-09 Flowmedica, Inc. Method and apparatus for selective drug infusion via an intra-aortic flow diverter delivery catheter
US20060036218A1 (en) * 2002-09-20 2006-02-16 Flowmedica, Inc. Method and apparatus for selective material delivery via an intra-renal catheter
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system
US20050049542A1 (en) * 2003-08-25 2005-03-03 Sigg Daniel C. Electroporation catheter with sensing capabilities
US20060004430A1 (en) * 2004-06-30 2006-01-05 Cvrx, Inc. Connection structures for extra-vascular electrode lead body
US20060004417A1 (en) * 2004-06-30 2006-01-05 Cvrx, Inc. Baroreflex activation for arrhythmia treatment

Cited By (456)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9713483B2 (en) 1995-10-13 2017-07-25 Medtronic Vascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
US9707035B2 (en) 2002-04-08 2017-07-18 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US20110202098A1 (en) * 2002-04-08 2011-08-18 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20070265687A1 (en) * 2002-04-08 2007-11-15 Ardian, Inc. Apparatuses for renal neuromodulation
US9265558B2 (en) 2002-04-08 2016-02-23 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US20090036948A1 (en) * 2002-04-08 2009-02-05 Ardian, Inc. Renal nerve stimulation methods for treatment of patients
US9192715B2 (en) 2002-04-08 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal nerve blocking
US7647115B2 (en) 2002-04-08 2010-01-12 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US9364280B2 (en) 2002-04-08 2016-06-14 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US9289255B2 (en) 2002-04-08 2016-03-22 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US7717948B2 (en) 2002-04-08 2010-05-18 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US10245429B2 (en) 2002-04-08 2019-04-02 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US20100137860A1 (en) * 2002-04-08 2010-06-03 Ardian, Inc. Apparatus for performing a non-continuous circumferential treatment of a body lumen
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9757193B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9743983B2 (en) 2002-04-08 2017-08-29 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9186198B2 (en) 2002-04-08 2015-11-17 Medtronic Ardian Luxembourg S.A.R.L. Ultrasound apparatuses for thermally-induced renal neuromodulation and associated systems and methods
US20100222851A1 (en) * 2002-04-08 2010-09-02 Ardian, Inc. Methods for monitoring renal neuromodulation
US20100222854A1 (en) * 2002-04-08 2010-09-02 Ardian, Inc. Apparatuses for inhibiting renal nerve activity via an intra-to-extravascular approach
US20100268307A1 (en) * 2002-04-08 2010-10-21 Ardian,Inc. Methods for intravascularly-induced neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US9186213B2 (en) 2002-04-08 2015-11-17 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US10130792B2 (en) 2002-04-08 2018-11-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs
US9731132B2 (en) 2002-04-08 2017-08-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US10124195B2 (en) 2002-04-08 2018-11-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US10111707B2 (en) 2002-04-08 2018-10-30 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of human patients
US9814873B2 (en) 2002-04-08 2017-11-14 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US10179235B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US10272246B2 (en) 2002-04-08 2019-04-30 Medtronic Adrian Luxembourg S.a.r.l Methods for extravascular renal neuromodulation
US10293190B2 (en) 2002-04-08 2019-05-21 Medtronic Ardian Luxembourg S.A.R.L. Thermally-induced renal neuromodulation and associated systems and methods
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US10376312B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for monopolar renal neuromodulation
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8131372B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Renal nerve stimulation method for treatment of patients
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8150518B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US10850091B2 (en) 2002-04-08 2020-12-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US9314630B2 (en) 2002-04-08 2016-04-19 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US9320561B2 (en) 2002-04-08 2016-04-26 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US10376311B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravascularly-induced neuromodulation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US10105180B2 (en) 2002-04-08 2018-10-23 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravascularly-induced neuromodulation
US8444640B2 (en) 2002-04-08 2013-05-21 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8454594B2 (en) 2002-04-08 2013-06-04 Medtronic Ardian Luxembourg S.A.R.L. Apparatus for performing a non-continuous circumferential treatment of a body lumen
US9023037B2 (en) 2002-04-08 2015-05-05 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatus for renal neuromodulation
US9138281B2 (en) 2002-04-08 2015-09-22 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation via catheter apparatuses having expandable baskets
US10376516B2 (en) 2002-04-08 2019-08-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US9131978B2 (en) 2002-04-08 2015-09-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US10039596B2 (en) 2002-04-08 2018-08-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatus for renal neuromodulation via an intra-to-extravascular approach
US8548600B2 (en) 2002-04-08 2013-10-01 Medtronic Ardian Luxembourg S.A.R.L. Apparatuses for renal neuromodulation and associated systems and methods
US8551069B2 (en) 2002-04-08 2013-10-08 Medtronic Adrian Luxembourg S.a.r.l. Methods and apparatus for treating contrast nephropathy
US10034708B2 (en) 2002-04-08 2018-07-31 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US9125661B2 (en) 2002-04-08 2015-09-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9439726B2 (en) 2002-04-08 2016-09-13 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8620423B2 (en) 2002-04-08 2013-12-31 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermal modulation of nerves contributing to renal function
US8728137B2 (en) 2002-04-08 2014-05-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US9827040B2 (en) 2002-04-08 2017-11-28 Medtronic Adrian Luxembourg S.a.r.l. Methods and apparatus for intravascularly-induced neuromodulation
US9445867B1 (en) 2002-04-08 2016-09-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation via catheters having expandable treatment members
US8684998B2 (en) 2002-04-08 2014-04-01 Medtronic Ardian Luxembourg S.A.R.L. Methods for inhibiting renal nerve activity
US8721637B2 (en) 2002-04-08 2014-05-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons
US8771252B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US8986294B2 (en) 2002-04-08 2015-03-24 Medtronic Ardian Luxembourg S.a.rl. Apparatuses for thermally-induced renal neuromodulation
US8626300B2 (en) 2002-04-08 2014-01-07 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for thermally-induced renal neuromodulation
US8728138B2 (en) 2002-04-08 2014-05-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US10420606B2 (en) 2002-04-08 2019-09-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US9827041B2 (en) 2002-04-08 2017-11-28 Medtronic Ardian Luxembourg S.A.R.L. Balloon catheter apparatuses for renal denervation
US8740896B2 (en) 2002-04-08 2014-06-03 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons
US8768470B2 (en) 2002-04-08 2014-07-01 Medtronic Ardian Luxembourg S.A.R.L. Methods for monitoring renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US9757192B2 (en) 2002-04-08 2017-09-12 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US9675413B2 (en) 2002-04-08 2017-06-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US8983595B2 (en) 2002-04-08 2015-03-17 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients with chronic heart failure
US8784463B2 (en) 2002-04-08 2014-07-22 Medtronic Ardian Luxembourg S.A.R.L. Methods for thermally-induced renal neuromodulation
US9072527B2 (en) 2002-04-08 2015-07-07 Medtronic Ardian Luxembourg S.A.R.L. Apparatuses and methods for renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9629679B2 (en) 2002-04-08 2017-04-25 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal denervation
US10441356B2 (en) 2002-04-08 2019-10-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation via neuromodulatory agents
US9326817B2 (en) 2002-04-08 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating heart arrhythmia
US8818514B2 (en) 2002-04-08 2014-08-26 Medtronic Ardian Luxembourg S.A.R.L. Methods for intravascularly-induced neuromodulation
US10179027B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable baskets for renal neuromodulation and associated systems and methods
US10194983B2 (en) 2002-04-08 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal denervation
US8845629B2 (en) 2002-04-08 2014-09-30 Medtronic Ardian Luxembourg S.A.R.L. Ultrasound apparatuses for thermally-induced renal neuromodulation
US8852163B2 (en) 2002-04-08 2014-10-07 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods
US9456869B2 (en) 2002-04-08 2016-10-04 Medtronic Ardian Luxembourg S.A.R.L. Methods for bilateral renal neuromodulation
US8880186B2 (en) 2002-04-08 2014-11-04 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients with chronic heart failure
US9867663B2 (en) 2002-04-08 2018-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal denervation
US9895195B2 (en) 2002-04-08 2018-02-20 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US9907611B2 (en) 2002-04-08 2018-03-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation for treatment of patients
US10179028B2 (en) 2002-04-08 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating patients via renal neuromodulation
US9956410B2 (en) 2002-04-08 2018-05-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US8934978B2 (en) 2002-04-08 2015-01-13 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US9463066B2 (en) 2002-04-08 2016-10-11 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9968611B2 (en) 2002-04-08 2018-05-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for renal nerve blocking
US8958871B2 (en) 2002-04-08 2015-02-17 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US11033328B2 (en) 2002-04-08 2021-06-15 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for renal neuromodulation
US8948865B2 (en) 2002-04-08 2015-02-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating heart arrhythmia
US9486270B2 (en) 2002-04-08 2016-11-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for bilateral renal neuromodulation
US9474563B2 (en) 2002-04-08 2016-10-25 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US9468497B2 (en) 2002-04-08 2016-10-18 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9327122B2 (en) 2002-04-08 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9616234B2 (en) 2002-05-03 2017-04-11 Trustees Of Boston University System and method for neuro-stimulation
US9339618B2 (en) 2003-05-13 2016-05-17 Holaira, Inc. Method and apparatus for controlling narrowing of at least one airway
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US10953170B2 (en) 2003-05-13 2021-03-23 Nuvaira, Inc. Apparatus for treating asthma using neurotoxin
US9125666B2 (en) 2003-09-12 2015-09-08 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation of atherosclerotic material
US9510901B2 (en) 2003-09-12 2016-12-06 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation
US10188457B2 (en) 2003-09-12 2019-01-29 Vessix Vascular, Inc. Selectable eccentric remodeling and/or ablation
US8939970B2 (en) 2004-09-10 2015-01-27 Vessix Vascular, Inc. Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
US9125667B2 (en) 2004-09-10 2015-09-08 Vessix Vascular, Inc. System for inducing desirable temperature effects on body tissue
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8805545B2 (en) 2004-10-05 2014-08-12 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9950161B2 (en) 2004-10-05 2018-04-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US10537734B2 (en) 2004-10-05 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9108040B2 (en) 2004-10-05 2015-08-18 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US9402992B2 (en) 2004-10-05 2016-08-02 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for multi-vessel renal neuromodulation
US8433423B2 (en) 2004-10-05 2013-04-30 Ardian, Inc. Methods for multi-vessel renal neuromodulation
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US9486355B2 (en) 2005-05-03 2016-11-08 Vessix Vascular, Inc. Selective accumulation of energy with or without knowledge of tissue topography
US8989859B2 (en) 2005-07-22 2015-03-24 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US8504147B2 (en) 2005-07-22 2013-08-06 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US8676309B2 (en) 2005-07-22 2014-03-18 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US9345538B2 (en) 2005-07-22 2016-05-24 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for neuromodulation for treatment of disorders associated with nerve conduction
US20100010567A1 (en) * 2005-07-22 2010-01-14 The Foundry, Llc Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction
US20110166499A1 (en) * 2005-09-20 2011-07-07 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US20070112327A1 (en) * 2005-11-03 2007-05-17 Yun Anthony J Methods and compositions for treating a renal disease condition in a subject
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US8840537B2 (en) 2005-11-10 2014-09-23 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US20070106337A1 (en) * 2005-11-10 2007-05-10 Electrocore, Inc. Methods And Apparatus For Treating Disorders Through Neurological And/Or Muscular Intervention
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US7747324B2 (en) 2005-11-10 2010-06-29 Electrocore Llc Electrical stimulation treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US7711430B2 (en) 2006-02-10 2010-05-04 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US8099167B1 (en) 2006-02-10 2012-01-17 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8204598B2 (en) 2006-02-10 2012-06-19 Electrocore Llc Methods and apparatus for treating bronchial restriction using electrical modulation
US8010197B2 (en) 2006-02-10 2011-08-30 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US7725188B2 (en) 2006-02-10 2010-05-25 Electrocore Llc Electrical stimulation treatment of hypotension
US8612004B2 (en) 2006-02-10 2013-12-17 ElectroCore, LLC Electrical stimulation treatment of hypotension
US8483835B2 (en) 2006-02-10 2013-07-09 ElectroCore, LLC Methods and apparatus for treating anaphylaxis using electrical modulation
US7869879B2 (en) 2006-02-10 2011-01-11 Electrocore Llc Electrical stimulation treatment of hypotension
US8233988B2 (en) 2006-02-10 2012-07-31 Electrocore Llc Electrical stimulation treatment of hypotension
US10265521B2 (en) 2006-03-03 2019-04-23 Palo Alto Investors Methods and compositions for treating a renal associated condition in a subject
US9320894B2 (en) 2006-03-03 2016-04-26 Palo Alto Investors Methods and compositions for treating a renal associated condition in a subject
US20070208382A1 (en) * 2006-03-03 2007-09-06 Yun Joonkyoo A Methods and compositions for treating a renal associated condition in a subject
US8571650B2 (en) 2006-03-03 2013-10-29 Palo Alto Investors Methods and compositions for treating a renal associated condition in a subject
US9808300B2 (en) 2006-05-02 2017-11-07 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US20090076409A1 (en) * 2006-06-28 2009-03-19 Ardian, Inc. Methods and systems for thermally-induced renal neuromodulation
US9345900B2 (en) 2006-06-28 2016-05-24 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for thermally-induced renal neuromodulation
US11801085B2 (en) 2006-06-28 2023-10-31 Medtronic Ireland Manufacturing Unlimited Company Devices for thermally-induced renal neuromodulation
US10722288B2 (en) 2006-06-28 2020-07-28 Medtronic Ardian Luxembourg S.A.R.L. Devices for thermally-induced renal neuromodulation
US9314644B2 (en) 2006-06-28 2016-04-19 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for thermally-induced renal neuromodulation
US10413356B2 (en) 2006-10-18 2019-09-17 Boston Scientific Scimed, Inc. System for inducing desirable temperature effects on body tissue
US10213252B2 (en) 2006-10-18 2019-02-26 Vessix, Inc. Inducing desirable temperature effects on body tissue
US9974607B2 (en) 2006-10-18 2018-05-22 Vessix Vascular, Inc. Inducing desirable temperature effects on body tissue
US20080119907A1 (en) * 2006-11-22 2008-05-22 Cardiac Pacemakers, Inc. Renal function modulation via application of electrical energy stimulation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US11058879B2 (en) 2008-02-15 2021-07-13 Nuvaira, Inc. System and method for bronchial dilation
US8731672B2 (en) 2008-02-15 2014-05-20 Holaira, Inc. System and method for bronchial dilation
US8489192B1 (en) 2008-02-15 2013-07-16 Holaira, Inc. System and method for bronchial dilation
US9125643B2 (en) 2008-02-15 2015-09-08 Holaira, Inc. System and method for bronchial dilation
US8226638B2 (en) 2008-05-09 2012-07-24 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9668809B2 (en) 2008-05-09 2017-06-06 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8808280B2 (en) 2008-05-09 2014-08-19 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8821489B2 (en) 2008-05-09 2014-09-02 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961508B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961507B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US10149714B2 (en) 2008-05-09 2018-12-11 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9327100B2 (en) 2008-11-14 2016-05-03 Vessix Vascular, Inc. Selective drug delivery in a lumen
US8725249B2 (en) 2008-12-09 2014-05-13 Nephera Ltd. Stimulation of the urinary system
US9498624B2 (en) 2008-12-09 2016-11-22 Nephera Ltd. Stimulation of the urinary system
US8923970B2 (en) 2008-12-09 2014-12-30 Nephera Ltd. Stimulation of the urinary system
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100168731A1 (en) * 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100168739A1 (en) * 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8808345B2 (en) 2008-12-31 2014-08-19 Medtronic Ardian Luxembourg S.A.R.L. Handle assemblies for intravascular treatment devices and associated systems and methods
US8777942B2 (en) 2008-12-31 2014-07-15 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US10561460B2 (en) 2008-12-31 2020-02-18 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation systems and methods for treatment of sexual dysfunction
US10537385B2 (en) 2008-12-31 2020-01-21 Medtronic Ardian Luxembourg S.A.R.L. Intravascular, thermally-induced renal neuromodulation for treatment of polycystic ovary syndrome or infertility
US20100179620A1 (en) * 2009-01-14 2010-07-15 Ramesh Wariar System and method for promoting diuresis and natriuresis by the application of electric fields to the kidney
US8457761B2 (en) 2009-01-14 2013-06-04 Cardiac Pacemakers, Inc. System and method for promoting diuresis and natriuresis by the application of electric fields to the kidney
US11707629B2 (en) 2009-05-28 2023-07-25 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US9675412B2 (en) 2009-10-27 2017-06-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9017324B2 (en) 2009-10-27 2015-04-28 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9005195B2 (en) 2009-10-27 2015-04-14 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8777943B2 (en) 2009-10-27 2014-07-15 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9931162B2 (en) 2009-10-27 2018-04-03 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8932289B2 (en) 2009-10-27 2015-01-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US20110112400A1 (en) * 2009-11-06 2011-05-12 Ardian, Inc. High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation
US10610283B2 (en) 2009-11-11 2020-04-07 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US11712283B2 (en) 2009-11-11 2023-08-01 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9649154B2 (en) 2009-11-11 2017-05-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US11389233B2 (en) 2009-11-11 2022-07-19 Nuvaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US20110200171A1 (en) * 2010-01-19 2011-08-18 Ardian, Inc. Methods and apparatus for renal neuromodulation via stereotactic radiotherapy
US20110208173A1 (en) * 2010-02-24 2011-08-25 Medtronic Vascular, Inc. Methods for Treating sleep apnea via renal Denervation
US9155590B2 (en) 2010-03-03 2015-10-13 Medtronic Ablation Frontiers, Llc Variable-output radiofrequency ablation power supply
US9277955B2 (en) 2010-04-09 2016-03-08 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8870863B2 (en) 2010-04-26 2014-10-28 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses, systems, and methods for renal neuromodulation
US8728075B2 (en) 2010-04-26 2014-05-20 Medtronic Ardian Luxembourg S.A.R.L. Multi-directional deflectable catheter apparatuses, systems, and methods for renal neuromodulation
US8880185B2 (en) 2010-06-11 2014-11-04 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US10004550B2 (en) 2010-08-05 2018-06-26 Medtronic Ardian Luxembourg S.A.R.L. Cryoablation apparatuses, systems, and methods for renal neuromodulation
US9855097B2 (en) 2010-10-21 2018-01-02 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses, systems, and methods for renal neuromodulation
US9636173B2 (en) 2010-10-21 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for renal neuromodulation
US10342612B2 (en) 2010-10-21 2019-07-09 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses, systems, and methods for renal neuromodulation
US9084610B2 (en) 2010-10-21 2015-07-21 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses, systems, and methods for renal neuromodulation
US8956352B2 (en) 2010-10-25 2015-02-17 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods
US8998894B2 (en) 2010-10-25 2015-04-07 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods
US11129674B2 (en) 2010-10-25 2021-09-28 Medtronic Ardian Luxembourg S.A.R.L. Microwave catheter apparatuses, systems, and methods for renal neuromodulation
US9345530B2 (en) 2010-10-25 2016-05-24 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US11116572B2 (en) 2010-10-25 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods
US9750560B2 (en) 2010-10-25 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US9066720B2 (en) 2010-10-25 2015-06-30 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US11006999B2 (en) 2010-10-25 2021-05-18 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US10182865B2 (en) 2010-10-25 2019-01-22 Medtronic Ardian Luxembourg S.A.R.L. Microwave catheter apparatuses, systems, and methods for renal neuromodulation
US10076382B2 (en) 2010-10-25 2018-09-18 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods
US10179020B2 (en) 2010-10-25 2019-01-15 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US10188445B2 (en) 2010-10-26 2019-01-29 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9439708B2 (en) 2010-10-26 2016-09-13 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US10842547B2 (en) 2010-10-26 2020-11-24 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9060754B2 (en) 2010-10-26 2015-06-23 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US8945107B2 (en) 2010-10-26 2015-02-03 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9066713B2 (en) 2010-10-26 2015-06-30 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9060755B2 (en) 2010-10-26 2015-06-23 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9848946B2 (en) 2010-11-15 2017-12-26 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US10292754B2 (en) 2010-11-17 2019-05-21 Medtronic Ardian Luxembourg S.A.R.L. Therapeutic renal neuromodulation for treating dyspnea and associated systems and methods
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9649156B2 (en) 2010-12-15 2017-05-16 Boston Scientific Scimed, Inc. Bipolar off-wall electrode device for renal nerve ablation
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9919144B2 (en) 2011-04-08 2018-03-20 Medtronic Adrian Luxembourg S.a.r.l. Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery
US10588682B2 (en) 2011-04-25 2020-03-17 Medtronic Ardian Luxembourg S.A.R.L. Apparatus and methods related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls
US9579030B2 (en) 2011-07-20 2017-02-28 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
US9186209B2 (en) 2011-07-22 2015-11-17 Boston Scientific Scimed, Inc. Nerve modulation system having helical guide
US8965511B2 (en) 2011-08-30 2015-02-24 Valencia Technologies Corporation Implantable electroacupuncture system and method for reducing hypertension
US10518082B2 (en) 2011-08-30 2019-12-31 Valencia Technologies Corporation Methods and systems for treating hypertension using an implantable electroacupuncture device
US9789304B2 (en) 2011-08-30 2017-10-17 Valencia Technologies Corporation Methods and systems for treating hypertension using an implantable electroacupuncture device
US8805512B1 (en) 2011-08-30 2014-08-12 Valencia Technologies Corporation Implantable electroacupuncture device and method for reducing hypertension
US11400278B2 (en) 2011-08-30 2022-08-02 Valencia Bioscience, Inc. Methods and systems for treating hypertension using an implantable stimulator
US10299986B2 (en) 2011-09-23 2019-05-28 Valencia Technologies Corporation Methods and systems for treating cardiovascular disease using an implantable electroacupuncture device
US11013921B2 (en) 2011-09-23 2021-05-25 Valencia Bioscience, Inc. Methods and systems for treating cardiovascular disease using an implantable electroacupuncture device
US9603773B2 (en) 2011-09-23 2017-03-28 Valencia Technologies Corporation Methods and systems for treating cardiovascular disease using an implantable electroacupuncture device
US8996125B2 (en) 2011-09-23 2015-03-31 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating cardiovascular disease
US8938297B2 (en) 2011-09-23 2015-01-20 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating cardiovascular disease
US11707624B2 (en) 2011-09-23 2023-07-25 Valencia Bioscience, Inc. Methods and systems for treating cardiovascular disease using an implantable electroacupuncture device
US9757196B2 (en) 2011-09-28 2017-09-12 Angiodynamics, Inc. Multiple treatment zone ablation probe
US11779395B2 (en) 2011-09-28 2023-10-10 Angiodynamics, Inc. Multiple treatment zone ablation probe
US11478403B2 (en) 2011-09-29 2022-10-25 Valencia Bioscience, Inc. Implantable electroacupuncture system and method for treating depression and similar mental conditions
US10307331B2 (en) 2011-09-29 2019-06-04 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating depression and similar mental conditions
US9198828B2 (en) 2011-09-29 2015-12-01 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating depression, bipolar disorder and anxiety
US9173811B2 (en) 2011-09-29 2015-11-03 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating depression and similar mental conditions
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
US10085799B2 (en) 2011-10-11 2018-10-02 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
US9079000B2 (en) 2011-10-18 2015-07-14 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
US9162046B2 (en) 2011-10-18 2015-10-20 Boston Scientific Scimed, Inc. Deflectable medical devices
US9327123B2 (en) 2011-11-07 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Endovascular nerve monitoring devices and associated systems and methods
US8951251B2 (en) 2011-11-08 2015-02-10 Boston Scientific Scimed, Inc. Ostial renal nerve ablation
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US11179195B2 (en) 2011-12-02 2021-11-23 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and devices for treatment of polycystic kidney disease
US9192766B2 (en) 2011-12-02 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and devices for treatment of polycystic kidney disease
US9827042B2 (en) 2011-12-02 2017-11-28 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and devices for treatment of polycystic kidney disease
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
US9028472B2 (en) 2011-12-23 2015-05-12 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9186211B2 (en) 2011-12-23 2015-11-17 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9174050B2 (en) 2011-12-23 2015-11-03 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9592386B2 (en) 2011-12-23 2017-03-14 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9402684B2 (en) 2011-12-23 2016-08-02 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9072902B2 (en) 2011-12-23 2015-07-07 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9037259B2 (en) 2011-12-23 2015-05-19 Vessix Vascular, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US8954165B2 (en) 2012-01-25 2015-02-10 Nevro Corporation Lead anchors and associated systems and methods
US8942816B2 (en) 2012-03-06 2015-01-27 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating dyslipidemia
US9314399B2 (en) 2012-03-06 2016-04-19 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating dyslipidemia and obesity
US9566213B2 (en) 2012-03-06 2017-02-14 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating dyslipidemia and obesity
US11730673B2 (en) 2012-03-06 2023-08-22 Valencia Bioscience, Inc. Implantable electroacupuncture system and method
US10299987B2 (en) 2012-03-06 2019-05-28 Valencia Technologies Corporation Implantable electroacupuncture system and method
US9949893B2 (en) 2012-03-06 2018-04-24 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating dyslipidemia and obesity
US11730672B2 (en) 2012-03-06 2023-08-22 Valencia Bioscience, Inc. Implantable electroacupuncture system and method
US9066845B2 (en) 2012-03-06 2015-06-30 Valencia Technologies Corporation Electrode configuration for an implantable electroacupuncture device
US8954143B2 (en) 2012-03-06 2015-02-10 Valencia Technologies Corporation Radial feed through packaging for an implantable electroacupuncture device
US9433786B2 (en) 2012-03-06 2016-09-06 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating Parkinson's disease and essential tremor
US10940033B2 (en) 2012-03-06 2021-03-09 Valencia Bioscience, Inc. Implantable electroacupuncture device and method for treating erectile dysfunction
US9827134B2 (en) 2012-03-06 2017-11-28 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating erectile dysfunction
US9364390B2 (en) 2012-03-06 2016-06-14 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating obesity
US9566212B2 (en) 2012-03-06 2017-02-14 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating dyslipidemia and obesity
US9078801B2 (en) 2012-03-06 2015-07-14 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating erectile dysfunction
US10792219B2 (en) 2012-03-06 2020-10-06 Valencia Technologies Corporation Implantable electroacupuncture system and method
US10342592B2 (en) 2012-03-07 2019-07-09 Medtronic Ardian Luxembourg S.A.R.L. Selective modulation of renal nerves
US10874455B2 (en) 2012-03-08 2020-12-29 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9883909B2 (en) 2012-03-08 2018-02-06 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
US10368791B2 (en) 2012-03-08 2019-08-06 Medtronic Adrian Luxembourg S.a.r.l. Devices and associated methods for monitoring of neuromodulation using biomarkers
US11013549B2 (en) 2012-03-08 2021-05-25 Medtronic Ardian Luxembourg S.A.R.L. Gastrointestinal neuromodulation and associated systems and methods
US9510777B2 (en) 2012-03-08 2016-12-06 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US9974593B2 (en) 2012-03-08 2018-05-22 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the treatment of sexual dysfunction
US11515029B2 (en) 2012-03-08 2022-11-29 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the management of pain
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US10737123B2 (en) 2012-03-08 2020-08-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the management of pain
US11338140B2 (en) 2012-03-08 2022-05-24 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US9597018B2 (en) 2012-03-08 2017-03-21 Medtronic Ardian Luxembourg S.A.R.L. Biomarker sampling in the context of neuromodulation devices, systems, and methods
US10729365B2 (en) 2012-03-08 2020-08-04 Medtronic Ardian Luxembourg S.A.R.L. Biomarker sampling in the context of neuromodulation devices, systems, and methods
US9827428B2 (en) 2012-03-12 2017-11-28 Valencia Technologies Corporation Circuits and methods for using a high impedance, thin, coin-cell type battery in an implantable electroacupuncture device
US10576293B2 (en) 2012-03-12 2020-03-03 Valencia Technologies Corporation Circuits and methods for using a high impedance, thin, coin-cell type battery in an implantable electroacupuncture device
US9089716B2 (en) 2012-03-12 2015-07-28 Valencia Technologies Corporation Circuits and methods for using a high impedance, thin, coin-cell type battery in an implantable electroacupuncture device
US8942808B2 (en) 2012-03-12 2015-01-27 Valencia Technologies Corporation Stimulation paradigm to improve blood pressure dipping in an implantable electroacupuncture device
US9827421B2 (en) 2012-03-12 2017-11-28 Valencia Technologies Corporation Methods and systems for treating a chronic low back pain condition using an implantable electroacupuncture device
US9327134B2 (en) 2012-03-12 2016-05-03 Valencia Technologies Corporation Implantable electroacupuncture device and method
US10940313B2 (en) 2012-03-12 2021-03-09 Valencia Bioscience, Inc. Methods and systems for treating a chronic low back pain condition using an implantable electroacupuncture device
US11020176B2 (en) 2012-04-27 2021-06-01 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized disease treatment by ablation
US10905490B2 (en) 2012-04-27 2021-02-02 Medtronic Ardian Luxembourg S.A.R.L. Cryotherapeutic devices for renal neuromodulation and associated systems and methods
US10258791B2 (en) 2012-04-27 2019-04-16 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods
US9848950B2 (en) 2012-04-27 2017-12-26 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized disease treatment by ablation
US11751931B2 (en) 2012-04-27 2023-09-12 Medtronic Ardian Luxembourg S.A.R.L. Cryotherapeutic devices for renal neuromodulation and associated systems and methods
US11213674B2 (en) 2012-04-27 2022-01-04 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods
US9872718B2 (en) 2012-04-27 2018-01-23 Medtronic Adrian Luxembourg S.a.r.l. Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods
US9241752B2 (en) 2012-04-27 2016-01-26 Medtronic Ardian Luxembourg S.A.R.L. Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods
US9943354B2 (en) 2012-04-27 2018-04-17 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized inhibition of inflammation by ablation
US10660703B2 (en) 2012-05-08 2020-05-26 Boston Scientific Scimed, Inc. Renal nerve modulation devices
US9138292B2 (en) 2012-05-11 2015-09-22 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods
US9452017B2 (en) 2012-05-11 2016-09-27 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods
US9855096B2 (en) 2012-05-11 2018-01-02 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods
US10512504B2 (en) 2012-05-11 2019-12-24 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods
US8888773B2 (en) 2012-05-11 2014-11-18 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods
US8951296B2 (en) 2012-06-29 2015-02-10 Medtronic Ardian Luxembourg S.A.R.L. Devices and methods for photodynamically modulating neural function in a human
US10321946B2 (en) 2012-08-24 2019-06-18 Boston Scientific Scimed, Inc. Renal nerve modulation devices with weeping RF ablation balloons
US8612022B1 (en) 2012-09-13 2013-12-17 Invatec S.P.A. Neuromodulation catheters and associated systems and methods
US9173696B2 (en) 2012-09-17 2015-11-03 Boston Scientific Scimed, Inc. Self-positioning electrode system and method for renal nerve modulation
US10549127B2 (en) 2012-09-21 2020-02-04 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10398464B2 (en) 2012-09-21 2019-09-03 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
US9724512B2 (en) 2012-09-28 2017-08-08 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating parkinson's disease and essential tremor through application of stimului at or near an acupoint on the chorea line
US10835305B2 (en) 2012-10-10 2020-11-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
US9744333B2 (en) 2012-10-19 2017-08-29 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems and methods
US10080864B2 (en) 2012-10-19 2018-09-25 Medtronic Ardian Luxembourg S.A.R.L. Packaging for catheter treatment devices and associated devices, systems, and methods
US10188829B2 (en) 2012-10-22 2019-01-29 Medtronic Ardian Luxembourg S.A.R.L. Catheters with enhanced flexibility and associated devices, systems, and methods
US11147948B2 (en) 2012-10-22 2021-10-19 Medtronic Ardian Luxembourg S.A.R.L. Catheters with enhanced flexibility and associated devices, systems, and methods
US9399115B2 (en) 2012-10-22 2016-07-26 Medtronic Ardian Luxembourg S.A.R.L. Catheters with enhanced flexibility and associated devices, systems, and methods
US9044575B2 (en) 2012-10-22 2015-06-02 Medtronic Adrian Luxembourg S.a.r.l. Catheters with enhanced flexibility and associated devices, systems, and methods
US9492635B2 (en) 2012-10-22 2016-11-15 Medtronic Ardian Luxembourg S.A.R.L. Catheters with enhanced flexibility and associated devices, systems, and methods
US9095321B2 (en) 2012-11-21 2015-08-04 Medtronic Ardian Luxembourg S.A.R.L. Cryotherapeutic devices having integral multi-helical balloons and methods of making the same
US9017317B2 (en) 2012-12-06 2015-04-28 Medtronic Ardian Luxembourg S.A.R.L. Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
US9956033B2 (en) 2013-03-11 2018-05-01 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
US10543037B2 (en) 2013-03-15 2020-01-28 Medtronic Ardian Luxembourg S.A.R.L. Controlled neuromodulation systems and methods of use
US9066726B2 (en) 2013-03-15 2015-06-30 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode apposition judgment using pressure elements
US9297845B2 (en) 2013-03-15 2016-03-29 Boston Scientific Scimed, Inc. Medical devices and methods for treatment of hypertension that utilize impedance compensation
US9510773B2 (en) 2013-03-15 2016-12-06 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode apposition judgment using pressure elements
US9827039B2 (en) 2013-03-15 2017-11-28 Boston Scientific Scimed, Inc. Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US10433905B2 (en) 2013-03-15 2019-10-08 Medtronic Ardian Luxembourg S.A.R.L. Multi-electrode apposition judgment using pressure elements
US10792098B2 (en) 2013-03-15 2020-10-06 Medtronic Ardian Luxembourg S.A.R.L. Helical push wire electrode
US9888961B2 (en) 2013-03-15 2018-02-13 Medtronic Ardian Luxembourg S.A.R.L. Helical push wire electrode
US9179974B2 (en) 2013-03-15 2015-11-10 Medtronic Ardian Luxembourg S.A.R.L. Helical push wire electrode
US10548663B2 (en) 2013-05-18 2020-02-04 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices, systems, and methods
US10022182B2 (en) 2013-06-21 2018-07-17 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
US9943365B2 (en) 2013-06-21 2018-04-17 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
US9265935B2 (en) 2013-06-28 2016-02-23 Nevro Corporation Neurological stimulation lead anchors and associated systems and methods
US9687649B2 (en) 2013-06-28 2017-06-27 Nevro Corp. Neurological stimulation lead anchors and associated systems and methods
US9833283B2 (en) 2013-07-01 2017-12-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10413357B2 (en) 2013-07-11 2019-09-17 Boston Scientific Scimed, Inc. Medical device with stretchable electrode assemblies
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
US9925001B2 (en) 2013-07-19 2018-03-27 Boston Scientific Scimed, Inc. Spiral bipolar electrode renal denervation balloon
US10342609B2 (en) 2013-07-22 2019-07-09 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US10695124B2 (en) 2013-07-22 2020-06-30 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US10722300B2 (en) 2013-08-22 2020-07-28 Boston Scientific Scimed, Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
US9339332B2 (en) 2013-08-30 2016-05-17 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with nerve monitoring features for transmitting digital neural signals and associated systems and methods
US10292610B2 (en) 2013-08-30 2019-05-21 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods
US9326816B2 (en) 2013-08-30 2016-05-03 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods
US9931047B2 (en) 2013-08-30 2018-04-03 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with nerve monitoring features for transmitting digital neural signals and associated systems and methods
US9895194B2 (en) 2013-09-04 2018-02-20 Boston Scientific Scimed, Inc. Radio frequency (RF) balloon catheter having flushing and cooling capability
US11213678B2 (en) 2013-09-09 2022-01-04 Medtronic Ardian Luxembourg S.A.R.L. Method of manufacturing a medical device for neuromodulation
US9138578B2 (en) 2013-09-10 2015-09-22 Medtronic Ardian Luxembourg S.A.R.L. Endovascular catheters with tuned control members and associated systems and methods
US10952790B2 (en) 2013-09-13 2021-03-23 Boston Scientific Scimed, Inc. Ablation balloon with vapor deposited cover layer
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
US9962223B2 (en) 2013-10-15 2018-05-08 Boston Scientific Scimed, Inc. Medical device balloon
US10945786B2 (en) 2013-10-18 2021-03-16 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires and related methods of use and manufacture
US10433902B2 (en) 2013-10-23 2019-10-08 Medtronic Ardian Luxembourg S.A.R.L. Current control methods and systems
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
US11202671B2 (en) 2014-01-06 2021-12-21 Boston Scientific Scimed, Inc. Tear resistant flex circuit assembly
US11154353B2 (en) 2014-01-27 2021-10-26 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters having jacketed neuromodulation elements and related devices, systems, and methods
US10166069B2 (en) 2014-01-27 2019-01-01 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters having jacketed neuromodulation elements and related devices, systems, and methods
US9907609B2 (en) 2014-02-04 2018-03-06 Boston Scientific Scimed, Inc. Alternative placement of thermal sensors on bipolar electrode
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
US10492842B2 (en) 2014-03-07 2019-12-03 Medtronic Ardian Luxembourg S.A.R.L. Monitoring and controlling internally administered cryotherapy
US11406437B2 (en) 2014-03-07 2022-08-09 Medtronic Ardian Luxembourg S.A.R.L. Monitoring and controlling internally administered cryotherapy
US10463424B2 (en) 2014-03-11 2019-11-05 Medtronic Ardian Luxembourg S.A.R.L. Catheters with independent radial-expansion members and associated devices, systems, and methods
US10433907B2 (en) 2014-03-13 2019-10-08 Medtronic Ardian Luxembourg S.A.R.L. Low profile catheter assemblies and associated systems and methods
US9579149B2 (en) 2014-03-13 2017-02-28 Medtronic Ardian Luxembourg S.A.R.L. Low profile catheter assemblies and associated systems and methods
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US11464563B2 (en) 2014-04-24 2022-10-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters and associated systems and methods
US10736690B2 (en) 2014-04-24 2020-08-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters and associated systems and methods
US10610292B2 (en) 2014-04-25 2020-04-07 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology
US10709490B2 (en) 2014-05-07 2020-07-14 Medtronic Ardian Luxembourg S.A.R.L. Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods
US11154712B2 (en) 2014-08-28 2021-10-26 Medtronic Ardian Luxembourg S.A.R.L. Methods for assessing efficacy of renal neuromodulation and associated systems and devices
US11311205B2 (en) 2014-10-01 2022-04-26 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for evaluating neuromodulation therapy via hemodynamic responses
US10368775B2 (en) 2014-10-01 2019-08-06 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for evaluating neuromodulation therapy via hemodynamic responses
US11013554B2 (en) 2014-11-14 2021-05-25 Medtronic Ardian Lexembourg S.A.R.L. Catheter apparatuses for modulation of nerves in communication with pulmonary system and associated systems and methods
US11154351B2 (en) 2014-11-14 2021-10-26 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses for modulation of nerves in communication with the pulmonary system and associated systems and methods
US10667736B2 (en) 2014-12-17 2020-06-02 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing sympathetic nervous system tone for neuromodulation therapy
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
US11446359B2 (en) 2015-04-27 2022-09-20 Tulavi Therapeutics, Inc. Systems and methods for cardiac plexus neuromodulation
US11813456B2 (en) 2015-11-30 2023-11-14 Palo Alto Investors LP Methods of enhancing homeostatic capacity in a subject by increasing homeostatic system component responsiveness, and devices for use in practicing the same
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
US11918595B2 (en) 2016-02-09 2024-03-05 Tulavi Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
US10736692B2 (en) 2016-04-28 2020-08-11 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation and associated systems and methods for the treatment of cancer
US11154547B2 (en) 2016-06-29 2021-10-26 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
US10231784B2 (en) 2016-10-28 2019-03-19 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics
US11311340B2 (en) 2016-10-28 2022-04-26 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics
US11382513B2 (en) 2016-11-08 2022-07-12 Palo Alto Investors Methods and compositions for treating a condition in a subject
US11723710B2 (en) 2016-11-17 2023-08-15 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US10646713B2 (en) 2017-02-22 2020-05-12 Medtronic Ardian Luxembourg S.A.R.L. Systems, devices, and associated methods for treating patients via renal neuromodulation to reduce a risk of developing cognitive impairment
US11116564B2 (en) 2017-07-05 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating anxiety disorders in patients via renal neuromodulation
US10945788B2 (en) 2017-07-05 2021-03-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating depression in patients via renal neuromodulation
US11284934B2 (en) 2017-07-05 2022-03-29 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating sleep disorders in patients via renal neuromodulation
US11160982B2 (en) 2017-07-05 2021-11-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating post-traumatic stress disorder in patients via renal neuromodulation
US11304749B2 (en) 2017-11-17 2022-04-19 Medtronic Ardian Luxembourg S.A.R.L. Systems, devices, and associated methods for neuromodulation with enhanced nerve targeting
US11478298B2 (en) 2018-01-24 2022-10-25 Medtronic Ardian Luxembourg S.A.R.L. Controlled irrigation for neuromodulation systems and associated methods
US10959669B2 (en) 2018-01-24 2021-03-30 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing the efficacy of neuromodulation therapy
US11116561B2 (en) 2018-01-24 2021-09-14 Medtronic Ardian Luxembourg S.A.R.L. Devices, agents, and associated methods for selective modulation of renal nerves
US11253189B2 (en) 2018-01-24 2022-02-22 Medtronic Ardian Luxembourg S.A.R.L. Systems, devices, and methods for evaluating neuromodulation therapy via detection of magnetic fields
US11890393B2 (en) 2018-07-02 2024-02-06 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap
US11633120B2 (en) 2018-09-04 2023-04-25 Medtronic Ardian Luxembourg S.A.R.L. Systems and methods for assessing efficacy of renal neuromodulation therapy
US11931096B2 (en) 2021-06-14 2024-03-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient

Also Published As

Publication number Publication date
US20190183568A1 (en) 2019-06-20
US20150374996A1 (en) 2015-12-31
US20130013024A1 (en) 2013-01-10
US9757192B2 (en) 2017-09-12
US8880186B2 (en) 2014-11-04
US20120130345A1 (en) 2012-05-24
US20050228459A1 (en) 2005-10-13
US20070173899A1 (en) 2007-07-26
US7647115B2 (en) 2010-01-12
US20140088561A1 (en) 2014-03-27
US9907611B2 (en) 2018-03-06
US20170007319A1 (en) 2017-01-12
US20130253603A1 (en) 2013-09-26
US20050234523A1 (en) 2005-10-20
US7162303B2 (en) 2007-01-09
US20160325098A1 (en) 2016-11-10
US10179028B2 (en) 2019-01-15
US20170265937A1 (en) 2017-09-21
US20030216792A1 (en) 2003-11-20
US20150080872A1 (en) 2015-03-19
US8983595B2 (en) 2015-03-17
US20180228535A1 (en) 2018-08-16
US9743983B2 (en) 2017-08-29
US8150518B2 (en) 2012-04-03
US20170007320A1 (en) 2017-01-12
US9314630B2 (en) 2016-04-19
US20090036948A1 (en) 2009-02-05
US8131372B2 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
US10179028B2 (en) Methods for treating patients via renal neuromodulation
US10272246B2 (en) Methods for extravascular renal neuromodulation
EP1804905B1 (en) Apparatus for renal neuromodulation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION